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ABSTRACT 
Mycobacterium ulcerans is the etiological agent of Buruli ulcer (BU), a serious tropical, 
necrotizing skin disease that can cause terrible deformities and disabilities if not treated at early 
stages. This pathogen was first identified in 1948 by MacCallum and colleagues in Australia; 
however, until the last decade, BU has received little attention from the scientific community. 
BU affects mainly rural and poor communities in Africa. Different control measures have 
been suggested, however, associated with BU, there is a strong social stigma, and BU is often 
seen as a curse rather than a disease. Thus, the development of a specific vaccine would be the 
most satisfactory strategy to control BU. It is therefore critical to advance the knowledge on the 
host/parasite interactions concerning this enigmatic disease. 
 
The pathology of BU is closely associated with mycolactone, a polyketide exotoxin 
produced by M. ulcerans and which is the major virulence factor of the agent of BU. It is known 
that cell wall-associated mycolactone or free toxin that diffuses across the tissues, induces 
apoptosis and necrosis of cells, and, ultimately, the formation of ulcers. Indeed, tissue necrosis 
and extracellular clumps of M. ulcerans bacilli are the histopathological hallmark of BU. The 
extensiveness of necrotic areas devoid of cells, which expand, possibly due to mycolactone 
diffusion, beyond areas where M. ulcerans bacilli can be found, has lead to the assumption that 
M. ulcerans induces low or absent cellular inflammatory responses. Additionally, the presence of 
large clumps of free bacteria in the central acellular areas directed early investigators to classify 
M. ulcerans as an extracellular pathogen, an exception among pathogenic mycobacteria. In 
contrast, many reports have described the occurrence of cell-mediated immunity (CMI) and 
delayed-type hypersensitivity (DTH) responses in BU patients, strongly suggesting that 
macrophages play an effector role in the control of infection. 
The use of an animal model of infection, in which it is possible to analyze the entire 
lesion at very early time points, is essential to understand the interaction of M. ulcerans with the 
host immune cells, particularly phagocytes. Previous work from our laboratory in the mouse 
footpad model of infection has shown that inoculation of M. ulcerans in the subcutaneous tissue 
induces an inflammatory cellular response with the involvement of macrophages and 
neutrophils. Moreover, our group has shown that even in advanced lesions, inflammatory cells 
are consistently present, although restricted to the periphery of the necrotic infectious center. 
 
 ix
The constant availability of phagocytes to interact with M. ulcerans, at the persistent 
areas of inflammatory cellular infiltration, directed me to reevaluate the interaction of this 
pathogenic mycobacterium with the host macrophages, in the context of my PhD thesis, both in 
human and in experimental infections. 
In experimental murine infections, we showed that M. ulcerans bacilli were 
phagocytosed in the subcutaneous tissue early after infection. At later time points, as previously 
described, we found free M. ulcerans organisms concentrated in central necrotic acellular areas. 
Surrounding these necrotic areas, where inflammatory infiltrates could be seen, M. ulcerans 
bacilli were however found mainly within macrophages. A histological evaluation of serial 
sections of BU tissue samples from 15 African patients with inflammatory infiltrates, confirmed 
the occurrence in 8 patients of intracellular bacilli within phagocytes infiltrating the peripheral 
areas. In vitro, at low multiplicities of infection (MOI), we found that M. ulcerans was efficiently 
phagocytosed by macrophages, at similar rates as those for the intracellular pathogens 
Mycobacterium tuberculosis and Mycobacterium bovis BCG. Within macrophages, M. ulcerans 
was found surrounded by the phagosomal membrane in tight or spacious phagosomes. We also 
demonstrated that both virulent, mycolactone-producing, as well as mutant, nonproducing 
strains grew inside cultured macrophages when low MOIs were used to prevent mycolactone-
associated cytotoxicity. After this initial phase of intracellular residence and proliferation, 
mycolactone-producing strains were found to lyse the macrophage, becoming extracellular. 
These results suggest that M. ulcerans is an intracellular pathogen like the other virulent 
mycobacteria, which explains the reported occurrence of CMI and DTH in model and human 
cases of M. ulcerans infection.  
Following the demonstration of an intramacrophage growth phase for the agent of BU, 
our work focused on the role played by cytokines that are associated with the host resistance to 
intracellular pathogens. 
Tumor necrosis factor (TNF) and interferon-gamma (IFN-γ) are two cytokines with a key 
role in the activation of macrophages, required to the control of intracellular mycobacteria. A 
previous report showed that a lipidic fraction of M. ulcerans culture filtrates containing 
mycolactone suppressed the production of TNF by cultured human monocytes. On the other 
hand, the expression of TNF has been reported in BU lesions. Therefore, we considered 
pertinent to study the effect of the infection with different strains of M. ulcerans on the 
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production of this cytokine by macrophages, as well as to assess in vivo the role played by TNF 
in infections by M. ulcerans. 
We confirmed previous observations of other authors by showing that mycolactone 
inhibits TNF production, in a dose-dependent manner, and we have expanded these observations 
by using a model of primary mouse macrophages infected with live M. ulcerans bacilli producing 
different types of mycolactone and displaying different degrees of virulence. Our work shows that 
macrophages infected with highly virulent M. ulcerans produce much lower levels of TNF, as 
compared with macrophages infected with intermediate or nonvirulent strains. The reduced 
production of TNF, including at low MOIs, was not due to an early death of infected 
macrophages, since the production of the inflammatory chemokine macrophage inflammatory 
protein-2 (MIP-2) was not inhibited in macrophages infected with the highly virulent strain. 
Finally, we showed that TNF induced during M. ulcerans infection plays a protective role, since 
TNF-p55-defficient mice were more susceptible to nonvirulent and intermediate virulent strains of 
M. ulcerans when compared to wild-type mice. 
IFN-γ is a key cytokine in the activation of the macrophage’s microbicidal mechanisms 
required for the control of intracellular pathogens. We showed that IFN-γ-deficient mice displayed 
an increased susceptibility to infection by nonvirulent and intermediate virulent strains of M. 
ulcerans, but not to a highly virulent strain. In vitro, IFN-γ-activated macrophages control the 
proliferation of the nonvirulent strain as well as the intermediate virulent strain at a low MOI. For 
the nonvirulent strain, the intramacrophage mechanism of control was nitric oxide (NO) 
dependent, since with the inhibition of NO production, macrophages were no longer able to 
control the proliferation of this strain. Contrarily, NO production was not detected in 
macrophages infected with intermediate and highly virulent strains. However, macrophages 
infected with the intermediate virulent, as well as with the nonvirulent strain, expressed LRG-47, 
being this indicative of phagosome maturation. 
 
In summary, we have shown that M. ulcerans, like the other pathogenic mycobacteria, 
has a phase of intramacrophage residence and multiplication. Additionally, we demonstrated 
that M. ulcerans induces the production of TNF by infected macrophages and that this cytokine 
plays a protective role in experimental BU; however, mycolactone, the toxin produced by M. 
ulcerans, inhibits the production of this cytokine. We also demonstrate that IFN-γ is required to 
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the induction of NO and phagosome maturation which are the macrophage’s microbicidal 
mechanisms required to control intracellularly M. ulcerans proliferation. 
Taken together, the results here presented are in accordance with the data in the 
literature showing that resistance to M. ulcerans infections are associated with CMI and DTH. 
The peculiarity of the immunology of M. ulcerans infections lies in the association of the 
mycobacterial nature of this microorganism with its unique capacity to secrete a potent cytotoxic 
exotoxin which influences CMI. 
These findings have potential relevance for the development of a vaccine against BU 
targeting cellular immune mechanisms associated with the activation of the macrophage effector 
functions. 
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RESUMO 
A bactéria Mycobacterium ulcerans é o agente etiológico da úlcera do Buruli (BU), uma 
doença tropical necrotizante que afecta a pele, causando deformidades terríveis se não for 
tratada numa fase precoce. Este agente patogénico foi identificado pela primeira vez por 
MacCallum et al. em 1948 na Austrália; no entanto, até à última década, a BU passou, 
praticamente, despercebida à comunidade científica.  
A BU afecta essencialmente comunidades rurais, pobres, de Africa. Diferentes medidas 
têm sido sugeridas para controlar a BU, no entanto, associado a esta doença existe um estigma 
social muito forte, sendo que, frequentemente, a BU é vista como uma maldição e não como 
uma doença. Assim sendo, o desenvolvimento de uma vacina contra a BU seria a estratégia 
mais adequada para a controlar a doença. Para tal, é essencial aumentar o reduzido 
conhecimento existente, no que respeita à interacção hospedeiro/agente infeccioso. 
 
A patologia da BU está intimamente associada com a micolactona, uma exotoxina 
produzida pelo M. ulcerans, sendo este o factor de virulência mais importante do agente da BU. 
É sabido que a micolactona associada à parede celular, ou livre, que se difunde pelos tecidos, 
induz apoptose e necrose das células do hospedeiro, levando à formação de úlceras. De facto, a 
necrose dos tecidos e a localização extracelular do M. ulcerans são as características 
histopatológicas distintivas da BU. A extensão das lesões necróticas desprovidas de células que, 
possivelmente devido à difusão da toxina, se expandem para além das áreas onde o bacilo se 
encontra, levou à interpretação que o M. ulcerans induzia respostas inflamatórias celulares 
reduzidas ou ausentes. Adicionalmente, a presença de grumos de bacilos livres na área central, 
acelular, do foco da infecção, levou à caracterização do M. ulcerans como uma micobactéria 
extracelular, uma excepção entre o grupo das micobactérias patogénicas. No entanto, diversos 
estudos descreveram a ocorrência de imunidade mediada por células (CMI), assim como de 
hipersensibilidade do tipo retardado (DTH), em doentes com BU, o que sugere um papel efector 
do macrófago no controlo desta infecção. 
 
A utilização de um modelo animal de infecção, que possibilite a análise completa da 
lesão em tempos precoces, é essencial para que seja possível entender a interacção de M. 
ulcerans com as células do sistema imunológico, nomeadamente com os fagócitos. Trabalho 
prévio do nosso laboratório mostrou que, no modelo murino de infecção da almofada plantar, a 
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infecção subcutânea com M. ulcerans induz uma resposta inflamatória celular com a presença 
de macrófagos e neutrófilos. Adicionalmente, o nosso grupo mostrou que, mesmo em estadios 
avançados da lesão, as células inflamatórias se encontravam constantemente presentes na 
lesão, restritas, no entanto, à periferia do centro necrótico acelular.  
 
A constante disponibilidade de fagócitos para interagir com o M. ulcerans, nas zonas de 
infiltrado à periferia da lesão, direccionou o meu trabalho de doutoramento no sentido de 
reavaliar a interacção deste agente patogénico com os fagócitos do hospedeiro, quer em lesões 
humanas, quer em infecções experimentais.  
Em infecções experimentais no modelo murino, mostrámos que o M. ulcerans era 
fagocitado no tecido subcutâneo em tempos curtos após a infecção. Mais tardiamente, conforme 
anteriormente descrito, o M. ulcerans encontrava-se essencialmente na área necrótica, acelular 
da lesão. À periferia desta área central necrótica, e nos locais onde encontrava o infiltrado 
inflamatório, o M. ulcerans era observado essencialmente no interior de macrófagos. A análise 
histopatológica de cortes seriados de 15 amostras de lesões de BU, contendo infiltrados 
inflamatórios e colhidas de doentes Africanos, confirmou, em 8 amostras, a localização 
intracelular do bacilo em fagócitos presentes nas áreas periféricas da lesão. In vitro, a baixas 
multiplicidades de infecção (MOI), mostrámos que o M. ulcerans é eficientemente fagocitado por 
macrófagos, a níveis similares aos encontrados para o Mycobacterium tuberculosis e 
Mycobacterium bovis BCG. No interior dos macrófagos, o M. ulcerans foi encontrado rodeado 
pela membrana do fagossoma. Mostrámos, também, que, quer estirpes virulentas, produtoras 
de micolactona, quer estirpes mutantes, deficientes em micolactona, crescem dentro de 
macrófagos, quando baixas MOIs são usadas, prevenindo-se, assim, a citotoxicidade associada à 
produção de micolactona. Após esta fase inicial de residência e multiplicação intracelular, as 
estirpes produtoras de micolactona provocam a lise dos macrófagos, tornando-se extracelulares. 
Estes resultados sugerem que o M. ulcerans é um agente patogénico intracelular, tal como as 
outras micobactérias patogénicas, o que explica a ocorrência de CMI e DTH, descritas em 
infecções humanas e em infecções experimentais. 
Após a demonstração da existência de uma fase intracelular no ciclo de vida de M. 
ulcerans, o trabalho focou-se no papel das citocinas que estão associadas à resistência do 
hospedeiro a agentes patogénicos intracelulares. 
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O factor de necrose tumoral (TNF) e interferão-gama (IFN-γ) são duas citocinas com um 
papel chave na activação dos mecanismos microbicidas do macrófago, necessários para o 
controlo intracelular das micobactérias. Resultados anteriormente publicados mostram que uma 
fracção lipídica, contendo micolactona, suprime a produção de TNF por monócitos humanos 
cultivados in vitro. No entanto, a expressão de TNF foi reportada em lesões humanas da BU. 
Tendo estes aspectos em consideração, considerou-se pertinente estudar o efeito da infecção, 
por diferentes estirpes de M. ulcerans, na produção desta citocina por macrófagos infectados, 
assim como a relevância biológica do TNF em infecções por M. ulcerans. 
O nosso trabalho confirmou resultados previamente publicados, mostrando que a 
micolactona inibe a produção de TNF, de uma forma dependente da dose, e expandiu essas 
observações, usando um modelo de macrófagos primários infectados com estirpes de M. 
ulcerans que produzem diferentes tipos de micolactona e que apresentam diferentes níveis de 
virulência. Verificámos, de facto, que macrófagos infectados com estirpes virulentas de M. 
ulcerans produzem menores quantidades de TNF, comparativamente com macrófagos 
infectados com estirpes avirulentas ou de virulência intermédia. A reduzida produção de TNF, 
incluindo a baixas MOIs, não se deveu a uma morte prematura dos macrófagos infectados, uma 
vez que e a produção de proteína inflamatória de macrófagos-2 (MIP-2) não era inibida pelas 
estirpes virulentas. Finalmente, mostrámos que o TNF induzido após infecção tem um papel 
protector, uma vez que ratinhos deficientes no receptor P55 do TNF são mais susceptíveis à 
infecção por estirpes de M. ulcerans avirulentas ou de virulência intermédia, quando 
comparados com ratinhos selvagem. 
 
O IFN-γ é uma citocina chave na activação dos mecanismos microbicidas do macrófago, 
necessários para o controlo da proliferação de agentes patogénicos intracelulares. Neste 
trabalho, mostrámos que ratinhos deficientes na produção de IFN-γ são mais susceptíveis à 
infecção por estirpes de M. ulcerans avirulentas ou de virulência intermédia, o mesmo não se 
verificando com uma estirpe de elevada virulência. In vitro, verificámos que macrófagos 
activados com IFN-γ controlam a proliferação de estirpes de M. ulcerans avirulentas e, também, 
de virulência intermédia, quando foi testada uma baixa MOI. Para a estirpe avirulenta, os 
mecanismos de controlo intramacrofágico mostraram ser dependentes da produção de óxido 
nítrico (NO), uma vez que, inibindo-se a produção de NO, os macrófagos activados deixam de 
controlar a sua proliferação. Contrariamente à infecção pela estirpe avirulenta, a produção de NO 
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não foi detectada para as outras estirpes testadas. No entanto, macrófagos infectados com a 
estirpe de M. ulcerans de virulência intermédia expressavam LRG-47, o que sugere a ocorrência 
de maturação do fagossoma. 
 
Em resumo, mostrámos que o M. ulcerans, tal como as outras micobactérias 
patogénicas, tem uma fase de residência e multiplicação intracelular. Mostrámos, também, que 
o M. ulcerans induz a produção de TNF por macrófagos infectados, tendo esta citocina um papel 
chave na resposta protectora contra infecções experimentais por M. ulcerans; no entanto, a 
micolactona, a toxina produzida por M. ulcerans, inibe a produção desta citocina. Demonstrámos 
ainda, que o IFN-γ é necessário para a indução da produção de NO e para a maturação do 
fagosoma, sendo estes os mecanismos microbicidas necessários para controlar a proliferação 
intramacrofágica de M. ulcerans. 
No seu conjunto, os resultados aqui apresentados estão em acordo com resultados 
previamente publicados que mostram que a resistência à infecção por M. ulcerans está 
associada com CMI e DTH. A peculiaridade da resposta imune ao M. ulcerans encontra-se na 
associação entre a natureza micobacteriana deste microorganismo e a sua capacidade de 
produzir uma exotoxina citotóxica, influenciando assim a resposta imune celular. 
 Estes resultados têm uma relevância potencial para o desenvolvimento de uma vacina 
contra a BU, tendo como alvo mecanismos imunes mediados por células, associados com a 
activação dos mecanismos efectores do macrófago. 
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THESIS PLANNING 
The present dissertation is organized in 5 different chapters. The chapters concerning the 
experimental work (chapters 2 to 4) are presented in form of articles. The manuscripts presented 
in chapter 2 and 3 have been published already in Infection and Immunity, while the manuscript 
presented in chapter 4 is being prepared for publication.  
 
In chapter 1, a general introduction to M. ulcerans infection is presented. A review of the 
literature on Buruli ulcer (BU), including a brief historical overview and global distribution, 
microbiology, M. ulcerans virulence factors, transmission of the disease, clinical presentation and 
histopathology, immune response against M. ulcerans including innate and acquired immune 
mechanisms, strategies used to control and treat BU and the use of experimental models to 
study M. ulcerans infection are presented.  
 
In chapter 2, the work “Evidence for an intramacrophage growth phase of 
Mycobacterium ulcerans” is presented, describing for the first time the intracellular lifestyle of M. 
ulcerans, based on the study of BU lesion samples and samples collected from experimentally 
infected mice, as well as from cultured macrophages infected with M. ulcerans. 
 
In chapter 3, the work “Mycolactone-mediated inhibition of tumor necrosis factor 
production by macrophages infected with Mycobacterium ulcerans has implications for the 
control of infection” is presented, showing that macrophages infected with different clinical 
isolates of M. ulcerans produce different amounts of tumor necrosis factor (TNF). Additionally, an 
inhibition of TNF production by the mycolactone produced by intramacrophage M. ulcerans is 
also demonstrated. Finally, the biological relevance of TNF in vivo is presented and discussed. 
 
In chapter 4, the work “Interferon-gamma plays a protective role in Mycobacterium 
ulcerans infection through the activation of nitric oxide production and LRG-47 expression” is 
presented, showing that Interferon-gamma (IFN-γ)-activated macrophages control the 
proliferation of nonvirulent and intermediate virulent strains of M. ulcerans in vitro. In 
accordance, IFN-γ-deficient mice are more susceptible to infection with those strains of M. 
ulcerans. IFN-γ-activated macrophages infected with nonvirulent, but not intermediate or highly 
virulent, strains of M. ulcerans produce high amounts of nitric oxide. Nonetheless, macrophages 
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infected with intermediate virulent strains express LRG-47, being this associated with phagosome 
maturation. 
 
The general discussion of the present dissertation, as well as the main conclusions of 
the experimental work, is presented in chapter 5. 
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OBJECTIVES 
 Work from our laboratory in experimental Myocobacterium ulcerans infections started 
with the characterization of the inflammatory response induced during infection with different 
strains of M. ulcerans in the mouse footpad, a model that allows the continuous microbiological 
and histopathological monitorization of the entire lesion (111). In that work it was shown, at the 
periphery of the lesion, a constant influx of inflammatory cells with a neutrophilic and 
mononuclear profile. In that specific area of the lesion, M. ulcerans was frequently seen co-
localizing with macrophages and neutrophils. These initial observations raised additional 
questions regarding the intracellular/extracellular lifestyle of M. ulcerans in the host which are 
explored in the present dissertation. Furthermore, the relevance of tumor necrosis factor (TNF) 
and interferon-gamma (IFN-γ) and of the macrophage antimycobacterial mechanisms in M. 
ulcerans infections needs further investigation. 
Therefore, the specific aims of the present dissertation are: 
 
TO CLARIFY THE LIFESTYLE OF M. ULCERANS IN THE HOST:  
Buruli ulcer (BU) has been described as an infection associated with minimal or absent 
inflammation, caused by the extracellular multiplication of M. ulcerans. However, resistance to 
infection by this pathogen is associated with cell-mediated immunity (CMI) and delayed-type 
hypersensitivity (DTH) responses, both in humans and in animal models. Therefore, this 
association does not fit the classical description of the histopathology of BU, and, in fact, 
suggests the existence of an intracellular growth phase of M. ulcerans in the host. The first aim of 
the present dissertation is to clarify this point. 
 
TO ELUCIDATE THE BIOLOGICAL RELEVANCE OF TNF IN EXPERIMENTAL M. ULCERANS INFECTIONS:  
TNF is an important cytokine in the activation of macrophage’s antimicrobial 
mechanisms and therefore a key cytokine in the control of intracellular pathogens. Although 
purified mycolactone had been shown to inhibit TNF production by bacterial lipopolysaccharide 
(LPS)-activated monocytes, the capacity of mycolactone produced by intracellular bacilli to inhibit 
TNF production and the biological relevance of this cytokine in M. ulcerans in vivo infections were 
never addressed. 
 xxiii
TO ELUCIDATE THE MICROBICIDAL MECHANISMS USED BY ACTIVATED MACROPHAGES TO CONTROL 
M. ULCERANS PROLIFERATION:  
It has been suggested that IFN-γ is associated with resistance to infections by M. 
ulcerans. Of the macrophage’s microbicidal mechanisms activated by IFN-γ, phagosome 
maturation and nitric oxide production are known to be very important to control, intracellularly, 
the proliferation of intracellular parasites. To elucidate the relevance of IFN-γ and the 
macrophage microbicidal mechanisms activated by IFN-γ, leading to control M. ulcerans 
proliferation, in vivo and in vitro, is another aim of the current dissertation. 
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INTRODUCTION 
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1.1. MYCOBACTERIUM ULCERANS  HUMAN INFECTION  (BURULI ULCER) 
Mycobacterium ulcerans infection causes a devastating, necrotizing, skin disease, known 
as Buruli ulcer (BU), which can also affect the bone. The first description of M. ulcerans was 
published in 1948, when MacCallum and colleagues reported 6 cases of an unusual skin 
infection in six Australian patients, caused by acid-fast bacilli (AFB) that could only be cultivated 
in Löwenstein-Jensen (LJ) medium when the incubation temperature was set lower than for 
Mycobacterium tuberculosis (90). However, the disease was already known for a long time in 
Africa, where in 1897 Sir Albert Cook had reported ulcerative lesions, most likely caused by M. 
ulcerans, in Uganda (189).  
 
Since its first description, many reports on BU have been done across several tropical 
countries.  
Prior to the 1980s, reports came mainly from sub-Saharan Africa, including Congo 
(156), Gabon, Nigeria (113), Cameroon, Ghana (18) and Uganda (173, 174). In fact, the 
designation “Buruli ulcer” came from the Buruli county, in Uganda, where large numbers of 
cases were described in the 1960s (174). Since the 1980s, an increase in BU cases was 
reported in West Africa, including Nigeria, followed by reports from Ghana, Liberia, Gabon, Benin, 
Ivory Coast, and Burkina Faso (78). New foci were also discovered recently in Togo (103) and 
Angola (16) and older ones have been rediscovered in Cameroon (110). Other epidemic foci are 
present in some regions of Australia, Papua New Guinea, Sri Lanka and South America (FIG. 1). 
Nowadays, BU is the third most common mycobacterial infection worldwide, exceeded 
only by tuberculosis and leprosy (103). Although obtaining data on accurate disease burdens is 
difficult, it is known that in highly endemic areas, the number of BU cases may even exceed 
those of tuberculosis and leprosy, affecting up to 22% of the community (9). In Benin, for 
instance, a recent study has reported detection rates of 21.5/100,000 per year, a value higher 
than for either tuberculosis or leprosy (37). The same was observed in Ghana, where the 
prevalence in 1999 was estimated to be 20.7/100,000, exceeding that of leprosy (8).  
In recent years, in addition to the increase in the actual number of cases in West African 
countries and Australia, there was also an increasing geographical spread of the disease within 
these countries (189). Thus far, BU has been reported in at least 30 countries, mainly in tropical 
and subtropical regions (FIG. 1), and the number of reported cases is growing, indicating that BU 
is an emerging infectious disease. The World Health Organization (WHO) recognized the 
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significance of M. ulcerans as an emerging pathogen establishing the Global Buruli ulcer Initiative 
(GBUI) in 1998. The primary objectives of the GBUI are to raise awareness of the disease, to 
mobilize support for affected countries, to promote and to coordinate research activities and to 
coordinate the work of nongovernmental organizations and other partners (190). 
 
 
 
 
 
 
 
 
 
 
 
FIG. 1. Countries were Buruli ulcer was reported. Adapted from (78). 
 
More than 50% of those affected with BU are children under the age of 15 years who live 
in remote rural areas and have little or no access to health services (13). Mortality caused by BU 
is low, but morbidity is high. In poor rural areas of Africa, a high percentage of BU patients seek 
medical treatment too late, when extensive lesions, that cause severe disabilities, have already 
taken place (77). Accordingly, in a recent study in Ghana, of the 75 patients admitted to the 
study, 45 (58%) had a reduced range of motion of the affected joint (47). In fact, patients try to 
cure BU within their community by self-treatment with herbs or by visiting local healers (162). 
One reason for delay in seeking treatment is financial difficulties (162). This is not surprising, 
since BU results in very high indirect costs for patients and their families (13). However, fear of 
the treatment, such as amputation, and social stigma are also reasons pointed by patients for not 
seeking medical care (14, 162).  
The disabilities caused by BU have a great impact in the patient’s life. Some discontinue 
school or work due to the social stigma associated with BU (162) or simply because they could 
not afford school fees after paying the high costs of the treatment (13). 
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1.2. MICROBIOLOGY OF M. ULCERANS 
Phylogenetically, M. ulcerans is genetically closely related to Mycobacterium marinum 
and M. tuberculosis (FIG. 2) (178), two typical intracellular pathogens.  
 
 
 
 
 
 
 
 
 
 
FIG. 2. Phylogenetic tree based on the alignment of partial 16S rRNA gene sequences illustrating the positions of 
strains of M. ulcerans, M. marinum, M. tuberculosis and Mycobacterium haemophilum and other slowly growing 
mycobacterial species. The tree was rooted by use of N. asteroides as an outgroup. The bar indicates a 10-
nucleotide (10-nt) difference. Adapted from (178). 
 
Like M. marinum, M. ulcerans optimal growth temperature is of approximately 32ºC and 
it grows poorly or not at all at temperatures higher than 35ºC. Therefore, incubation at 32ºC is 
essential for its isolation in primary culture (126). Attempts to isolate the organism from clinical 
samples fails in over half of the cases (183). In fact, primary cultures of M. ulcerans may take 8 
weeks, or more, to become positive (181). While the growth rate is slow, M. ulcerans will grow 
readily on most egg-based media with LJ medium being optimal. It will also grow easily in 
Middlebrook 7H9 broth media, supplemented with albumin, dextrose and catalase. Another 
important factor is oxygen concentration. M. ulcerans growth was shown to be enhanced at low 
concentrations of oxygen, suggesting the preference for microaerophilic environments (116). 
 
Since primary cultures of M. ulcerans may take several weeks to become positive, and, 
in some cases, clinically and histopathologically typical Buruli ulcers are reported as culture 
negative (103, 120, 130), polymerase chain reaction (PCR) amplification of the pathogen’s genes 
is the most widely and accurate method used to detect M. ulcerans. Unlike culture, PCR 
diagnosis permits the confirmation of the clinical diagnosis in a short time.  
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The first PCR method described for detection of M. ulcerans was based on amplification 
of a region of the 16S rRNA gene (128). The insertion sequences (IS)2404 and IS2606 have 
been also used to detect M. ulcerans in the environment and in clinical samples (143, 144). 
However, these insertion sequences were also found in other mycobacteria (193), which 
indicates that these markers cannot be used as the sole evidence for M. ulcerans presence. 
 
1.3. M. ULCERANS VIRULENCE FACTORS  
A remarkable characteristic of M. ulcerans is the production of a unique lipidic family of 
exotoxins, mycolactones, first isolated and identified in 1999 by George and colleagues (61) (FIG. 
3). However, early investigators had already suggested that M. ulcerans pathology was closely 
associated with the production of a toxin (30, 84, 137). The main reason for that suggestion was 
the fact that BU necrotic lesions extended well beyond the areas where AFB could be seen, and 
thus only a diffusible toxin could cause the necrosis of the tissue. Recently, the genes required to 
produce mycolactone were shown to be encoded in a giant plasmid (165).  
Mycolactones are hybrid polyketides composed of a lactone core and a fatty acid side 
chain (69). All strains of M. ulcerans recently isolated from BU patients produce a major 
mycolactone species along with several minor congeners (23, 74, 108), and the pattern of 
mycolactones produced is conserved in specific geographic areas (108). African strains produce 
mycolactone A/B as major lipid species, whereas Australian strains produce mainly mycolactone 
C (108).  
 
 
 
 
 
 
FIG. 3. Mycolactone B structure. Adapted from (69). 
 
In vitro, mycolactone was shown to enter cells through passive diffusion (158), inducing 
a cell cycle arrest in G0/G1 state, followed by apoptosis (62). However, recent in vitro data 
suggested that apoptosis would only occur in cells when low concentrations of mycolactone are 
added to the culture medium, the presence of high concentrations of toxin inducing necrosis (4). 
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However, the possibility has to be considered of mycolactone-induced necrosis representing 
apoptotic secondary necrosis (111). 
Injection of mycolactone into the dermis of guinea pigs is sufficient to induce ulcers (61). 
On the other hand, mycolactone negative mutant strains of M. ulcerans were shown to be 
nonvirulent for mice and guinea pigs, reinforcing the critical role of mycolactone in M. ulcerans 
pathology (61, 111). In water bugs, unlike wild-type (WT) strains, also mycolactone negative 
mutant strains failed to colonize the host, suggesting that mycolactone plays a role in the ability 
of M. ulcerans to colonize reservoir species (95).  
Although no receptor was identified for mycolactone, a key feature of this toxin is the 
capacity to inhibit, in vitro, the intracellular signalling of tumour necrosis factor (TNF) (115). In 
addition, mycolactone was also associated with the reduction of phagocytic uptake of M. ulcerans 
by macrophages (4, 33). Both these effects of mycolactone on macrophages will be later further 
discussed.  
 
Comparative genomics of mycobacterial strains has revealed several chromosomal 
regions that are absent from the genomes of the less virulent strains (22, 89, 92). This analysis 
has focused particular attention on one region, termed region of difference 1 (RD1), which 
encompasses nine genes (from Rv3871–Rv3879c), because this region is present in virulent M. 
tuberculosis and Mycobacterium bovis, but missing in M. bovis bacillus Calmette-Guérin (BCG) 
(89, 92). The function of the RD1 genes still is not known, although two of those genes encode 
the immunodominant antigens early secretory antigen target – 6 (ESAT-6) and culture filtrate 
protein – 10 (CFP-10). 
An important role for RD1 in mycobacterial pathogenesis has been demonstrated 
experimentally in several models. Incorporation of M. tuberculosis RD1 genes in Mycobacterium 
microti or BCG enhances the virulence of these organisms for mice (134); conversely, a deletion 
of RD1 genes from M. tuberculosis greatly decreases its virulence for mice and cultured 
macrophages (89). RD1 genes were also shown to be present in some strains of M. ulcerans 
(109). In fact, whereas African, Malaysian, and Australian M. ulcerans strains lack RD1 genes, 
these genes are present in East Asian, Mexican, and South American M. ulcerans isolates (109). 
Studies on the virulence of different M. ulcerans isolates in guinea pigs showed that Mexican and 
Asian isolates were less virulent and induced a greater granulomatous response when compared 
with African or Australian strains (109). Because ESAT-6 and CFP-10 are strong antigens, the 
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authors suggested that genes from the RD1 cluster could be involved in the differences in 
virulence observed (109). However, the highly virulent African strains of M. ulcerans lack RD1 
while some of the less virulent strains have RD1 (109), which indicates that these genes are not 
important for M. ulcerans virulence.  
Recently, phospholipase C and D were identified in whole-cell extracts and culture filtrates of 
M. ulcerans (64). Phospholipases are known to be an important virulence factor for different 
bacteria (175), including M. tuberculosis (54, 82), but in M. ulcerans infection the role of these 
enzymes in the pathogenesis of the disease is still not elucidated.  
 
It is known that noncytotoxic M. ulcerans strains do not induce significant pathology in 
the mouse footpad; however they can persist in mice for at least 12 months postinoculation 
(111). Therefore, although it is unquestionable that mycolactones play a central role in M. 
ulcerans virulence, more research is required to fully understand the mechanisms of participation 
of this toxin in the pathogenicity of this mycobacterium as well as to identify other possible 
virulence factors of M. ulcerans. 
 
1.4. TRANSMISSION OF M. ULCERANS 
There is strong epidemiological evidence that links the source of M. ulcerans to swamps 
and slow-flowing water (17, 185). For instance, the high incidence of Buruli ulcer in the Kinyara 
refugee settlement, located adjacent to swampy regions near the Nile river, fell substantially 
when the refugees were moved elsewhere (173). In Nigeria, infections have emerged when a 
small stream was dammed to make an artificial lake (113). In Phillip Island, Australia, an 
outbreak of the disease was temporally associated with the formation of a small swamp that, 
after its improved drainage, was followed by a cessation of cases (185). 
 Although bodies of stagnant water appear to be the main reservoir of M. ulcerans in the 
environment, Barker and colleagues (17) suggested that contaminated grasses may also provide 
the means for inoculating M. ulcerans in the upper parts of the body (17). Hayman postulated 
that M. ulcerans is an environmental microorganism living in the soil, in symbiosis with the roots 
of certain plants in tropical rain forests, and that transmission to humans may only occur when 
the soil microenvironment is disturbed. In those circumstances, M. ulcerans may enter in slow 
moving or stagnant water bodies and start proliferating (70).  
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Although transmission of BU still is a matter of investigation, most investigators believe 
that M. ulcerans infection is acquired through small injuries in the skin, allowing the entrance of 
the bacterium to the subcutaneous tissue. Once in the subcutaneous tissue, the low temperature 
allows M. ulcerans growth. Accordingly, Meyers and colleagues showed evidence of antecedent 
trauma at the site of an M. ulcerans lesion (102). This may explain why children under 15 years 
of age are more affected by BU than adults, and why, among adults, women are more frequently 
affected (9). In fact, the use of trousers and long-sleeved shirts was reported to be preventive for 
BU in communities with a high prevalence of the disease (77, 99, 183). 
 Since, until now, M. ulcerans could not be directly cultivated from environmental 
samples, considering M. ulcerans an environmental pathogen is only a hypothesis. M. ulcerans 
genetic material has been detected in the environment by using PCR (143, 164). Although, as 
discussed above, this technique is not totally safe for the identification of M. ulcerans genetic 
material,  the possibility should be considered of M. ulcerans existing in the environment in a 
“viable but nonculturable” (VBNC) state, as has been known to be the case of other pathogens 
like Legionella pneumophila (21). In the VBNC, state the ability to return to an actively 
metabolizing and culturable form, as well as virulence, is retained (112). It is relevant that 
mycobacteria are also known to enter the VBNC state (150, 151).  
Portaels and colleagues showed the presence of IS2404 in specimens from water bugs 
of the Belostomatidae and Naucoridae family and advanced for the first time the hypothesis of 
BU being transmitted from the environmental niches to humans through insect biting (129). 
Later, Marsollier and colleagues successfully transmitted the disease to animal models through 
biting of mice tails by Naucoridae insects, which, after having been fed with M. ulcerans-infected 
grubs (Phormia terrae novae), harbored the pathogen in the salivary glands, where they multiply 
(97). Moreover, M. ulcerans was found to colonize the salivary glands of Naucoridae insects in 
BU endemic areas (97), and the mechanisms through which M. ulcerans reaches the salivary 
glands after being ingested by Naucoridae insects were also recently described (95). In the 
environment, it is possible that M. ulcerans persists in association with aquatic plants that may 
enhance proliferation and biofilm formation, as it was shown in culture media supplemented with 
crude extracts from green algae (98). Snails and small fish that feed from these plants may 
became infected with M. ulcerans, as it was experimentally shown (97), concentrating M. 
ulcerans from these sources (46). Higher in the food chain, Naucoridae, or other aquatic 
predator insects, may became infected after feeding with infected snails or small fish, 
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concentrating M. ulcerans even further and then transmit the disease to humans through biting. 
In accordance, activities in riverbanks, such as swimming, are considered a risk factor for BU (5). 
These results support the initial hypothesis (129) that aquatic insects could be vectors of M. 
ulcerans transmission, explaining some of the outbreaks of BU after environmental changes (97). 
However, the actual relevance of biting by M. ulcerans-infected aquatic insects in the 
transmission of BU is not clarified, and other forms of transmission of M. ulcerans to humans, 
including skin trauma, have also been considered (153).  
 
1.5. CLINICAL PRESENTATION AND HISTOPATHOLOGY OF BURULI ULCER 
As discussed before, M. ulcerans is genetically very closely related to M. marinum and 
M. tuberculosis (FIG. 2). However, and largely due to secretion of mycolactones by M. ulcerans, 
the pathology caused by infection with the agent of BU is unique in key aspects, when compared 
to other mycobacterioses.  
As mentioned above, M. ulcerans infection probably starts by the penetration, following a 
skin trauma (102) or an insect bite (97), of the infectious agent into the subcutaneous tissue 
where bacilli multiply. The evolution of the disease is dependent on many factors such as the 
immune status of the host, the size of the inoculum and the characteristics of the M. ulcerans 
strain. The lesions can be nonulcerative (FIG. 4A-D) or ulcerative (FIG. 4E) 
(http://www.afip.org/Departments/infectious/bu/index.html). If not treated, the initial 
nonulcerative stages of the disease usually progress to ulcers. In African patients, the disease 
usually starts as a nodule (FIG. 4A). However, in these patients, pre-ulcerative lesions also 
include plaques (FIG. 4B), which are large areas of indurated tissue, and oedemas (FIG. 4C) 
(183). The presentation of pre-ulcerative lesions after infection by M. ulcerans appears to vary 
between strains from different regions. In Australia, the most common form of pre-ulcerative 
lesions is the papule (FIG. 4D), with no nodular stage (183). It is currently not known why the 
clinical presentation and the severity of the disease differs among geographical regions, but it 
might be associated with differences in M. ulcerans virulence, including production of different 
types of mycolactone (108). In accordance, Australian strains produce mycolactone C, a 
mycolactone known to be less cytotoxic than the mycolactone A/B produced by African strains 
(108). However, other phenotypic characteristics seem to differentiate African, Australian, and 
American M. ulcerans strains (130).  
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The active M. ulcerans infection develops in association with bacillary multiplication and 
mycolactone production, with expansion of tissue necrosis and ulcer formation, possibly due to 
the cytotoxicity of mycolactone and to ischemia associated with vasculopathy (68), which leads to 
vessel occlusion. Many AFB are present in the infectious focus, but the necrosis extends well 
beyond bacilli localization (30), possibly due to the diffusion of the M. ulcerans toxin, as proposed 
long ago (30, 84, 137). Ulceration can be extensive and disfiguring, often affecting 50% or more 
of a limb or extensive areas of the trunk (FIG. 4E). Sometimes, in advanced lesions, the infection 
spreads, and affects the bone by continuity (contiguous osteomyelitis) or by the haematogeneous 
route (metastatic osteomyelitis) (121, 127). In Benin, more than 10% of the patients have severe 
osteomyelitis (37, 87). 
 
  A   B   C 
 
 
 
 
  D   E   F  
 
 
 
 
FIG. 4. Clinical forms of BU. A, Nodule; B, papule; C, Oedema; D, Plaque; E, Ulcer; F, Contracture caused by a 
healed ulcer. Adapted from (189, 190). 
 
Following inoculation of the etiologic agent, the incubation period can vary from weeks to 
years, but lesions usually take up 2 to 3 months to develop (183). The histopathology of the 
earliest phases of this process has never been observed in human infections. When available for 
sudy, infected tissues primarily reveal microcolonies containing large numbers of extracellular 
AFBs in the central portion of the necrosis. Also common in the necrotic areas are the “ghost 
cells” (adipocytes that die and lose their nuclei).  
The pre-ulcerative stages are symmetrically circumscribed areas of contiguous necrosis 
in the dermis, with intact epidermis. In the ulcerative stage, a necrotic slough develops at the 
base of the ulcer and the surrounding skin is undermined, indurated, and hyperpigmentated (1, 
183, 189). Ulcerative lesions have been characterized by extensive necrosis of the subcutaneous 
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tissue and epidermis, alongside clusters of extracellular acid-fast bacilli in the slough. As 
described below, inflammatory cellular responses have been described as minimal in human 
samples. Spread of bacilli is known to occur, leading to the development of new lesions, 
including in the bone, as described above. 
Healing of BU lesions is known to occur, characterized by an influx of lymphocytes, 
macrophages and Langerhans’ giant cells. This is followed by the formation of mature 
tuberculoid granulomas, regeneration and epithelialisation of the epidermis (171, 183). During 
this healing phase, few if any mycobacteria are found in the sections (30). 
 
1.6. IMMUNE RESPONSE TO INFECTION BY M. ULCERANS 
 
1.6.1.    INFLAMMATORY RESPONSE TO M. ULCERANS INFECTION 
Thus far, the immune response against M. ulcerans has been far less studied than that 
against other mycobacteria such as M. tuberculosis and Mycobacterium leprae. The 
inflammatory response to mycobacterial infections is characterized histopathologically by an 
early, acute, predominantly neutrophilic response (117, 146, 149, 154), which changes over 
time to a chronic, mononuclear, granulomatous pattern (35, 81). This biphasic response is 
characteristic of infections caused by the M. ulcerans related species M. tuberculosis and M. 
marinum (25, 81, 105, 117, 149, 179). 
In contrast with the above data, M. ulcerans infection has been described as inducing 
low or absent inflammatory responses due to mycolactone production (50). However, the 
dynamics of the infection process and host inflammatory response at different stages of infection 
with M. ulcerans are still poorly understood, in part due to difficulties in getting samples of 
human lesions at early stages. 
 
The interpretation that a low or absent inflammatory response is characteristic of BU 
lesions came from the histopathological observation in BU lesion samples of extensive skin 
necrotic acellular areas.  
Studies on experimental BU are sparse and with contradictory results regarding the 
inflammatory response induced by M. ulcerans. In some studies, the occurrence of an 
inflammatory response was reported (84, 90, 137) while in others minimal inflammation was 
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observed (61, 62, 187). For a detailed analysis of the cellular response occurring after infection 
with different clinical isolates of M. ulcerans, including in the initial phases, Oliveira and 
colleagues, using the mouse footpad model of infection, found that M. ulcerans induces relevant, 
virulence-dependent persistent inflammatory responses (111). A mycolactone-negative, 
noncytotoxic strain that does not produce progressive infection induces an initial acute 
neutrophilic response that switches to a chronic mononuclear infiltrate associated with 
granuloma-like structures, in the absence of necrosis (111). On the other hand, mycolactone-
positive, cytotoxic strains multiply progressively and induce a mixed inflammatory response, with 
neutrophils and some macrophages, that is permanently present during the infectious process, 
although at spatially restricted areas surrounding a central necrotic, acellular focus that expands 
with the progress of the disease (111). These results, not only show that M. ulcerans induces an 
inflammatory response, but also that the phagocyte recruitment is biphasic, as it happens with 
other pathogenic mycobacteria, as reviewed above.  In a recent study, Guarner and colleagues 
reported the occurrence of infiltrates with neutrophils and mononuclear cells in 92% of 78 
biopsies of confirmed BU, although such an inflammatory response was recognized as minimal 
(68). 
Neutrophil recruitment to the infection focus is one of the early events after infection. 
These cells are known to play an important role against extracellular pathogens, but their role in 
M. ulcerans infection is still not known. Nevertheless, several authors had suggested a protective 
role for this population of cells, early after infection by other pathogenic mycobacteria such as 
Mycobacterium avium or M. tuberculosis (117, 119, 139, 154, reviewed by 10). The protective 
role of neutrophils in these infections would not be through the classical mechanisms of 
phagocytosis and further destruction of the phagocytosed microorganism, but by transferring 
neutrophil antimicrobial molecules to macrophages with an increase in their microbicidal activity 
(154, 167), and by modulating the immune response through the production of Interleukin (IL)-
12 and TNF that, in turn, will induce the production of interferon-gamma (IFN-γ) by other cells of 
the immune system (117, 119). 
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1.6.2.     THE INTRACELLULAR/EXTRACELLULAR LIFESTYLE OF M. ULCERANS: 
A CONTROVERSIAL ISSUE 
Present knowledge on BU pathogenesis is mainly based on the analysis of biopsies and 
surgically excised tissues from human disease, and on the study of animal models of M. 
ulcerans infection. While animal models allow the analysis of the evolution of M. ulcerans 
infections from the beginning, human samples of the initial phases of the infection are not 
usually available. 
Different observations have led investigators to classify M. ulcerans as an extracellular 
pathogen, therefore representing an exception among mycobacteria (32): (i) the presence of 
large clumps of free bacilli in the centre of the lesion (30), in areas completely devoid of cells; (ii) 
virulent M. ulcerans and mycolactones, under some in vitro conditions, were shown to inhibit the 
phagocytic activity of macrophages (4, 33); (iii) virulent M. ulcerans and mycolactones induce 
apoptosis of cells in vivo  and in vitro (4, 62); and (iv) virulent M. ulcerans fails to grow inside 
macrophages in vitro (136). 
Although the histopathological hallmark of BU is the presence of extracellular bacilli in 
necrotic, acellular areas, because this is the pattern predominating in most biopsies of advanced 
BU lesions, early investigators have reported M. ulcerans bacilli inside macrophages, both in 
human and in experimental BU. In fact, in the initial description of human M. ulcerans infection 
MacCallum wrote:  “The report on the first biopsy specimen drew attention to (…) the distribution 
of the bacteria in large numbers in phagocytes, recalling that of Mycobacterium leprae 
sometimes seen in skin leprosy” (90). Fenner, by using the experimental footpad infection of 
mice, described the presence of “scattered mononuclear cells packed with AFB, together with 
some ‘cords’ of extracellular acid-fast bacilli” (52). Krieg and colleagues, by using a guinea pig 
model of infection, described clumps and aggregates of AFB, both within macrophages and free 
in the tissue (84). Similarly, Read and colleagues found that 24 hours after infection of guinea 
pigs with M. ulcerans, most of the AFB appeared in clumps in polymorphonulear phagocytes and 
macrophages (137). These authors also showed that, as the infection progresses, many of the 
phagocytic cells containing bacilli degenerated, leaving clumps of AFB free in the tissue (137). 
The recent paper by Oliveira and colleagues (111) also described the frequent presence of high 
number of M. ulcerans bacilli colocalizing with inflammatory cells in the mouse footpad model of 
infection. 
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On the other hand, resistance to infection by M. ulcerans in humans and in animal 
models has been associated with cell-mediated immunity (CMI) and delayed-type hypersensitivity 
(DTH) responses (see below) (44, 65, 66, 71, 72, 83, 90, 99, 110, 124, 133, 142, 159, 163, 
168, 188).  
This set of results does not fit with the current characterization of BU histopathology and 
with the extracellularity of M. ulcerans, and in fact suggests the existence of an intracellular 
lifestyle of M. ulcerans at least during a phase of its residence in the host, as it happens with M. 
marinum or M. tuberculosis. However, until now there are no studies reporting intracellular 
growth of M. ulcerans, either in vivo or in vitro. Although it is unquestionable that the presence of 
necrotic acellular areas with extracellular M. ulcerans is a diagnostic hallmark of BU, it is 
reasonable to admit that such a pattern only represents a partial histopathological counterpart of 
the host-parasite interactions with relevance for BU pathogenesis. To gather a comprehensive 
perspective integrating the classical description of BU histopathology, the peculiar features of an 
infection by a cytotoxic mycobacterium, and the type of immunity associated with the disease, an 
assessment is required of the dynamics of the interaction M. ulcerans/host cells in the entire 
infectious focus. 
   
1.6.3.    ROLE OF MACROPHAGES IN THE IMMUNE RESPONSE TO                 
M. ULCERANS 
Macrophages are central cells in the innate immune response to M. tuberculosis and 
other pathogenic mycobacteria (2, 145) for several reasons: (i) macrophages express receptors 
to promote phagocytosis of mycobacteria, being therefore the host cell for these intracellular 
pathogens and, at the same time, the effector cell of the immune response; (ii) macrophages 
have several antibacterial mechanisms being able to kill mycobacteria within the phagosome 
(discussed below); (iii) macrophages are able to present mycobacterial antigens to T cells, 
therefore being a link between innate and adaptive immune responses; (iv) macrophages 
produce cytokines and chemokines that recruit and activate new inflammatory cells to the 
infection focus; and (v) macrophages participate in the formation of the granuloma, an 
histological structure that is essential to the containment of mycobacterial infections. 
Macrophages, being present in all body territories as resident sentinels (184) are likely to 
be the first cells to encounter and phagocytose invading pathogens, including M. ulcerans when 
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entering the sub-cutaneous tissue. Macrophages initiate the immune response by producing 
cytokines such as IL-1, IL-6, TNF, IL-12, IL-18 and chemokines such as IL-8 and macrophage 
inflammatory protein-2 (MIP-2) (the murine homologue of the human IL-8 (170)) (81, 104, 147). 
The capacity of these macrophages to kill phagocytosed mycobacteria depends on its degree of 
activation that is modulated by cells recruited to the infection focus. Proinflammatory cytokines, 
mainly IL-1, IL-6 and TNF, and the chemokine IL-8, produced by infected macrophages not only 
induce the chemotaxis of other inflammatory cells to the infection focus but also stimulate 
endothelial cells to produce inflammatory mediators such as regulation on activation normal T 
cell expressed and secreted (RANTES) protein, MIP-1α and monocyte chemoattractant protein 
(MCP)-1 and the expression of adhesion molecules that will participate in the recruitment of cells 
(59, 81, 141).  
Some of these cytokines and chemokines have been shown to be expressed in M. 
ulcerans lesions in humans (118, 124, 133), however, not much is known about their biological 
relevance in the context of BU lesions.  
TNF is known to be a critical cytokine in the immune response to mycobacteria. Of the 
inflammatory cytokines produced by macrophages, TNF is one of the first to be produced upon 
infection, having an autocrine activity on the macrophage itself, increasing its microbicidal 
mechanisms (discussed bellow). In the infection focus, this cytokine is likely to be produced not 
only by macrophages, but also by activated T cells or natural killer (NK) cells (118).  
TNF has been shown to be expressed in BU lesions (124, 133), despite the capacity of 
mycolactone to inhibit its production in vitro (115). In addition, it was recently shown that TNF 
was expressed in macrophages infected with a mycolactone-negative M. ulcerans mutant, but not  
in macrophages infected with mycolactone-positive M. ulcerans (33), suggesting that, in vivo, this 
cytokine may be produced by newly recruited macrophages but not by infected macrophages.  
In addition to its effects on the activation of macrophage’s effector mechanisms, TNF is 
known to have an important role in M. tuberculosis granuloma development and maintenance 
(19, 59). Several authors reported that in BU, granuloma formation is associated with the 
process of healing of necrotic ulcers (1, 71, 72, 163, 183) and disseminated BU and 
osteomyelitis may be associated with defects in granuloma formation (73, 163). It is, therefore, 
possible that in BU, TNF is involved in the granulomatous response associated with the healing 
phase of the disease, but more studies are required in order to determine the exact role of this 
cytokine.  
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  A spatial analysis of BU lesions showed expression of IL-8 associated with areas of 
infiltrating neutrophils (118), suggesting that this chemokine may be important for the 
recruitment of neutrophils during M. ulcerans infection. Similar results were presented by Phillips 
and colleagues, showing higher expression of this chemokine in M. ulcerans infected tissues 
containing neutrophils (124). In vitro, the mouse homologue of IL-8, MIP-2, was shown to be 
expressed by macrophages infected with M. ulcerans (33). Interestingly, macrophages infected 
with mycolactone-producing strains were shown to express higher amounts of MIP-2 when 
compared with macrophages infected with mycolactone negative strains (33). The authors of this 
report suggested that mycolactone inhibit the production of proinflammatory cytokines but, in 
turn, stimulate chemokine production (33). The presence of IL-8 in BU lesions do not correlate 
with the classical description of low or absent inflammation associated with M. ulcerans infection, 
since IL-8 is a powerful neutrophil recruiter (15). A study using the mouse footpad model of M. 
ulcerans infection provided evidence suggesting that the lack of inflammatory infiltrates in the 
extensive areas of necrosis seen in advanced infections results from the destruction of 
continuously produced inflammatory infiltrates and not from M. ulcerans-induced local or 
systemic immunosuppression (111).  
Other cytokines and chemokines are probably involved in the innate phase of the 
immune response to M. ulcerans. However, until now, there is no solid data on the role of any 
cytokine or chemokine in the immune response to M. ulcerans. A better understanding of the role 
of cytokines and chemokines in BU will certainly help investigators to develop a specific vaccine 
against this disease. 
 
 After being phagocytosed by macrophages, M. tuberculosis and other mycobacteria are 
retained in the phagosome and can be subjected to intracellular killing via a variety of 
mechanisms, involving phagosome-lysosome fusion, generation of reactive oxygen intermediates 
(ROI) and reactive nitrogen intermediates (RNI), particularly nitric oxide (NO) (reviewed in 58). 
 The phagosome is a dynamic structure that interacts with endosomes (early endocytic 
pathway) and lysosomes (late endocytic pathway), thus forming the phagolysosome. During these 
interactions vesicle patches of membrane and luminal contents are exchanged, as summarized 
in the “kiss and run” model (42). Phagocytosed microorganisms will be subjected to 
intralysosomal degradation by acidic hydrolases, this highly regulated event being one of the 
most powerful antimicrobial mechanisms of phagocytes (27, 42, 43).  
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 In 1971, D’arcy Hart showed for the first time that M. tuberculosis inhibits the fusion of 
phagosomes with lysosomes (12). This virulence mechanism was later shown to be used by 
other intracellular parasites (60, 75, 80), and proven to be an important mechanism allowing 
intracellular parasites to survive in infected macrophages. The inhibition of phagosome-lysosome 
fusion by M. tuberculosis was later suggested to be due to the production of copious amounts of 
ammonia by the bacilli, which alkalinises the phagosome, preventing its fusion with late endocytic 
compartments (67). Although it is still not clear what is the mechanism by which ammonia 
prevents phagosome-lysosome fusion, because other bases capable of raising intralysosomal pH 
actually promote phagolysosome fusion (67), due to its capacity to produce significant amounts 
of ammonia, mycobacteria can evade the toxic environment within the lysosome vacuole by 
diminishing the potency of intralysosomal enzymes via alkalinisation. Later, it was shown that the 
exclusion of vacuolar ATPase proton pumps from phagosomes containing mycobacteria provides 
the main mechanism for relative lack of acidification of mycobacterial phagosomes (166).  
Although the mechanisms used by mycobacteria to inhibit phagolysosome formation are 
still not completely understood, it is thought that GTPase Rab family plays an important role. 
Rabs are small GTPases that regulate membrane fusion in eukaryotic cells. The mechanism by 
which Rabs control membrane fusion is still not completely understood (41). Of particular interest 
for mycobacterial phagosomes are Rab5 and Rab7. Rab5 has been strongly implicated in the 
interactions between phagosomes and the endocytic pathway in macrophages (7, 42, 43, 186). 
Rab7 regulates late endosomal membrane trafficking (132) and has been implicated in 
interactions between phagosomes and late endosomal compartments (43). As the phagosome 
matures, it acquires markers of late endocytic organelles such as Rab7 and lysosomal-associated 
membrane protein –1 (LAMP-1), a late endosomal/lysosomal marker, and loses markers of early 
endocytic organelles, such as Rab5 (176). 
M. tuberculosis phagosome was shown to retain Rab5 while excluding Rab7, showing the 
low interaction between phagosome and components of the late endocytic pathway (Reviewed by 
41). However, phagosomes harboring live M. avium or M. tuberculosis acquire LAMP-1 (26, 166, 
192), showing that mycobacterial phagosome fuses with vesicles in a dynamic process, excluding 
others to avoid the harmful effects of acidification. 
 
 The production of reactive intermediates is dependent on the degree of activation of the 
phagocytes. Macrophages, upon activation with appropriate agents, such as IFN-γ and TNF, 
 18 
produce high amounts of NO, the primary reactive product of nitric oxide synthases (NOS), and 
related RNI. NO is produced by different isoforms of the NOS enzyme. Although the three forms 
of NOS are expressed in mammals, NOS2 (also known as iNOS, inducible nitric oxide synthase 
(191)) is the responsible for the high-output production of NO by macrophages (91). NOS2 
protein is only expressed upon activation, being the activation agents dependent on the cell type. 
In mouse peritoneal macrophages, IFN-γ was the only agent shown to be effective when tested 
alone (91). On the other hand, bacterial lipopolysaccharide (LPS) alone is enough for the 
activation of NOS2 in the murine macrophage-like cell line RAW264.7 (91). However, the synergy 
afforded by the combination of TNF with any of the interferons is particularly important, because 
ingestion of most microbes elicits autocrine production and action of both TNF and IFN-α/β (91). 
In this context, another important example of synergy is that between IFN-γ and LPS (191), being 
LPS a strong inducer of TNF and IFNα/β production by macrophages (91). The physiological 
relevance of IFN-γ as an inducer of NOS2 is evident in the difficulty with which NOS2 is 
expressed in the macrophages of mice rendered deficient in IFN-γ (34) or its receptor (76). The 
biological relevance of NOS2 was already tested for a high number of pathogens by using NOS2 
deficient mice or by using nontoxic compounds that inhibit this class of enzymes (91). The high-
output NO pathway in macrophages has been shown to be detrimental for the host in some 
infections, due to the immunosuppressive properties of NO, but in most cases, its inhibition leads 
to an exacerbation of the infection (91).  
The significance of these toxic nitrogen intermediates in the host defence against 
mycobacterial infections is very well documented in the literature, both in vitro and in vivo, 
particularly in the murine system (58). In fact, to date, the only mechanism by which 
macrophages have been shown to kill M. tuberculosis is the generation of RNI via the NOS2 
enzyme (reviewed in 148). However the sensitivity to RNI by mycobacteria is species-dependent. 
M. avium, for instance, has been shown to be resistant to RNI (11). In fact, NOS2 deficient mice 
were shown to be more efficient clearing M. avium infection when compared with wild-type mice 
(63).  
 Although the importance of macrophage’s RNI in the host defence against some species 
of mycobacteria is proven, the role of ROI seems to be not as important. In fact, mycobacteria 
are capable of evading the toxic effect of ROI by different means (24). For instance, 
lipoarabinomannan (LAM) in the mycobacterial wall is a potent ROI scavenger. The production of 
catalase, that converts hydrogen peroxide in water, may also play a role in mycobacterial 
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virulence (93, 140). Even though, mice deficient in the nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase complex, responsible for ROI production in the macrophage 
phagosome, are slightly more susceptible to M. tuberculosis infection (3, 31). Therefore, the 
protective role of ROI in the host defence against M. tuberculosis can not be excluded.  
 
 Although different, these mechanisms act together, upon macrophage activation, in order 
to kill phagocytosed mycobacteria. The bacteriostatic activity of nitrites (a moderately stable anion 
formed by the reaction of NO, in water, with oxygen), is acidic-dependent, reflecting the formation 
of nitrous acid that dismutes in NO. These findings have impact on the milieu within 
phagolysosomes of activated macrophages, where low pH could serve to catalyze the recovery of 
NO and where low pH per se may help restrict microbial growth in conjunction with NO or its 
derivatives (91). Accordingly, M. tuberculosis and M. ulcerans were shown to be sensitive to 
acidic NaNO2 (122, 125). NO, by reacting with ROI, might become a more potent product. For 
example, the product of O2- and NO, peroxynitrite (ONOO-) has been shown to have a potent 
bactericidal activity against Salmonella enterica typhimurium (36) and Escherichia coli (114).  
 
1.6.4.     ADAPTIVE IMMUNE RESPONSES TO M. ULCERANS 
Pathogenic mycobacteria are the classical example of infectious agents for which the 
protective response relies on CMI. This is because, as stated before, mycobacteria are found and 
proliferate inside cells, mainly the macrophage, so that T cell-associated macrophage effector 
mechanisms rather than antibodies are required to control the infection. 
 Of the T cells involved in antimycobacterial effector mechanisms, the CD4+ subset is the 
most important. The important role of this T cell population in the defence against mycobacterial 
infections is supported by epidemiological evidences, showing the huge number of tuberculosis 
cases associated with human immunodeficiency virus (HIV) infections. In fact, M. tuberculosis is 
the most common opportunistic agent associated with HIV. Accordingly, HIV+ purified protein 
derivative (PPD)+ patients have 8–10% annual risk of developing active tuberculosis, compared to 
a 10% lifetime risk for PPD+ HIV- patients (58). Murine studies have shown, by antibody depletion 
of CD4+ T cells, adoptive transfer, or the use of gene-disrupted mice, that the CD4+ T cell subset 
is required for the control of mycobacterial infections (reviewed by 58).  
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 The main effector function of CD4+ T cells in mycobacterial infections is the production of 
IFN-γ that, in turn, will activate the macrophage functions described above, to control or eliminate 
the intracellular pathogen. This phenotype of cells is called T helper (Th) 1 and is dependent on 
IL-12 to develop. Another phenotype of cells, Th2, is dependent on IL-4 to develop and is very 
important for the control of extracellular parasites, since Th2 cells promote humoral immune 
responses, with the production of IgG1 and IgE (106).  
 
 Unlike tuberculosis or leprosy, only a limited number of studies were reported in animal 
models of BU designed to study the interaction of M. ulcerans with the different cell populations 
of the immune system. The most relevant data, to be discussed bellow, on the characteristics of 
the immune response against M. ulcerans, have been gathered from BU patients and healthy 
household contacts of BU patients from Africa, Australia and South America.  
 As for other mycobacterioses, studies with BU patients suggest that the macrophage-
activating cytokine IFN-γ is very important for the control of M. ulcerans infection. In fact, 
peripheral blood mononuclear cells (PBMC) from BU patients, but not from healthy contacts, 
display a low capacity to produce IFN-γ after in vitro stimulation with M. ulcerans bacilli (65, 
133). Using PCR, Gooding and colleagues have shown the expression of Th2 cytokines (IL-4, -5, -
6) and IL-10 by PMBC from BU patients (66). On the contrary, PBMC from healthy household 
contacts of BU patients showed a predominant expression of Th1 cytokines, mainly IFN-γ (65, 
66). These results were, however, only partially confirmed by Prevot and colleagues (133). These 
authors could not find Th2 cytokine expression in BU patients, but they did confirm that the 
expression of IL-10 was higher in BU patients than in healthy household contacts (133). 
Subsequent analyses of cytokine expression in nodular or ulcerative BU lesions showed a higher 
expression of IFN-γ and lower expression of IL-10 in the less severe nodular forms in contrast 
with lower expression of IFN-γ and higher expression of IL-10 in the ulcerative lesions (133). The 
expression of IL-10 may be associated to the development of severe forms of the disease, since it 
is well known that IL-10 is a powerful downregulator of IFN-γ production. In fact, it was 
hypothesized that mycolactone could stimulate the production of IL-10 in the skin (77). 
 In a more recent study, Phillips and colleagues reported findings that contradict the 
various observations since they found a lower expression of IFN-γ in BU patients with nodular 
lesions, although in some cases the production of this cytokine was above the median when 
compared with the group of ulcerative lesions (123). The suggestion of Prevot and colleagues 
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(133) that IL-10, and not Th2 cytokines, was responsible for the low IFN-γ responses in BU 
patients was also not confirmed by Phillips and colleagues (123), since patients with the nodular 
forms of the disease did show low IFN-γ responses in the presence of higher IL-10 responses, but 
patients with ulcerative disease had the highest IL-10 responses and, at the same time, showed 
high IFN-γ expression (123). In fact, these authors did not find any inverse correlation between 
IFN-γ and IL-10 (123).  
 Overall, this set of results suggests, but not prove, a protective role for the Th1 type of 
response in the control of M. ulcerans proliferation. This interpretation is in accordance with the 
reports of patients with progressive noncontrolled lesions being irresponsive to M. ulcerans 
derived antigens (burulin) on skin testing (159). Conversely, when spontaneous healing occurs, 
the burulin test tends to change from negative to positive (44, 99), indicating that a specific cell-
mediated response has developed.  
If the control of BU is determined by the ability of the host to mount a protective cell-
mediated response, it would be expected that HIV co-infection would influence its course. Some 
authors suggest that HIV infection may facilitate multifocal aggressive forms of BU (79, 177), but 
no long-term studies have been published to investigate an association between HIV infection and 
BU. The studies done so far have reported a low number of co-infections with M. ulcerans and 
HIV, being therefore, insufficient to draw a conclusion (6, 13, 40). 
  
1.7. CONTROL OF BURULI ULCER 
 
1.7.1.     GENERAL MEASURES 
BU has often been referred as a “disease of the poor” affecting, mainly, poor populations 
in remote rural areas where modern medical facilities are lacking. As other neglected tropical 
diseases, BU is treatable. However, the treatment can be very expensive, especially in later 
stages of the disease, with prolonged hospitalization, depending on the severity of the cases and 
time of presentation (13). Therefore, precautionary measures to prevent new cases of BU and to 
limit the spread of the disease in poor rural areas, where the cost of the treatment could pose a 
serious challenge to a struggling economy, are essential.  
One of the problems of applying precautionary measures in endemic areas is the fact 
that the means of transmission of M. ulcerans are still not completely known. Nonetheless, the 
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disease has been associated with water bodies, like slow flowing rivers, ponds, swamps or lakes; 
one of the precautionary measures that have been recommended is limiting contact of the 
population with this possible environmental source of M. ulcerans (45). However, this could be 
difficult to implement since these populations depend of the water courses for their daily 
activities, such as farming. The wearing of trousers and long sleeved shirts when on farms or 
swamps was shown to be effective to prevent BU (77, 99, 182). However, this is only a partial 
solution since the infection can affect every part of the body, including the face. 
Another important measure is the diagnosis of the disease. In endemic areas, most BU 
cases are diagnosed on clinical evidence (183) and a number of diseases can be confused with 
BU disease in each of its clinical stages. The diagnostic tests used to confirm BU are: (i) 
detection of M. ulcerans AFBs in smears stained with the Ziehl-Neelsen technique; (ii) positive 
culture of M. ulcerans; (iii) positive PCR for the detection of M. ulcerans DNA; and (iv) 
histopathological analysis of biopsy specimens. These tests vary in sensitivity, specificity, speed 
and cost, and in some cases can only be performed in reference laboratories, far from endemic 
areas (http://www.who.int/buruli/information/antibiotics/en/index1.html). A recently developed 
dry-reagent-based PCR has been developed that may be used in hospital laboratories in endemic 
countries (152). Therefore, simple and rapid diagnostic field tests are required in endemic areas 
to detect and treat BU in early stages. 
Education is very important in small rural communities as a precautionary measure (45). 
People in the community, due to fear of surgery or amputation, seek help from local healers. 
Education of these communities should focus on detection of early forms of the disease so that 
they can be treated without extensive surgery. Additionally, patients should be convinced that BU 
is a result of a mycobacterial infection rather than a result of sorcery (45).  
 
1.7.2.     VACCINATION 
At the present time, there is no specific vaccine against M. ulcerans infection. However, 
evidence from the literature suggests that M. bovis BCG confers some protection against M. 
ulcerans. BCG is a live attenuated strain of M. bovis that was derived from a virulent strain of M. 
bovis by continuous in vitro passages, being currently the only vaccine available against 
tuberculosis. 
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The first report on the protective effect of BCG against M. ulcerans infection was by 
Fenner in 1957 (53). In an experimental mouse model, the footpad or intravenous BCG 
administration conferred considerable protection against a small infectious dose, but only a 
reduced protection against a large dose of M. ulcerans given in the contralateral footpad (53).  
In the first clinical trial conducted by the Uganda Buruli Group at the Kyniara refugee’s 
settlement, a total of 2075 individuals were included in the study. Of the 1230 subjects with a 
negative tuberculin skin test, 606 received a BCG vaccination and 624 were left unvaccinated.  
From May 1967 to September 1968, a total of 79 new cases of BU were detected, 65 of them in 
the group of negative tuberculin skin test. In this clinical trial, the authors reported a protection 
rate of 47%. Of the 65 patients with a negative tuberculin skin test to whom BU was diagnosed 
during the period of the study, 21 had received the BCG vaccine, whereas 44 were unvaccinated 
(172). However, the protective effect seemed to be short lived, being only detected on the first 6 
mounts after vaccination. During the follow up, 73 of the 79 lesions in the population presented 
as pre-ulcerative lesions. Interestingly, 5 of the 6 ulcerated lesions were in the nonvacinated 
group and 1 in the BCG-vaccinated group (172), suggesting that BCG could offer some protection 
against that severe form of BU. However, the number of patients was too low to draw a reliable 
conclusion. In another study, Amofah and colleagues found that BCG vaccinated BU patients had 
a shorter duration of the ulcer when compared with non-BCG vaccinated patients (9). 
In a different trial in Uganda, BCG vaccination was shown to confer a similar degree of 
protection as that found in the previous study with an overall protection of 47% (157). 
Additionally, lesions developing in the vaccinated group, or in those with initial positive tuberculin 
reactions, were smaller than those in unvaccinated persons. This study also confirmed the short-
lived protective effect, since BCG offered no protection after the first year of vaccination (157). 
BCG is known to protect against the disseminated extrapulmonary forms of tuberculosis 
in young children (28, 88, 107, 180), but it is not very effective protecting against pulmonary 
tuberculosis in adults (28, 29, 55, 56, 160). In BU, BCG seems to confer a higher degree of 
protection against the severe form osteomyelitis in children (127). In a group of BU patients from 
Benin, Portaels and colleagues have shown that only 8,7% of children under 15 years old with 
BCG scar had osteomyelitis, while 25% of children that did not have BCG scar had osteomyelitis. 
In the adult’s group with BCG scar, 15,7% had osteomyelitis, while 35% that did not have BCG 
scar had osteomyelitis. These results suggest that effective BCG vaccination at birth provides 
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significant protection against the development of M. ulcerans osteomyelitis in children and adults 
(127). 
Although BCG is the most widely used vaccine in the world, the protection it affords 
against tuberculosis ranges only from 0-80%, depending on the geographical region (28, 29, 55, 
56, 160). In recent years, new vaccines have been developed against tuberculosis, with 
promising results as compared with the classical BCG vaccine. The search for a new vaccine 
against tuberculosis is centralized in two categories: improving BCG as a vaccine and developing 
sub-unit vaccines, containing purified immunodominant antigens rather than an entire organism. 
Improved BCG vaccines have never been tested in M. ulcerans infection; however the use of a 
DNA vaccine encoding the Antigen 85 (Ag85) of M. bovis BCG showed to induce strong 
proliferative Th1 type cytokine responses upon stimulation of cells with BCG or its purified Ag85 
complex, in the mouse model (168). Tanghe and colleagues showed also that this vaccine, like 
BCG, could reduce significantly the bacterial load in the footpads of M. ulcerans infected mice 
(168). However, the kinetics of M. ulcerans growth in vaccinated animals would be necessary to 
disclose if the protective effect is lost over time, like it happens with BCG.  
Although M. ulcerans, M. tuberculosis and M. bovis BCG share a large number of highly 
conserved antigens, even small sequence changes can result in the loss of immunodominant 
epitopes. Therefore, it was speculated that an attenuated vaccine based on M. ulcerans could 
offer a better and more specific protection than BCG (77). However, this hypothesis remains to 
be proven. 
 
Being Naucoridae insect bites a possible mode of M. ulcerans transmission (97), 
Marsollier and colleagues (96) hypothesized that Naucoridae salivary proteins, that were shown 
to cover bacilli transmitted to mice by M. ulcerans-infected insects, could be used to develop a 
vaccine against BU. Indeed, the authors found that mice repeatedly bitten by M. ulcerans-free 
insects became protected and thus, when these mice were exposed to bites by insects 
harbouring M. ulcerans, pre-ulcerative and ulcerative lesions did not develop. Although this 
protective status did not prevent M. ulcerans from proliferating, the bacterial loads were two log10 
lower than in control animals. Moreover, these authors showed that the presence of human 
antibodies against insect salivary proteins was an immune signature correlating with protection in 
areas in which BU is endemic (96). However, the relevance and contribution of insect biting in 
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the transmission of M. ulcerans still is not known and thus whether or not a vaccine based on 
insect salivary proteins could be useful against BU awaits further studies (153).  
The development of a better or specific vaccine against BU is urgent to prevent a 
devastating disease with serious complications and high treatment costs that pose a serious 
challenge to a struggling rural economy and its health system. 
 
1.8. TREATMENT OF BURULI ULCER  
Different therapeutic strategies have been attempted to treat BU, including surgical 
excision of the lesion, antibiotic therapy and hyperbaric oxygenation or elevation of the 
temperature in the lesion (155). Some of these treatments, although effective to treat BU without 
surgical excision, that in certain situations can lead to lifetime scars and disabilities, have never 
been widely used due to the lack of controlled trials, and the high costs. 
 
1.8.1.     SURGICAL EXCISION 
The treatment of the early phases of the disease by surgical excision of the nodule, under 
local anaesthesia, is curative (183). Unfortunately, many patients do not present until there is 
extensive and disfiguring ulceration, when there is no alternative but wide excision followed by 
skin-grafting, and sometimes even amputation (190). 
Surgical excision of the ulcerative lesion is indeed more complicate, especially if 
extensive contractures, ankylosis caused by ulceration or fibrosis involving joints are seen. In 
these cases, physiotherapy or plastic surgery may be required.  Standard recommendations 
include that all necrotic tissue is excised, until normal skin and subcutaneous tissue are reached 
(189). However, relapses are not infrequent. Teelken and colleagues showed that relapse after 
surgery may occur in 15-47% of cases (169) and thus the WHO now recommends the use of 
selected antibiotics combined with surgery to prevent relapses of BU (78), as discussed below.  
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1.8.2.     ANTIMICROBIAL CHEMOTHERAPY 
Although M. ulcerans is sensitive to most antimycobacterial drugs in vitro, including 
some aminoglycosides, ethambutol, rifampicin, and clarithromycin (131), the use of drugs to 
treat BU has been disappointing, especially in ulcerative cases of the disease (183). Controlled 
trials in humans suggest that both clofazamine (138) and cotrimoxazole (51) are ineffective for 
ulcers and that also rifampin and dapsone combined have limited efficacy for ulcerative lesions 
(48). Combinations of rifampin with either streptomycin or amikacin, in the mouse footpad model 
of infection, have shown to be effective, with the size of the mouse footpad decreasing 
progressively, reduction of the mean colony forming units (CFU) counts and with no relapses (38, 
39). A human trial has recently showed that early nodular lesions may be rendered culture 
negative after a minimum of 4 weeks therapy with rifampicin plus streptomycin (49). 
Based on these successful reports and some observational studies, provisional WHO 
guidelines now recommend the treatment of BU with a combination of rifampicin and 
streptomycin for eight weeks, as a first-line treatment for all forms of the active disease 
(http://www.who.int/buruli/information/antibiotics/en/index1.html). With this regimen, it is 
expected to reduce the indications of surgery or, at least, the extent of surgery and also to 
decrease the relapse rate (155). 
 
1.8.3.     ALTERNATIVE TREATMENTS 
 Since M. ulcerans optimal growth temperature is 32-33ºC, it does not affect internal 
organs and therefore the skin is the affected organ, with the exception of bone involvement in 
cases of osteomyelitis. Treatments have been tried in several patients by applying heat to the 
skin lesion, to maintain a local temperature of approximately 40ºC. These patients did not require 
subsequent surgery and all lesions healed without local recurrences (101). In the same way, M. 
ulcerans growth, in vitro, is impaired at high oxygen partial pressures (116). Therefore, 
hyperbaric oxygenation was suggested as an alternative therapeutic approach, and showed to be 
effective to treat M. ulcerans infection in mice (85, 86).  
Although these treatments have been found to be effective in a limited number of 
patients, and apart from the high cost that may render them impracticable in endemic areas, 
evidence of efficacy from control trials is lacking (183). 
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1.9. EXPERIMENTAL MODELS TO STUDY M. ULCERANS INFECTION 
Experimental models are necessary to study the mechanisms of natural resistance and 
the formation of acquired protective immunity against mycobacteria, since it is difficult to work 
with human material, and there are several ethical problems associated with this. M. ulcerans is 
no exception. Moreover, the use of experimental models is essential to understand the initial 
steps of the immune response against M. ulcerans. Indeed, being M. ulcerans infections 
acquired from the environment, and the disease developing for some time without any signs, BU 
patients usually seek medical advice at later stages of the disease, many times after traditional 
treatment has failed. Therefore, samples from humans shortly after infection with M. ulcerans are 
usually unavailable and critical aspects of the interaction of M. ulcerans with cells of the innate 
immune system may be lost.  
 
1.9.1.     IN VITRO MODELS 
As discussed before, M. ulcerans infection is probably acquired through a lesion in the 
skin or a water bug bite. Being macrophages resident cells of different tissues, it is most likely 
these are the cells that first contact with M. ulcerans and start the events of the immune 
response. Therefore, the study of mycobacteria-macrophage interactions is obviously a priority.  
Different studies have been done in vitro to understand the interaction M. ulcerans-
macrophages. Since it is still not known if M. ulcerans is able to grow inside macrophages, as it 
happens with the related mycobacteria M. marinum and M. tuberculosis, Rastogi and colleagues 
used a model of M. ulcerans infection in the macrophage cell line J774A.1 to study in vitro the 
intramacrophagic growth of the bacilli (136). These authors did not find significant growth of M. 
ulcerans when macrophages were infected with the high multiplicity of infection (MOI) of 10:1 
(bacilli/macrophage ratio). In a more recent study, Adusumilli and colleagues suggested that 
both WT and mycolactone-negative mutant M. ulcerans strains could survive in J774A.1 
macrophages. However, infection with the WT strain at an MOI of 10:1 resulted in destruction of 
90% of the monolayer after two days of infection (4). 
Although cell lines are a common model to study mycobacteria-macrophage interactions, 
these cells are genetically altered, and multiply at fast rates, unlike macrophages in vivo.  A most 
widely used model of cell infection is the in vitro culture of bone marrow-derived macrophages 
(BMDM). These macrophages are derived in vitro from the bone marrow precursors by using L-
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cell conditioning medium. This way, it is possible to obtain a pure and homogeneous population 
of primary macrophages (161). In vitro, these cells maintain their effector functions and respond 
to IFN-γ activation by producing RNI and ROI. This population of macrophages was suggested to 
phagocytose M. ulcerans in vitro (33). BMDM were also used to study the expression of cytokines 
after infection with mycolactone-positive or negative strains of M. ulcerans (33).  
More studies are although necessary to understand the interactions M. ulcerans-
macrophages: what molecules are required to control M. ulcerans proliferation and how IFN-γ 
that, as discussed above, was suggested to be important for the control of M. ulcerans, acts on 
the macrophage to inhibit M. ulcerans proliferation.  
 
1.9.2.     IN VIVO MODELS 
There is no widely accepted animal model for M. ulcerans infection, although many have 
been used, including mice (52), rabbits (90), guinea pigs (61, 62, 84), calves (135), anole lizards 
(94),  and nine-banded armadillos (187). 
  
The mouse is the most frequently used animal model to study the immune response to 
mycobacteria, given the huge database of reagents now available, including antibodies to 
lymphocyte markers, and the growing number of available gene-disrupted strains. Although mice 
and humans have some known immunological differences (100), this model has been providing 
very useful information towards a better understanding of the infectious process in other 
mycobacterial infections, such as tuberculosis (57). 
  In the same way as M. leprae, M. ulcerans murine experimental infection is usually 
carried out in the footpad, given its optimal growth temperature of 32ºC. The mouse footpad 
model of M. ulcerans infection was first used by Fenner (52). Since then, this model was shown 
to be useful to screen the virulence of different M. ulcerans isolates, by their capacity to induce 
footpad swelling (111, 137), and to test in vivo the efficacy of several antimycobacterial drugs 
against M. ulcerans (20, 39). Oliveira and colleagues used the mouse model to evaluate the 
different stages of the M. ulcerans experimental infection and associated inflammatory response 
(111). As discussed above, the immune response against M. ulcerans is poorly known and, due 
to the high availability of knock-out inbred mouse strains, it will be very important to determine in 
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this model the biological role of different cell populations, as well as cytokines and chemokines, 
in the immune response to M. ulcerans. 
 Another animal model widely used for research on M. ulcerans experimental infection is 
the guinea pig. However, few immunological reagents are available for guinea pigs, which limit 
the ability to perform definitive experimentation. Even though, this model was used to study the 
inflammatory response after M. ulcerans infection. Microscopic changes induced by M. ulcerans 
in guinea pigs were shown to be similar to those of early human infection, proving the usefulness 
of this animal model (137). The important role of a toxin in the pathogenesis of M. ulcerans was 
shown for the first time in this model (84) before the eventual confirmation by the isolation of 
purified mycolactone (61). 
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Mycobacterium ulcerans is the etiologic agent of Buruli ulcer (BU), an emerging tropical skin disease. Virulent
M. ulcerans secretes mycolactone, a cytotoxic exotoxin with a key pathogenic role. M. ulcerans in biopsy
specimens has been described as an extracellular bacillus. In vitro assays have suggested a mycolactone-
induced inhibition ofM. ulcerans uptake by macrophages in which its proliferation has not been demonstrated.
Therefore, and uniquely for a mycobacterium, M. ulcerans has been classified as an extracellular pathogen. In
specimens from patients and in mouse footpad lesions, extracellular bacilli were concentrated in central
necrotic acellular areas; however, we found bacilli within macrophages in surrounding inflammatory infil-
trates. We demonstrated that mycolactone-producing M. ulcerans isolates are efficiently phagocytosed by
murine macrophages, indicating that the extracellular location of M. ulcerans is not a result of inhibition of
phagocytosis. Additionally, we found that M. ulcerans multiplies inside cultured mouse macrophages when low
multiplicities of infection are used to prevent early mycolactone-associated cytotoxicity. Following the prolif-
eration phase within macrophages, M. ulcerans induces the lysis of the infected host cells, becoming extracel-
lular. Our data show that M. ulcerans, like M. tuberculosis, is an intracellular parasite with phases of intram-
acrophage and extracellular multiplication. The occurrence of an intramacrophage phase is in accordance with
the development of cell-mediated and delayed-type hypersensitivity responses in BU patients.
Mycobacterium ulcerans is the etiologic agent of Buruli ulcer
(BU), an emerging, devastating, difficult-to-treat skin disease
reported in many countries, mostly in tropical areas (16), and
BU has become the third most common mycobacterial infec-
tion in humans after tuberculosis and leprosy. BU assumes
various nonulcerative clinical forms that can progress to ulcers.
M. ulcerans (26, 41, 47, 59), M. tuberculosis (24, 38, 42), M.
marinum (25, 57), and M. haemophilum (23) are known to have
cytotoxic activity, M. ulcerans being the most cytotoxic of all
known mycobacteria. The M. ulcerans toxin is a mycolactone, a
unique polyketide lipid exotoxin that has a potent destructive
activity for cells that provokes the extensive necrotic lesions
characteristic of BU (26). Mycolactone is considered to be the
major virulence factor of this pathogen (1, 26, 41).
Intracellular parasites are defined on the basis of their life-
styles in the infected hosts and of the types of immune re-
sponses elicited (7, 37): they live and multiply predominantly
within host cells, typically macrophages, and therefore are able
to survive and grow within cultured macrophages. The host
immune response against intramacrophage parasites involves
mechanisms of cell-mediated immunity (CMI) accompanied by
delayed-type hypersensitivity (DTH).
Genetic analysis places M. ulcerans very close to M. marinum
and M. tuberculosis (71), two species of mycobacteria that are
typical intracellular parasites that grow within macrophages in
vivo (7, 12, 15, 31) and in vitro (25, 42, 45, 57, 58, 66) and elicit
CMI and DTH responses (7, 9, 12, 14, 15, 18, 46, 72). Several
reports indicate that M. ulcerans infections are also associated,
at least at some stage of the disease, with CMI and DTH (18,
27, 28, 33, 39, 43, 44, 50, 54, 56, 61, 67, 68, 70, 74), strongly
suggesting the existence of an intracellular phase in the life
cycle of M. ulcerans inside macrophages. It is therefore intrigu-
ing that M. ulcerans has been described as an extracellular
pathogen in humans and experimentally infected animals (1,
11, 12, 17, 26, 29, 33, 52), implying that this organism is an
exception among pathogenic mycobacteria (12).
The interpretation that M. ulcerans is an extracellular patho-
gen stems mainly from reports that BU tissues show predom-
inantly free bacilli in extensive necrotic acellular areas (8, 17,
20, 29, 35). Other arguments advanced in support of that in-
terpretation are that (i) M. ulcerans and mycolactone, under
some in vitro conditions, inhibit the phagocytic activity of mac-
rophages (1, 13, 55, 58) and (ii) M. ulcerans fails to grow within
macrophages in vitro (1, 58).
The observation that extracellular acid-fast bacilli (AFB)
predominate in necrotic areas devoid of cells has also led to the
concept that the total absence of, or only minimal, inflamma-
tion is typical of M. ulcerans infections (11, 17, 29, 33, 35).
Although such a histopathological pattern is a diagnostic hall-
mark of BU, it may not reflect the actual host-parasite inter-
actions at the active foci of infection in patients with BU,
interactions that so far have not been analyzed in detail. How-
ever, a recent publication (32) reported inflammatory infil-
trates with neutrophils and mononuclear cells in 92% of 78 BU
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specimens with AFB, but no description of the relative loca-
tions of bacilli and inflammatory cells was given. Additionally,
we have recently described the consistent occurrence of in-
flammatory infiltrates with neutrophils and macrophages in the
mouse model, with M. ulcerans bacilli colocalizing with the
phagocytic cells and extracellular bacilli in necrotic acellular
areas (51). Other, earlier investigators have reported bacilli
within macrophages in experimental M. ulcerans infections (21,
41, 59). In this context, it is worth recalling that the initial
description of BU noted large numbers of bacilli within phago-
cytes (43).
Because M. ulcerans infections are associated with CMI and
DTH responses, and because of our previous observations with
mice, we postulated that M. ulcerans would be an intracellular
pathogen with a phase of extracellular existence.
The objective of the present work is to clarify the lifestyle of
M. ulcerans by reevaluating M. ulcerans-phagocyte interactions
in BU tissues, mouse tissues, and cultured macrophages. One
advantage of the mouse footpad model is that it is possible to
systematically observe the entire lesion and surrounding
healthy tissues even in advanced infections. We complemented
these observations with in vitro studies involving the interac-
tions of M. ulcerans with mouse bone marrow-derived macro-
phages (BMDM) and with the macrophage cell line J774A.1.
Our results show that, in a considerable percentage of BU
biopsy specimens containing AFB and inflammatory infiltrates,
intramacrophage mycobacteria are present in the infiltrates at
the peripheries of the necrotic acellular areas. In this model of
infection, we also found that virulent mycolactone-producing
strains of M. ulcerans are efficiently phagocytosed by macro-
phages in vitro and in vivo, can be found within macrophages
during the entire course of infection, and grow intracellularly
within cultured macrophages. These data show that M. ulcer-
ans, like M. tuberculosis, is an intracellular parasite with phases
of extracellular and intramacrophage multiplication.
MATERIALS AND METHODS
BU biopsy specimens. We studied 24 paraffin-embedded biopsy specimens
from African patients with ulcerative or nonulcerative BU lesions, confirmed by
histopathological features and the presence of AFB, from the pathology archives
of the Armed Forces Institute of Pathology, Washington, DC. Serial sections of
the entire specimens were viewed under the Olympus BX61 light microscope
following staining with Ziehl-Neelsen stain (ZN; Merck, Darmstadt, Germany)
and hematoxylin (Merck) or methylene blue.
For the isolation of M. ulcerans from BU samples, the tissues (1 g) were
homogenized in 1 ml saline, decontaminated, and inoculated onto Lo¨wenstein-
Jensen medium. The inoculated tubes were incubated for up to 12 months at
33°C and were observed weekly. For detection of the RD1 gene cluster, primers
for esxA (Esat-6, 5-GACAGAACAGCAGTGGAATTTCG-3 and 5-CTTCT
GCTGCACACCCTGGTA-3) and esxB (Cfp-10, 5-TTTTGAAGAACGATGC
CGCTAC-3 and 5-TGACGGATGTTCGTCGAAATC-3) were used (48). “M.
liflandii” ITM04-3050 and M. ulcerans ITM00-1240 were used as positive and
negative controls, respectively.
Mycobacterial strains and preparation of inocula for experimental work. M.
ulcerans strains were selected based on different degrees of virulence in mice. M.
ulcerans 98-912 and 97-1116 are highly virulent, and strain 5114 is avirulent (51).
The origins and genetic and phenotypic characteristics of strains 98-912 and 5114
have been previously described in detail (51). Strain 5114 contains the RD1 gene
cluster (48) and does not produce mycolactones (47, 69). Strain 97-1116 pro-
duces mycolactones A and B (47), and we found it to lack the RD1 gene cluster,
as is typical of African strains (48). Strain 98-912 possesses the RD1 gene cluster
(48) and produces mycolactones A and B slightly different from those in African
strains (34). For the determination of the percentage of phagocytosis, M. tuber-
culosis H37Rv and M. bovis BCG Pasteur were used as controls. M. tuberculosis
possesses RD1, and M. bovis BCG lacks this gene cluster (6).
The M. ulcerans strains were grown on Lo¨wenstein-Jensen medium at 32°C for
approximately 2 months, recovered from slants, diluted in phosphate-buffered
saline to a final concentration of 1 mg/ml, and vortexed by using 2-mm-diameter
glass beads. The number of AFB in the inocula was determined by the method
of Shepard and McRae (62) using ZN. The final suspensions revealed more than
90% of the cells to be viable as assessed with the LIVE/DEAD BacLight kit
(Molecular Probes, Leiden, The Netherlands).
Animals. Eight-week-old female BALB/c mice were obtained from Charles
River (Barcelona, Spain) and were housed under specific-pathogen-free condi-
tions with food and water ad libitum.
Peritoneal model of infection. Mice were infected in the peritoneal cavity with
0.1 ml of M. ulcerans suspensions containing 7 log10 AFB of M. ulcerans strain
98-912, 97-1116, or 5114. Phosphate-buffered saline was used as a control. At
different time points after infection, four mice per group were sacrificed and
peritoneal cells were recovered for cytospin preparations by peritoneal lavage.
Cytospin preparations were fixed with 10% Formol in ethanol, stained with ZN,
and counterstained with Hemacolor (Merck).
Footpad model of infection. Mice were infected in the left hind footpad with
0.03 ml of suspensions containing 6 log10 AFB of M. ulcerans 98-912 or 97-1116.
The right hind footpad was used as a control.
Culture of murine BMDM and J774A.1 macrophage cell line. BMDM were
prepared as previously described (51). For AFB counting and light microscopy
analysis, BMDM were seeded in 24-well plates at a density of 5  105 cells/well;
for electron microscopy, BMDM were seeded in 6-well plates at a density of
3.5  106 cells/well. The plates were kept at 37°C in a 5% CO2 atmosphere.
Twelve hours before infection, macrophages were incubated at 32°C in a 5% CO2
atmosphere and maintained under these conditions thereafter.
Because BMDM survive in vitro for only a short time, the macrophage cell line
J774A.1 was used for longer experimental infections. The J774A.1 mouse mac-
rophage cell line was seeded in 12-well plates at a density of 2  105 cells/well
and incubated at 37°C for 12 h to allow macrophage adherence. Cells were then
washed with Dulbecco modified Eagle medium (DMEM) and incubated at 32°C
in a 5% CO2 atmosphere and maintained in these conditions thereafter.
Macrophage infectivity assays. Bacterial suspensions were further diluted in
DMEM to obtain the selected multiplicity of infection (MOI; bacterium/macro-
phage ratio). For the assessment of phagocytosis and of intramacrophage growth
of M. ulcerans, BMDM and J774A.1 cells were infected with the appropriate
number of bacilli and incubated for 4 h at 32°C in a 5% CO2 atmosphere and
then washed with warm Hank’s balanced salt solution to remove noninternalized
bacteria. For growth experiments, the macrophages were reincubated at 32°C in
DMEM for maximum periods of 8 and 15 days, respectively. At 7 and 10 days
after infection, J774A.1 cultures were supplemented with fresh medium by add-
ing 1 ml of DMEM per well.
Since the M. ulcerans strains used in this study were found to grow in DMEM
and to be susceptible to 20 g/ml of amikacin (data not shown), this concentra-
tion of amikacin (Sigma, St. Louis, MO) was added to the culture wells after
infection and kept during the whole period of the experiment to prevent extra-
cellular M. ulcerans growth (45, 57).
To evaluate the intramacrophage growth of M. ulcerans, AFB were counted as
follows: macrophages were lysed with 0.1% saponin (final concentration; Sigma),
the suspensions were homogenized with 2-mm glass beads, and the AFB were
counted (62). Monolayers were not washed previous to AFB counting to avoid
losing nonadherent or loosely adherent cells.
Cytological analysis. Adhesion of BMDM was carried out on 13-mm-diameter
plastic coverslips (Nunc, Naperville, IL) in 24-well plates. For cytological anal-
ysis, plastic coverslips were removed and the cells were fixed with 10% Formol in
ethanol, stained with ZN, and counterstained with hematoxylin. Cells were an-
alyzed under a light microscope, and digital images were captured by using an
Olympus DP70 camera (Hamburg, Germany).
To quantify dead macrophages, the trypan blue (Gibco, Paisley, United King-
dom) exclusion assay was employed. J774A.1 macrophages were carefully
scraped off by using a cell scraper, stained, and counted.
For ultrastructural studies, BMDM cultures were processed for electron mi-
croscopy as previously described (63) and viewed and photographed under a
Zeiss EM10 electron microscope (Hallbergmoos, Germany).
Histological studies. Human macrophages were labeled with the antibody
NCL-LN5 (Novocastra, Newcastle, United Kingdom) that specifically stains the
cytoplasm of histocytes and macrophages (5) or with an isotype control antibody.
Briefly, the tissue sections were deparaffinized with xylene, followed by sequen-
tial immersion in graded ethanol solutions and hydration. The sections were
microwave incubated for 15 min with a commercial antigen retrieval solution,
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citrate buffer heat-induced epitope retrieval (Labvision Corporation, Fremont,
CA). Endogenous peroxidase activity was blocked with 3% H2O2 for 10 min, and
primary antibody was added and incubated for 1 h. Slides were developed with
the Ultravision anti-polyvalent horseradish peroxidase ready-to-use detection
system (Labvision Corporation). For diaminobenzidene detection, slides were
incubated with the Ultravision large-volume diaminobenzidene substrate system
(Labvision Corporation).
Excised tissues of mouse footpads were fixed in 10% phosphate-buffered
formalin. Whole paws were decalcified (Thermo Shandon TBD-1; Runcorn,
United Kingdom) and embedded in paraffin. Longitudinal sections of the entire
paw were stained with ZN. For labeling of mouse macrophages, the specific
marker antibody F4/80 or an isotype control antibody was used, according to the
procedure referred to above for immunohistochemical staining. All digital im-
ages were captured by using an Olympus DP70 camera.
The present study was conducted under the guidelines and approval of the
Research Ethics Committee of the Life and Health Sciences Research Institute.
RESULTS
BU biopsy specimens show intramacrophage M. ulcerans
bacilli in inflammatory infiltrates. M. ulcerans has been de-
scribed as an extracellular parasite, an exception among patho-
genic mycobacteria. On the other hand, reports of CMI and
DTH responses to M. ulcerans infections (18, 27, 28, 33, 39, 43,
44, 50, 54, 56, 61, 67, 68, 70, 74) point to an intracellular
residence of M. ulcerans. To reevaluate this issue, we started by
performing histopathological analyses of BU tissues.
Nineteen specimens from the Armed Forces Institute of
Pathology collection from active cases of African BU were
selected based on the presence of AFB and the absence of
secondary infections. Serial sections were searched for inflam-
matory infiltrates and for the localization of AFB in the extra-
cellular and intracellular compartments. Among the 19 cases,
inflammatory infiltrates were observed in 15 (Table 1). This
result agrees with a recent report describing cellular inflam-
matory responses in a high percentage of BU cases (32).
Among the 15 specimens containing inflammatory cells, 8
showed intracellular bacilli (Table 1), as shown for 2 represen-
tative specimens (Fig. 1A to F). In addition, NCL-LN5 anti-
body demonstrated that M. ulcerans bacilli were present within
macrophages (Fig. 1C). The histopathological hallmark of BU,
extracellular bacilli, was found in all cases and was particularly
abundant in the necrotic acellular areas (Fig. 1B), while bacilli
colocalizing with inflammatory cells were found in the infil-
trates at the peripheries of the necrotic areas (Fig. 1A). Some
intracellular bacilli appeared as globus-like structures (Fig. 1F)
or within phagocytes undergoing apoptosis (Fig. 1E).
Detection of the gene cluster RD1 carried out with M. ul-
cerans strains from six of the studied BU specimens, with and
without detectable intracellular bacilli (Table 1), showed that
all these strains were RD1 negative as was previously found
with other M. ulcerans strains isolated from African patients
(48). This result suggests that there is no correlation between
the occurrence of intracellular bacilli and RD1.
Following experimental infections, M. ulcerans bacilli are
phagocytosed by resident macrophages in vivo and by BMDM
and J774A.1 macrophages in vitro. Murine peritoneal leuko-
cyte populations can be readily and precisely studied, and this
model proved useful in the elucidation of host interactions
with several species of mycobacteria (3, 53, 65). We have pre-
viously reported the recruitment of phagocytes to the perito-
neal cavity in response to inoculated M. ulcerans (51). There-
fore, we used this model to study the early interactions of
phagocytes and M. ulcerans.
Microscopic analyses revealed that for all the strains of M.
ulcerans tested (98-912, 97-1116, and 5114), bacilli were phago-
cytosed by resident macrophages and recruited neutrophils
after the first few hours postinfection, as shown in Fig. 2A for
strain 98-912. As previously described for experimental peri-
toneal infections caused by other mycobacteria (65), as well as
the livers of mice infected with Listeria monocytogenes (30) or
TABLE 1. Clinical data and histopathologic features evaluated for human biopsy specimens from patients with active BUa
Origin of specimen Clinical feature Extracellular AFB Inflammation Intracellular AFB RD1
Benin Nonulcerative    ND
Togo Nonulcerative    Negative
Benin Ulcer    ND
Democratic Republic of Congo Ulcer    Negative
Coˆte d’lvoire Ulcer    ND
Benin Nonulcerative    ND
Benin Nonulcerative    Negative
Coˆte d’lvoire Ulcer    ND
Democratic Republic of Congo Ulcer    ND
Democratic Republic of Congo Ulcer    ND
Democratic Republic of Congo Ulcer    ND
Benin Nonulcerative    ND
Benin Nonulcerative    ND
Benin Nonulcerative    Negative
Benin Nonulcerative    Negative
Democratic Republic of Congo Ulcer    ND
Democratic Republic of Congo Ulcer    ND
Benin Ulcer    ND
Benin Ulcer    Negative
Totalb 19 (100) 15 (79) 8 (42)
a , present; , absent; ND, not determined.
b Number of specimens with the indicated characteristic; numbers in parentheses are percentages of the total number of specimens examined.
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Salmonella enterica serovar Typhimurium (60), we found that
neutrophils containing ingested bacilli were progressively
phagocytosed by macrophages so that these bacteria were
eventually taken up by macrophages.
As in our previous study (51), we consistently found intra-
cellular M. ulcerans in the subcutaneous tissue of mouse foot-
pads infected with M. ulcerans when the histological analysis of
the entire footpad was performed. Mycolactone-producing M.
ulcerans bacilli (strains 98-912 and 97-1116) were phagocytosed
by mononuclear phagocytes and neutrophils a few hours post-
inoculation (Fig. 2B) and throughout the entire experimental
period (Fig. 2B to G). The intramacrophage location of M.
ulcerans was confirmed by specific immunohistochemical label-
ing (Fig. 2E). Some infected macrophages contained high
numbers of packed clusters of bacilli, reminiscent of globi seen
in lepromatous leprosy. These structures were seen both within
distended macrophages (Fig. 2G) and free in the extracellular
compartment (Fig. 2F and G), probably following the lysis of
infected macrophages. Such clusters of AFB in BU have been
previously described (10, 43) and were also found by his-
topathological analysis of BU specimens included in the
present study (Fig. 1F). The occurrence of macrophages with
high numbers of packed bacilli is suggestive of intracellular
multiplication, as in the case of M. leprae infections. In the
advanced lesions, the central necrotic acellular areas with high
numbers of extracellular bacilli were prominent (Fig. 2F and
G), but in the boundary between these areas and the surround-
ing inflammatory infiltrates, clumps of extracellular bacilli were
found (Fig. 2F and G). The sizes of the clumps of free bacilli
grew as the distance from the limit of the infiltrated areas
increased (Fig. 2F and G), suggesting extracellular multiplica-
tion of M. ulcerans.
We then established an in vitro model of BMDM infection
at 32°C to study the interactions of M. ulcerans with primary
macrophages. Preliminary studies showed that macrophage vi-
ability, assessed by cell rounding, shrinkage, and detachment
(26), as well as by terminal deoxynucleotidyltransferase-medi-
ated dUTP-biotin nick end labeling staining (51), was compro-
mised at high MOIs when mycolactone-producing, cytotoxic
M. ulcerans strains were tested (not shown). An early cytotoxic
FIG. 1. Intracellular M. ulcerans bacilli are found in specific areas of biopsy specimens from BU patients. The two cases shown (A to C and
D to F) are representative of the human biopsy specimens showing inflammation and intracellular bacilli. (A) Extracellular bacilli are shown in
the necrotic acellular area of the lesion, and bacilli colocalizing with inflammatory cells were found in the peripheral infiltrate. (B) Detail of the
abundant extracellular bacilli in the central acellular area. (C) Specifically stained macrophages with internalized bacilli in the peripheral
inflammatory area. (D to F) High magnifications of the areas containing inflammatory infiltrates colocalizing with AFB show intracellular bacilli
associated with destruction of phagocytes (E) and intracellular, as well as extracellular, globus-like structures (F). Histological sections were stained
with ZN and counterstained with hematoxylin or methylene blue. NCL-LN5 antibody was used to specifically label human macrophages.
Magnifications, 250 (A) and 1,250 (B, C, D, E, and F).
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effect on macrophages was also described for M. tuberculosis
and M. marinum at high MOIs, being absent at an MOI of 1:1
or lower (25, 42, 57). We therefore tested lower MOIs and
found that at an MOI of 1:1 to 1:3, the early cytotoxic effect
was abolished. Microscopic analysis showed that M. ulcerans
98-912, 97-1116, and 5114 were internalized by macrophages as
early as 4 h after infection at a 1:1 MOI, as shown in Fig. 3A
for strain 98-912 (see also Fig. 4E for quantitative data). Ul-
FIG. 2. M. ulcerans is phagocytosed by macrophages and neutrophils in vivo following experimental infections. (A) Cytospin preparations of
mouse peritoneal leukocytes 6 h after inoculation with 7 log10 AFB of M. ulcerans 98-912, stained with ZN and counterstained with Hemacolor.
(B to G) Mouse footpads infected subcutaneously with 6 log10 AFB of M. ulcerans 98-912, collected 24 h (B) and 15 (C to E) and 28 (F and G)
days after infection. (A and B) Bacilli inside neutrophils and macrophages (arrows) early after infection. (C and D) Extracellular bacilli in the
necrotic acellular center of the infection focus (shown in high magnification in panel D), surrounded by inflammatory cells with intracellular bacilli.
(E) Higher magnification of the peripheral area with inflammatory infiltrates shows specific immunohistochemical staining of a macrophage with
internalized bacilli. (F and G) Central acellular necrotic areas and peripheral inflammatory infiltrates in advanced lesions, with both intramac-
rophage and free bacilli, some packed in globus-like structures with intracellular (arrowheads) or extracellular (white asterisks) locations.
Histological sections were stained by ZN and counterstained with methylene blue or hematoxylin. The F4/80 antibody was used to specifically label
murine macrophages. Magnifications, 1,250 (A, B, D, and E), 550 (C and F), and 1,000 (G).
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trastructural analysis confirmed the presence of intramacroph-
age M. ulcerans, including the more-cytotoxic strain 98-912
(Fig. 3B and C). Bacilli were present within spacious (Fig. 4A)
or tight (Fig. 4B and D) phagosomes, as described previously
for other mycobacteria (4). Quantitative assessment of phago-
cytosis of M. ulcerans by BMDM showed that after 4 h at an
MOI of 1:1, 26.3%  7.5% of the inoculum was internalized
for the mycolactone-negative strain 5114; 22.1%  4.2% and
29.9% 8.7% of the bacteria were within macrophages for the
mycolactone-producing strains 98-912 and 97-1116, respec-
tively (Fig. 4E). The phagocytosis index of M. ulcerans at an
MOI of 1:1 in the macrophage murine cell line J774A.1 was
found to be similar to that in BMDM, as shown for strain
97-1116 (Fig. 4E). Similar values were found for M. tuberculosis
H37Rv and M. bovis BCG (30.3% 11.4% and 24.9% 5.7%,
respectively). These results suggest that RD1-positive and
RD1-negative mycobacteria behave similarly regarding phago-
cytosis by BMDM at low MOIs, since M. tuberculosis H37Rv
and M. ulcerans 5114 and 98-912 are RD1 positive (6, 48) and
M. bovis BCG (6) and M. ulcerans 97-1116 (data not shown)
are RD1 negative.
Taken together, these results show that soon after experi-
mental infection with M. ulcerans, irrespective of the cytotox-
icity of the clinical isolate, bacilli are phagocytosed by cultured
macrophages as well as by resident macrophages and recruited
neutrophils in vivo. Furthermore, intramacrophage bacilli are
consistently seen in the inflammatory infiltrates at the periph-
eries of the necrotic acellular areas where extracellular bacilli
accumulate.
M. ulcerans proliferates within cultured macrophages. Fol-
lowing our observation of intramacrophage M. ulcerans both in
vitro and in vivo, we evaluated the intracellular growth of M.
ulcerans within BMDM by counting AFB. Amikacin was used
to prevent extracellular bacterial multiplication (45, 57). At an
MOI of 1:1, we found a 0.6 log10 increase in intracellular AFB
counts at 8 days for the mycolactone-negative strain 5114 and
the mycolactone-producing strain 97-1116 (Fig. 5A). However,
for the most cytotoxic strain, 98-912 (51), bacterial counts did
not increase when the same MOI was used (Fig. 5A). This is
due to the macrophage damage induced by M. ulcerans 98-912,
as shown by the necrotic alterations in most infected macro-
phages (Fig. 3C). Necrotic macrophages lose cytoplasmic
membrane integrity (75), permitting access of amikacin to ba-
cilli. However, at an MOI of 1:3, a significant growth of 0.6
log10 was observed over the 8-day experimental period (Fig.
5B), showing that this cytotoxic strain also proliferates inside
macrophages when early damage to the macrophages is pre-
vented.
M. ulcerans lyses infected macrophages after an initial phase
of intracellular proliferation. We then questioned whether or
not the continuous intracellular growth of a cytotoxic M. ulcer-
ans strain in macrophages would result in the lysis of the
infected cells due to the activity of mycolactone, leading to the
shedding of bacilli. To address this question, we infected
J774A.1 macrophages, which can be cultured for 15 days, with
the mycolactone-producing M. ulcerans strain 97-1116 or the
mycolactone-negative strain 5114 at different MOIs in the
presence of amikacin.
As with infected BMDM, we found that both the 97-1116
and 5114 M. ulcerans strains are phagocytosed and grow inside
FIG. 3. Intracellular M. ulcerans bacilli are found in mouse BMDM
infected in vitro. BMDM were infected with M. ulcerans 98-912 (MOI,
1:1). (A) Coverslips were removed 4 h postinfection, and the cells were
washed, stained with ZN, and counterstained with methylene blue. Mi-
croscopic analysis shows bacilli inside macrophages (arrowheads). Mag-
nification, 1,250. (B) Electron microscopy of BMDM infected for 4 h
with M. ulcerans 98-912 and photographed 4 days later, showing bacilli
inside an intact macrophage (arrowheads). Bar 1 m. (C) Six bacilli are
seen within a lysing macrophage; one bacillus is inside the nucleus (N),
which has ruptured nuclear membranes. This macrophage shows features
typical of necrosis (75), namely, rupture of the cytoplasmic and nuclear
membranes, condensation of chromatin, swelling and disruption of mito-
chondria, and loss of the normal density of the cytosol. Bar  1 m.
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J774A.1 macrophages (Fig. 5C and D). With strain 97-1116 at
an MOI of 1:1, the bacterial load increased, reaching 5.68 
0.11 log10 AFB by day 10 postinfection, when an arrest in
bacterial proliferation was observed (Fig. 5C). At this time
point, the number of dead macrophages had increased from
4.35  0.16 log10 at time zero to 5.29  0.15 log10 (an 8.7-fold
increase). With strain 5114 at an MOI of 1:1, the bacterial load
at 10 days was 5.61  0.10 log10 AFB, with an increase in
FIG. 4. M. ulcerans is found within macrophage phagosomes, and all tested strains are phagocytosed by BMDM at an MOI of 1:1, irrespective
of their cytotoxic activity. For electron microscope studies (A to D), BMDM were infected for 4 h with M. ulcerans 98-912 (MOI, 1:1) and sampled
4 days after infection. Intracellular bacilli can be found within spacious (A) or tight (B) phagosomes. Bars  0.5 m. PM, phagosomal membrane.
(C) Detailed image of the cell envelope of extracellular bacilli. The typical layers of mycobacterial envelopes (64) are visible, namely, the
cytoplasmic membrane (CM) covered by the cell wall with an innermost electron-dense peptidoglycan layer (PGL), an intermediate electron
transparent layer (ETL), and an outer electron-dense layer (OL). Bar  0.1 m. (D) High magnification of the bacillary envelope at the zone
labeled with an arrow in panel B, showing the same envelope layers shown in panel C plus a tightly apposed phagosomal membrane outside the
OL. Bar  0.1 m. (E) BMDM (solid bars) were infected for 4 h with M. ulcerans 5114, 97-1116, or 98-912 (MOI, 1:1) or, for comparison, with
M. tuberculosis H37Rv or M. bovis BCG (MOI, 1:1). To assess the phagocytosis of M. ulcerans by a different macrophagic cell, J774A.1 cultures
were infected with M. ulcerans 97-1116 as described for BMDM (striped bar). Student’s t test for the rates of phagocytosis gave nonsignificant P
values. Results are from one representative experiment out of three independent experiments.
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macrophage mortality of only 1.3-fold; bacterial growth con-
tinued, reaching 5.85  0.17 log10 AFB by day 15, when mac-
rophage mortality increased only 1.6-fold. When the higher
MOI of 3:1 was tested, the cytotoxic load of strain 97-1116 was
achieved at day 3, when the number of AFB reached 5.48 
0.17 log10 (Fig. 5D) and the number of dead macrophages was
5.26  0.12 log10 (an 8.1-fold increase). At this MOI, strain
5114 reached 5.58  0.13 log10 AFB at day 3, when macro-
phage mortality increased only 1.2-fold; growth continued,
reaching 6.19  0.09 log10 AFB by day 15. At this time point,
the number of dead macrophages had increased only 3.5-fold.
In contrast, with strain 97-1116 at the same MOI, the number
of dead macrophages had increased 12.6-fold by day 15, with a
lower bacterial load (5.54  0.14 log10 AFB).
Altogether, these findings show that after an initial phase of
intracellular proliferation, cytotoxic M. ulcerans becomes ac-
cessible to amikacin, suggesting that lysis of infected macro-
phages occurs when a certain bacterial load is reached. In vivo,
intracellular growth of mycobacteria occurs by cycles of mul-
tiplication in individual macrophages followed by their lysis,
egress of replicated bacilli, and entry of these bacilli into new
macrophages where the growth cycle is repeated (25). The use
in our in vitro experiments of amikacin to prevent extracellular
proliferation of M. ulcerans (45, 57) blocks the spreading of the
infection from lysed infected macrophages to healthy macro-
phages, resulting in an underestimation of the capacity of cy-
totoxic M. ulcerans to grow in cells.
DISCUSSION
The prevailing concept is that M. ulcerans is an extracellular
pathogen in humans and experimentally infected animals (1,
11, 12, 17, 26, 29, 33, 52). This concept represents an exception
among pathogenic mycobacteria (12) and is based mainly on
the description of absent or minimal inflammation as a typical
feature of M. ulcerans infections and on the fact that BU
tissues show predominantly free bacilli in extensive necrotic
acellular areas (8, 17, 20, 26, 29, 35). In our previous study, we
demonstrated with the mouse model of BU that inflammatory
infiltrates containing bacilli are consistently present at the pe-
ripheries of necrotic acellular areas. From this observation, we
concluded that studies directed toward the evaluation of the
interactions between phagocytes and M. ulcerans in human
infections were justified (51). We have shown here that among
tissue specimens from 19 BU patients, 8 of 15 specimens with
inflammatory exudates and AFB revealed intramacrophage M.
ulcerans in the inflammatory cells at the peripheries of the
extensive necrotic acellular areas. This picture clearly parallels
the scenario we described for footpads of mice with experi-
mental BU. Intramacrophage M. ulcerans bacilli were readily
found in the mouse model, because the entire lesion could be
evaluated histopathologically. In specimens from BU patients,
however, this phenomenon was not often appreciated because
inflammatory exudates and bacilli were not always represented
in the tissue fragments. BU lesions are usually extensive, and
the chances that a fragment of tissue will fail to include areas
of inflammatory infiltrates and bacilli are high. In many in-
stances, intramacrophage M. ulcerans bacilli were found only
after multiple consecutive sections had been evaluated.
Another argument has been put forward in favor of the
concept that M. ulcerans is an extracellular pathogen: under
some in vitro conditions, M. ulcerans and mycolactone inhibit
the phagocytic activity of macrophages (1, 13, 55, 58). Extend-
ing previous data from our group (51), we now show quanti-
tatively that mycolactone-producing M. ulcerans strains are
efficiently ingested in vivo as well as by mouse macrophages in
vitro at rates comparable to those for a mycolactone-negative
M. ulcerans strain and for M. tuberculosis and M. bovis BCG.
Our present results suggest that previous data showing inhibi-
FIG. 5. M. ulcerans clinical isolates grow within mouse BMDM and
J774A.1 macrophages before inducing cell lysis and becoming extra-
cellular. All macrophage infections were performed in the presence of
amikacin. (A and B) BMDM were infected for 4 h at an MOI of 1:1
with M. ulcerans 5114 (closed circles), 97-1116 (closed triangles), or
98-912 (closed squares) (A) or at an MOI of 1:3 (open squares) with
M. ulcerans 98-912 (B). At an MOI of 1:1, M. ulcerans 5114 and
97-1116, but not M. ulcerans 98-912, proliferate inside macrophages for
a period of 8 days. At a lower MOI, the early cytotoxic effect of M.
ulcerans 98-912 is reduced and intracellular growth was detected. Sta-
tistically significant differences between results at day 0 and day 4 or 8,
as evaluated by Student’s t test, are labeled with double asterisks (P 
0.01) or triple asterisks (P  0.001). (C and D) J774A.1 cells were
infected for 4 h with the mycolactone-positive M. ulcerans strain 97-
1116 (triangles) or the mycolactone-negative strain 5114 (circles) at an
MOI of 1:1 (C) or 3:1 (D) for a period of 15 days. Panels C and D show
the numbers of AFB/well, demonstrating that M. ulcerans 97-1116
grows inside macrophages before inducing their death and becoming
extracellular as indicated by an arrest in bacterial growth (at day 3 for
an MOI of 3:1 and day 10 for an MOI of 1:1). In contrast, strain 5114
at both MOIs grew continuously until the end of the experiment.
Statistical significance was calculated by using Student’s t test, com-
paring the results at each time point with those of the previous time
point, and significant differences are labeled with a single asterisk (P
0.05) or double asterisks (P  0.01). Results are from one represen-
tative experiment out of two independent experiments.
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tion of phagocytosis of M. ulcerans in vitro (1, 55, 58) are
explained by the use of high MOIs resulting in early mycolac-
tone-induced damage to the macrophages (26). The only pre-
vious study using low MOIs (13) concluded that M. ulcerans
bacilli “were efficiently captured by RAW264.7 macrophages,
bone marrow-derived macrophages, and the dendritic cell line
FSDC after a 3 h contact,” showing only a partial, dose-de-
pendent inhibition of the phagocytosis of wild-type M. ulcerans
compared to that of a mycolactone-negative isogenic mutant.
These findings and our results indicate that the presence of
extracellular M. ulcerans in infectious foci is not due to the
blockage of phagocytosis and explain the persistent occurrence
of intramacrophage M. ulcerans in infected tissues. A recent
publication on mouse intradermal M. ulcerans experimental
infection (13) reports intracellular bacilli primarily within neu-
trophils and rarely in macrophages and only in the initial stages
of the infection. Note, however, that a few early studies did
report intramacrophage bacilli in experimental (21, 41, 59) and
human (43) M. ulcerans infections.
The presence of M. ulcerans within macrophages in the focus
of infection is not evidence that in vivo this mycobacterium is
primarily an intracellular parasite. However, using in vitro
models of macrophage infection, we show that M. ulcerans
multiplies intracellularly in macrophages, as is the case for the
M. ulcerans-related intracellular parasites M. marinum and M.
tuberculosis (25, 42, 45, 57, 58, 66). Previous attempts to grow
M. ulcerans within mammalian macrophages were unsuccessful
(1, 58) due to the cytotoxicity of bacilli for macrophages at the
high MOIs used (10:1 to 20:1). We avoided this early cytotoxic
effect by using MOIs of 1:1 to 1:3, as previously done with M.
tuberculosis and M. marinum (25, 42, 57). Our data show for
the first time that virulent, mycolactone-producing strains of
M. ulcerans grow inside mammalian macrophages at 32°C.
It would be intuitive to expect intracellular pathogens to
have low direct cytotoxicity so that no damage would be im-
parted to the host cells. Indeed, it has been considered that one
of the characteristics of intracellular pathogens is low cytotox-
icity (37) and that cytokines produced locally by immune cells
would be responsible for mycobacterium-associated cell de-
struction as seen in pulmonary tuberculosis (14, 22). However,
it is becoming progressively evident that intracellular parasites
can directly lyse macrophages to exit the cell efficiently after
termination of the intracellular proliferation phase and pro-
ceed to infect other cells in the same host (extending the
infection) or to pass to a new host (spreading the disease) and
that direct microbial cytotoxicity is a mechanism that promotes
cell lysis. In fact, it is known that many intracellular pathogens,
including M. tuberculosis and M. marinum, have direct cytotox-
icity toward professional and occasional phagocytes in vivo and
macrophages in vitro (19, 24, 25, 38, 42, 57). In addition, it has
been reported that several intracellular parasites, including not
only M. ulcerans-related mycobacteria (14, 25, 31) but also
Legionella pneumophila, Salmonella spp., and Shigella spp. (2,
40, 49, 60), also use cytotoxic mechanisms to lyse infected
macrophages at the end of their life cycles within the host cell,
thus becoming extracellular.
The consequences of the potentially conflicting features of
an intracellular lifestyle and cytotoxicity would be minimized if
M. ulcerans orchestrated a pattern of transcriptional control of
gene expression to turn off the synthesis of mycolactone during
intramacrophage growth. The genes involved in mycolactone
synthesis would later be switched on, resulting in the lysis of
the infected cells and egress of fully replicated bacilli. It has
been reported for infections with Salmonella spp. (40) and
Legionella pneumophila (2) that the pathogen machinery re-
sponsible for the lysis of host cells is turned off after the entry
of the pathogen into the macrophage and expressed only at the
end of an intramacrophage multiplication phase. Our results
showing that multiplication of M. ulcerans at different MOIs
within J774A.1 macrophages yields similar maximal bacterial
loads and induces similar macrophage viability losses, although
at different times, are compatible with the hypothesis of a
temporal switching off of mycolactone synthesis within macro-
phages.
The above-described observations showing that several
pathogens are able to reconcile cytotoxicity with intracellular
parasitism are in accordance with the concept that low cyto-
toxicity is a conditional rather than an absolute characteristic
of intracellular parasites (37).
In the mouse footpads and in BU tissues from humans,
extracellular bacilli colocalized with inflammatory cells but
were more abundant in the acellular necrotic areas. The pres-
ence of extracellular bacteria is compatible with intracellular
parasitism. Accumulation of extracellular bacilli in necrotic
areas, following the lysis of macrophages infected with intra-
cellular mycobacteria, has been previously reported for human
(31) and murine (36, 73) pulmonary tuberculosis, for human
skin lesions due to M. haemophilum (17), and for animals
infected with M. marinum (21, 25).
Our observation of progressive enlargement of the clumps of
extracellular AFB away from the areas of colocalization with
inflammatory cells suggests that there is extracellular growth of
M. ulcerans following the shedding of the bacilli from lysed,
infected macrophages. Taking into consideration this observa-
tion and the results showing that M. ulcerans bacilli (i) are
efficiently phagocytosed by mouse macrophages in vivo and in
vitro, (ii) are present inside macrophages in mouse footpad
and peritoneal infections and in BU tissues, and (iii) grow
within cultured macrophages, we propose that the growth of
M. ulcerans would take place, in a manner similar to that of M.
tuberculosis, by both intracellular and extracellular multiplica-
tion in distinct areas of the lesion (14, 31).
According to our model, some of the bacilli shed from lysing
macrophages would be taken up by resident macrophages and
by monocytes that are continuously attracted to the infectious
foci (51) and resume intracellular growth. This continuous
intracellular multiplication at the areas of inflammatory infil-
trates in active, progressing infections depends on the perma-
nent availability of resident macrophages and incoming mono-
cytes as host cells (51). Our interpretation is that this focus of
intramacrophage M. ulcerans residence and multiplication at
the peripheries of the necrotic areas promotes the progression
of the lesion by the invasion of healthy tissues and explains the
occurrence of CMI, DTH, and granulomatous responses re-
ported in murine and human M. ulcerans infections (18, 27, 28,
33, 39, 43, 44, 50, 54, 56, 61, 67, 68, 70, 74). In contrast, the
extracellular bacilli abundant in the central necrotic acellular
areas may be ultimately eliminated in the slough of necrotic
tissue when the lesion becomes ulcerative, as is the case for
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extracellular M. tuberculosis in the necrotic caseous foci in
human pulmonary tuberculosis (31).
In conclusion, our results showing the uptake of M. ulcerans
by macrophages in experimentally infected mice and in vitro,
the presence of intramacrophage bacilli in inflammatory infil-
trates of M. ulcerans-infected tissues, and the multiplication of
bacilli within cultured macrophages indicate that this mycobac-
terium fulfils the essential features for classification as an in-
tracellular parasite like the other pathogenic mycobacteria.
This interpretation is further supported by the reported pro-
tective CMI and DTH responses in mouse and human M.
ulcerans infections and may have value for the design of novel
prophylactic and therapeutic approaches for BU.
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The pathogenicity of Mycobacterium ulcerans, the agent of Buruli ulcer, depends on the cytotoxic exotoxin
mycolactone. Little is known about the immune response to this pathogen. Following the demonstration of an
intracellular growth phase in the life cycle of M. ulcerans, we investigated the production of tumor necrosis
factor (TNF) induced by intramacrophage bacilli of diverse toxigenesis/virulence, as well as the biological
relevance of TNF duringM. ulcerans experimental infections. Our data show that murine bone marrow-derived
macrophages infected with mycolactone-negative strains ofM. ulcerans (nonvirulent) produce high amounts of
TNF, while macrophages infected with mycolactone-positive strains of intermediate or high virulence produce
intermediate or low amounts of TNF, respectively. These results are in accordance with the finding that TNF
receptor P55-deficient (TNF-P55 KO) mice are not more susceptible than wild-type mice to infection by the
highly virulent strains but are more susceptible to nonvirulent and intermediately virulent strains, demon-
strating that TNF is required to control the proliferation of these strains in animals experimentally infected
by M. ulcerans. We also show that mycolactone produced by intramacrophage M. ulcerans bacilli inhibits, in a
dose-dependent manner, but does not abrogate, the production of macrophage inflammatory protein 2, which
is consistent with the persistent inflammatory responses observed in experimentally infected mice.
Mycobacterium ulcerans is the etiological agent of Buruli
ulcer (BU), a devastating, necrotizing skin disease that has
increased dramatically over the past decade and has become
the third most common mycobacterial infection in humans,
after tuberculosis and leprosy (15, 85). In some African trop-
ical areas, the number of BU cases may even exceed those of
tuberculosis and leprosy (16, 86). BU has a huge socioeco-
nomic impact in the affected populations and represents an
important public health issue in terms of morbidity, treatment,
and functional disabilities (3). In addition to the increase in the
actual number of cases, there has also been an increasing
geographical spread of BU within some tropical countries (86).
Mycobacteria have developed several mechanisms to avoid
the harmful effects of the host immune response, including the
secretion of soluble factors that have cytotoxic activity against
the host cells, the impairment of the bactericidal activity of
macrophages, or the modulation of the immune response. My-
cobacterium tuberculosis, a mycobacterium closely related to M.
ulcerans (83), secretes culture filtrate protein 10, early secre-
tory antigen target 6, and Man-LAM that exhibit cytotoxic
activities against the infected cells or inhibit the production of
macrophage-activating cytokines, such as tumor necrosis factor
(TNF) (29, 45, 51, 77, 81). Furthermore, it has been suggested
that M. tuberculosis induces an increased production of inter-
leukin-10 (IL-10), a cytokine with immunosuppressive activity
(34). M. ulcerans also exhibits cytotoxic activity (32, 50, 56, 67).
However, unlike M. tuberculosis, M. ulcerans cytotoxicity is pri-
marily associated with the production of a unique polyketide lipid
exotoxin, mycolactone (32, 33). The genetic basis for mycolac-
tone production was elucidated with the discovery of a giant
plasmid that carries all the genes required for mycolactone
production (80). It is also known that M. ulcerans isolates from
different geographical origins produce diverse types of myco-
lactones (56). The African strains produce mainly mycolac-
tones A/B, whereas Australian strains produce mainly myco-
lactone C (56). These mycolactones are very similar, with the
exception that mycolactone C has one less hydroxyl group on
C-12 of the fatty acid side chain (46, 79). Despite this sole
difference between mycolactones A/B and C, the latter has
been shown to be less cytopathic (46, 56). The different profiles
in mycolactone production might contribute to the lower se-
verity of BU disease observed in Australia compared to that in
Africa (46). However, it cannot be excluded that production of
different amounts of mycolactone may also account for the
different degrees of virulence among M. ulcerans strains.
In the mouse fibroblast L929 cell line, mycolactone has a
cytopathic effect characterized by cell cycle arrest, cell round-
ing, detachment from the monolayer and, ultimately, apoptosis
(31–33, 56). Injection of mycolactone in the guinea pig skin
or infection with wild-type (WT) mycolactone-producing M.
ulcerans induces the formation of ulcers, while infection with a
mycolactone-negative mutant strain fails to induce ulceration
in this animal model (32). The pathology of M. ulcerans infec-
tions is therefore closely associated with the secretion of this
exotoxin, which is primarily responsible for the extensive ne-
* Corresponding author. Mailing address: Life and Health Sciences
Research Institute, School of Health Sciences, University of Minho,
4710-057 Braga, Portugal. Phone: 351-253-604833. Fax: 351-253-
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 Published ahead of print on 21 May 2007.
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crosis that characterizes BU. Additionally, it has been shown
that mycolactone inhibits TNF production (60).
TNF is an effector cytokine produced mainly by macro-
phages and has an autocrine effect on the activation of the
macrophage’s microbicidal activity against intracellular para-
sites, including Listeria monocytogenes (39), M. tuberculosis (17,
26), Mycobacterium bovis BCG (48), and some strains of My-
cobacterium avium (69). TNF is, therefore, critical for both the
antibacterial and the inflammatory host responses against my-
cobacteria (25). TNF and other cytokines and chemokines
produced by macrophages, such as IL-6, IL-1, and macrophage
inflammatory protein 2 (MIP-2) (the murine homologue of
human IL-8), have an impact on the recruitment of inflamma-
tory cells (5, 18), as well as on the activation and phenotype of
T cells (61, 73).
It has been recently shown that M. ulcerans has an intra-
macrophage growth phase (84), which is in accordance with the
occurrence of cell-mediated immunity and delayed-type hyper-
sensitivity responses in BU patients (20, 35, 36, 40, 41, 49, 53,
54, 58, 64, 66, 76, 78, 82, 86, 87). The correlation between the
amounts of TNF produced by macrophages infected with dif-
ferent strains of M. ulcerans and the mycolactones produced by
these strains, as well as the biological relevance of TNF in the
progression of infection by M. ulcerans, is currently unknown.
A previous report showed that a lipidic fraction of M. ulcerans
culture filtrates containing mycolactone suppressed in vitro the
production of TNF by human monocytes (60). On the other
hand, the expression of TNF is detected in high concentrations
in the lesions of BU patients (66). Furthermore, TNF is known
to participate in the formation of granulomas (25), which in
BU has been shown to occur during the healing phase of the
disease (1, 40, 41, 78, 86).
Taking these data into consideration, it is important to study
the effects of infection with different strains of M. ulcerans
on the cytokine production by macrophages, as well as to assess
the role of TNF in M. ulcerans infection in vivo. A panel of
strains of M. ulcerans that produce different types of mycolac-
tone or that are mycolactone negative was used in the present
work in order to characterize the production of both the proin-
flammatory cytokine TNF and the chemokine MIP-2 by in-
fected bone marrow-derived macrophages (BMDM). In addi-
tion, the biological relevance of TNF production in vivo was
assessed by using TNF receptor P55-deficient (TNF-P55 KO)
mice infected with different strains of M. ulcerans. To further
dissect the role of mycolactone on the production of TNF by
M. ulcerans-infected macrophages, we compared WT M. ulcer-
ans with isogenic mutants in which the mycolactone genes were
deleted or interrupted by transposon insertion.
We found that BMDM infected with highly virulent but not
with intermediately virulent or nonvirulent strains of M. ulcer-
ans produced low levels of TNF. In addition, we show that
mycolactone inhibits TNF production, in a dose-dependent
manner. Interestingly, MIP-2 production was decreased but
not abrogated, even in macrophages infected with highly viru-
lent strains. Finally, our data show that TNF induced during M.
ulcerans infection plays a protective role.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The M. ulcerans strains used in this
study were selected based on their geographical origin and on the type of
mycolactone produced (Table 1). Strain 97-1116 is an isolate from Benin that
produces a mycolactone A/B that is characteristic of African strains (57). Strain
98-912 was isolated from a Chinese patient and produces a mycolactone A/B
slightly different from those in African strains (44). Strain 94-1327 is an isolate
from Australia and produces the characteristic mycolactone C (56); its plasmid
lacks the gene MUP053 encoding a P450 hydroxylase required to hydroxylate the
mycolactone side chain at C-12 to produce mycolactone A/B (79). Strain 94-1331
is an isolate from Papua New Guinea that is similar to the mycolactone C-
producing Australian strains in the sense that its plasmid also lacks the gene
MUP053 that is necessary for mycolactone A/B production (79), although it was
suggested that this strain can also produce mycolactone A/B (43). Strain 5114 is
an isolate from Mexico and does not produce mycolactone (56) due to the loss
of key genes involved in the synthesis of this macrolide (79). Mycobacterium
marinum 00-1026, obtained from a patient living in France, is closely related
genetically to M. ulcerans and was used as a negative control for mycolactone
production (8, 89). Finally, the mycolactone-defective M. ulcerans 1615A, a
spontaneous mutant, was isolated from nonpigmented colonies of M. ulcerans
1615 (32), a strain from Malaysia that produces mycolactone A/B (56). All strains
used in this work, except for strain 1615, are from the collection of the Institute
of Tropical Medicine, Antwerp, Belgium.
The isolates were grown on Lo¨wenstein-Jensen medium at 32°C for approxi-
mately 1 month, recovered from slants, diluted in phosphate-buffered saline to a
final concentration of 1 mg/ml, and vortexed using 2-mm glass beads. The
number of acid-fast bacilli (AFB) in the inocula was determined according to the
method described by Shepard and McRae (72), using Ziehl-Neelsen staining
(Merck, Darmstadt, Germany). The final suspensions revealed more than 90%
viable cells as assessed with a LIVE/DEAD Baclight kit (Molecular Probes,
Leiden, The Netherlands).
Animals. Eight-week-old female BALB/c, C57BL/6, and TNF-P55 KO mice
were obtained from Charles River (Barcelona, Spain) and were housed under
specific-pathogen-free conditions with food and water ad libitum.
Footpad model of infection. Mice were infected in the left hind footpad with
0.03 ml of M. ulcerans suspension containing 5 log10 AFB. The right hind footpad
was used as a control.
Culture of murine BMDM. Macrophages were derived from the bone marrow
as follows: mice were sacrificed with CO2 and femurs removed under aseptic
conditions. Bones were flushed with 5 ml cold Hanks’ balanced salt solution
(HBSS; Gibco, Paisley, United Kingdom). The resulting cell suspension was
centrifuged at 500  g and resuspended in Dulbecco’s modified Eagle’s medium
(DMEM; Gibco) supplemented with 10 mM HEPES (Sigma, St. Louis, MO), 1
mM sodium pyruvate (Gibco), 10 mM glutamine (Gibco), 10% heat-inactivated
fetal bovine serum (Sigma), and 10% L929 cell conditioned medium (complete
DMEM [cDMEM]). To remove fibroblasts or differentiated macrophages, cells
were cultured for a period of 4 h on cell culture dishes (Nunc, Naperville, IL)
with cDMEM. Nonadherent cells were collected with warm HBSS, centrifuged at
500  g, distributed in 24-well plates at a density of 5  105 cells/well, and
incubated at 37°C in a 5% CO2 atmosphere. On day 4 after seeding, 0.1 ml of
L929 cell conditioned medium was added, and medium was renewed on the
seventh day. After 10 days in culture, cells were completely differentiated into
macrophages. Twelve hours before infection, macrophages were incubated at
TABLE 1. Mycobacterial strains
Species Strain
BU
clinical
form
Geographical
origin
Yr of
isolation
Type of
mycolactone
M. ulcerans 98-912 Ulcer China 1997 A/Ba
M. ulcerans 97-1116 Plaque Benin 1997 A/B
M. ulcerans 1615 Ulcer Malaysia 1964 A/B
M. ulcerans 94-1331 NDc Papua New
Guinea
1994 A/Bb
M. ulcerans 94-1327 Ulcer Australia 1994 C
M. ulcerans 5114 Ulcer Mexico 1953 
M. marinum 00-1026 d France 2000 
a Mycolactone A/B slightly different from those in African strains (44).
b Like mycolactone C-producing Australian strains, this strain lacks the plas-
mid gene MUP053 that is involved in mycolactone A/B production (79), although
it has been suggested that it also produces mycolactone A/B (43).
c ND, not determined.
d , negative result.
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32°C in a 5% CO2 atmosphere and maintained until the end of the experimental
infection as described elsewhere (59).
Macrophage infectivity assays. Bacterial suspensions were prepared as de-
scribed above and further diluted in cDMEM before infecting macrophage
monolayers. M. ulcerans suspensions (0.2 ml) were diluted in cDMEM and added
to each well in order to obtain the multiplicity of infection (MOI) indicated for
each experiment (bacterium/macrophage ratio). Cells were incubated for 4 h at
32°C in a 5% CO2 atmosphere and then washed four times with warm HBSS to
remove noninternalized bacteria and reincubated in cDMEM for a maximum
period of 6 days. To confirm the MOI, counting of AFB in infected macrophages
was performed at the beginning of experimental infection as described previously
(72).
Mycolactone purification. After purification of mycolactone as described else-
where (32, 56), the toxin was dissolved in ethanol (100%) and stored at 4°C. The
toxin was added to cultured cells by diluting the original preparation in culture
medium (DMEM) to a maximum concentration of 0.001% of ethanol. In addi-
tion, the wells with control, noninfected macrophages were kept with the same
amount of diluted ethanol that was found to be noncytotoxic for macrophages at
this residual concentration.
Cytokine analysis by ELISA. At selected time points postinfection, macro-
phage cultures were centrifuged and the supernatants removed and stored frozen
until cytokine analysis by enzyme-linked immunosorbent assay (ELISA). TNF
and MIP-2 were measured in the culture supernatant using commercial kits
(R&D Systems, Minneapolis, MN) according to the manufacturer’s specifica-
tions.
Statistical analysis. Statistical significance of values was determined using the
Student t test.
RESULTS
Different strains ofM. ulcerans exhibit diverse cytotoxicity in
vitro that correlates with mycolactone production and with
virulence for mice. It was previously shown that mycolactone
A/B-producing M. ulcerans bacilli exhibit cytotoxic activity
against infected macrophages (59), following an intramacro-
phage phase of proliferation (84). These same strains induced
progressive infections following experimental inoculation of
mouse footpads (59). On the other hand, a mycolactone-neg-
ative strain was shown to be noncytotoxic and unable to induce
lesions in infected footpads (59). In the present work, we
expanded our observations by evaluating the cytotoxic activi-
ties of a panel of M. ulcerans strains that produce diverse types
of mycolactone or are nonproducers of mycolactone, using a
model of BMDM infection at 32°C. Additionally, we investi-
gated the association between cytotoxicity and virulence for
experimentally infected mice.
Macrophages were infected at a 1:1 MOI with the mycolac-
tone-negative strain 5114 or with mycolactone-producing
strain 94-1331, 94-1327, 97-1116, or 98-912. As a control, mac-
rophages were infected with M. marinum 00-1026, which does
not produce mycolactone. The cytotoxicity of M. ulcerans was
assessed by the occurrence of the typical cytopathic changes
induced in cultured cells either by isolated mycolactone (31–
33) or by intracellular infection with mycolactone-producing
M. ulcerans bacilli (59, 84). Those cytopathic changes include
cell rounding and detachment from the monolayer followed by
cell death (31–33). The evaluation of virulence was performed
by measuring over time of the swelling of footpads infected
with 5.3 log10 AFB of M. ulcerans (59).
Confirming our previous observations (59), we found that
the M. ulcerans strains 98-912 and 97-1116, which produce
mycolactone A/B, were highly cytotoxic, inducing cell round-
ing, shrinkage, and detachment of more than 90% of cultured
macrophages at 6 days postinfection (Fig. 1A), and highly
virulent, as shown by the occurrence of footpad swelling be-
tween the second and fourth weeks following infection (Fig.
1A). In contrast, no significant alterations were found in mono-
layers infected with the noncytotoxic, mycolactone-negative
strain 5114 or with M. marinum 00-1026 (Fig. 1C), which also
did not induce measurable footpad swelling up to 25 weeks
FIG. 1. Cytotoxic activity and virulence of different strains of M.
ulcerans. (Left) BMDM were infected with different strains of M.
ulcerans at an MOI (bacilli/macrophages) of 1:1. Macrophages were
photographed by phase-contrast microscopy 6 days after infection. M.
ulcerans cytotoxicity was determined based on the microscopic obser-
vation of cell rounding and detachment from the monolayer. (Right)
Mice were infected in the left hind footpad with 5.3 log10 AFB of
different M. ulcerans strains. Virulence was determined by measuring
footpad swelling. For ethical reasons mice were sacrificed after the
emergence of ulceration. Results are from one representative experi-
ment out of three independent experiments.
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postinfection (Fig. 1C). The Australian mycolactone C-pro-
ducing strain, M. ulcerans 94-1327, showed intermediate cyto-
toxic activity in vitro and intermediate virulence for mice (Fig.
1B). Interestingly, strain 94-1331 from Papua New Guinea,
which, like Australian strains, lacks the gene MUP053 that
encodes the P450 hydroxylase necessary to hydroxylate C-12 to
form mycolactone A/B, also showed an intermediate pattern of
in vitro cytotoxicity and virulence (Fig. 1B).
These results confirm the importance of mycolactone as the
key pathogenic factor of M. ulcerans, showing a correlation
between mycolactone production and cytotoxic activity for
infected cells and virulence for the host.
BMDM infected with strains of M. ulcerans of diverse cyto-
toxicity/virulence produce different amounts of TNF. Macro-
phages are key elements in the immune response against in-
tracellular parasites. It is known that among other factors, the
autocrine activity of TNF on infected macrophages is critical to
control the proliferation of the intracellular mycobacterium M.
tuberculosis (17, 26) and M. avium (69). It was recently shown
that M. ulcerans has a phase of intramacrophage residence and
proliferation before it induces the mycolactone-dependent ly-
sis of infected host cells (84). It is therefore important to study
the production of TNF by macrophages infected with different
clinical isolates of M. ulcerans.
Following the characterization of cytotoxicity/virulence of
the panel of M. ulcerans strains, we found that infection of
BMDM at a 1:1 MOI with those strains led to the production
of different amounts of TNF. TNF production was highest in
BMDM infected with the mycolactone-negative, nonvirulent
strain 5114 or M. marinum 00-1026. In cells infected with
highly cytotoxic/virulent strains that produce mycolactone type
A/B, TNF levels were lower than 100 pg/ml (Fig. 2). Accord-
ingly, TNF production by strains of M. ulcerans of intermediate
cytotoxicity/virulence was intermediate (Fig. 2). To investigate
if the reduced production of TNF by macrophages infected
with mycolactone A/B-producing M. ulcerans strains was asso-
ciated with a decreased production of other macrophage-de-
rived proinflammatory cytokines, we evaluated the expression
of IL-1 and IL-6. Expression of high amounts of both cytokines
occurred in BMDM infected with the mycolactone-negative
strain 5114 but not with the mycolactone A/B-producing strain
98-912 (data not shown).
These results show that the production of proinflammatory
cytokines such as TNF by BMDM infected with M. ulcerans is
dependent on the strain’s mycolactone-associated toxicity.
The reduced production of TNF by BMDM infected with
mycolactone A/B-producing strains is not related to an early
cytotoxic effect or to cell death. It has been previously shown
that at high MOI, mycolactone-producing M. ulcerans strains
exhibit an early cytotoxic effect on cultured cells (13, 84).
However, the damage to monolayers was found to be pre-
vented when the experimental infection was performed at a
low MOI (84).
To evaluate if the inhibition of TNF production by the my-
colactone A/B-producing strains was due to an early cytotoxic
effect on BMDM, monolayers were infected with different
MOIs of M. ulcerans 98-912 or M. ulcerans 5114, as a control.
As shown in Fig. 3A, production of high amounts of TNF was
found at high MOIs in macrophages infected with M. ulcerans
FIG. 2. TNF production by BMDM infected with strains of M.
ulcerans that produce different amounts and types of mycolactone.
Strains of M. ulcerans from different origins were used to infect
BMDM at an MOI of 1:1. At days 2, 4, and 6 postinfection the
supernatants of three independent wells were removed for each strain
and frozen until cytokine measurement by ELISA. Low amounts of
TNF were produced by macrophages infected with high cytotoxic/
virulent strains (98-912 and 97-1116), whereas high amounts of TNF
were produced in the case of the low cytotoxicity/low virulence strain
5114 or M. marinum 00-1026. Intermediate levels of TNF are produced
with strains of intermediate cytotoxicity/virulence (94-1327 and 94-
1331). Error bars indicate standard deviations. Results are from one
representative experiment out of three independent experiments.
FIG. 3. TNF production by BMDM infected at different MOIs with
the mycolactone A/B-producing strain 98-912 or the mycolactone-
negative strain 5114. BMDM were infected at MOIs ranging from 10:1
to 1:15 with the M. ulcerans strains 5114 (A) or 98-912 (B). Twenty-
four hours postinfection, the supernatant from three independent
wells was removed for each strain and stored frozen until cytokine
measurement by ELISA. BMDM infected with M. ulcerans 5114 pro-
duce high amounts of TNF at high MOIs, and TNF production de-
creases as the MOI decreases. With M. ulcerans 98-912, production of
TNF is low, independent of the MOI. Results are from one represen-
tative experiment out of three independent experiments.
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5114, which diminished as the mycobacterium/macrophage ra-
tio decreased. In contrast, infection with strain 98-912 was not
associated with high amounts of TNF production by macro-
phages, even at a very low MOI (Fig. 3B), for which cytotoxic
activity was not observed (data not shown). Additionally, we
did not find significant levels of apoptosis in infected macro-
phages 24 h after infection and macrophages were metaboli-
cally active, since they could phagocytose latex beads (data not
shown). These results suggest that the very low production of
TNF by BMDM infected with the highly virulent strain M.
ulcerans 98-912 is not associated with an early death of mac-
rophages but possibly to an inhibitory effect of mycolactone.
Addition of mycolactone A/B to BMDM infected with a my-
colactone-defective strain inhibits or completely suppresses
the production of TNF in a dose-dependent manner. To ad-
dress the contribution of mycolactone to the inhibition of TNF
production by M. ulcerans-infected BMDM, we performed ex-
periments using isogenic strains: the WT, mycolactone A/B-
producing strain M. ulcerans 1615, which is virulent for mice
(13), and the isogenic mycolactone-deficient, nonvirulent
strain, M. ulcerans 1615A (32).
In Fig. 4A, we show that, as previously found for the myco-
lactone-negative strain 5114 (Fig. 2 and 3), high levels of TNF
were produced by macrophages infected with the mycolactone-
defective strain 1615A compared to WT, mycolactone-positive
M. ulcerans. The high levels of TNF produced by macrophages
infected with the mutant strain were particularly significant for
MOIs of 1:1 or higher (Fig. 4B). On the contrary, much lower
amounts of TNF were produced by macrophages infected with
WT M. ulcerans 1615 at high MOI (Fig. 4C). In fact, for a 1:1
MOI, the reduction of the amount of TNF produced was
4.5-fold, but at an MOI of 5:1 the reduction was 33-fold,
comparing the WT with the mutant strain. These results
strongly suggest that mycolactone plays a major role in the
inhibition of TNF production by M. ulcerans-infected BMDM
in a dose-dependent manner. To confirm if this inhibitory
effect was in fact mycolactone dependent, we infected BMDM
with M. ulcerans 1615A in the presence of different amounts of
mycolactone A/B. Figure 4D shows that the addition of myco-
lactone inhibited the TNF production induced by the M. ulcer-
ans mutant strain in a dose-dependent manner. The addition
of 5 ng of mycolactone, the minimal dose tested, reduced
significantly the production of TNF, and the highest dose
tested (50 ng) abrogated the production of this cytokine (Fig.
4D).
Overall, these results demonstrate that mycolactone plays a
major role in the inhibition of TNF production by BMDM
infected with virulent M. ulcerans.
Addition of mycolactone A/B to BMDM infected with a my-
colactone-defective strain moderates the production of MIP-2
in a dose-dependent manner but does not abrogate its produc-
tion. In contrast with previous descriptions, recent results de-
scribed inflammatory responses with infiltration of neutrophils
and mononuclear cells in a high percentage of cases of M.
ulcerans infection in humans (38, 84). In addition, it was shown
in the mouse model that M. ulcerans infection induces a per-
sistent inflammatory response, with the recruitment of neutro-
phils and macrophages to the infection focus (59). We hypoth-
esized that the recruitment of inflammatory cells in response to
infections by M. ulcerans strains associated with low levels of
FIG. 4. TNF production by BMDM infected with WT M. ulcerans
1615 or with the mycolactone-defective mutant 1615A: kinetics and effects
of MOI and supplementation with mycolactone. BMDM were infected
with a 1:1 MOI (A and D) or at different MOIs ranging from 10:1 to 1:15
(B and C) with M. ulcerans 1615A or 1615 WT, in the presence (D) or
absence (A to C) of mycolactone. For cytokine measurement by ELISA,
supernatants of three independent wells were collected from each exper-
imental group. (A) Higher amounts of TNF are produced with infection
by M. ulcerans 1615A in comparison to M. ulcerans 1615. (B and C)
BMDM infected with M. ulcerans 1615A produce large amounts of TNF
at high MOIs, and that production declines as the MOI is decreased. M.
ulcerans 1615 induces the production of smaller amounts of TNF peaking
at low MOI. (D) Addition of mycolactone to M. ulcerans 1615A-infected
macrophages diminishes or abrogates the production of TNF. TNF was
not detected in the presence of 50 ng mycolactone. Results are from one
representative experiment out of two independent experiments.
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TNF production could be mediated by macrophage-derived
chemokines, such as MIP-2. MIP-2 is a chemokine associated
with the recruitment of neutrophils and is produced mainly by
macrophages (88).
To address this point, we measured the production of MIP-2
following the infection of BMDM with M. ulcerans 1615 or
1615A. As shown in Fig. 5A, we found a relevant production of
MIP-2 by BMDM infected at a 1:1 MOI, with either strain,
although with higher values for the mycolactone-defective
strain. For low MOIs, both M. ulcerans 1615 as well as the
mutant strain defective in mycolactone induced the production
of high levels of MIP-2 (Fig. 5B and C). In BMDM infected
with the WT strain, low levels of MIP-2 production were only
found at high MOIs (Fig. 5C). In fact, at 1:1 and 1:5 MOIs, the
reduction of MIP-2 production by BMDM infected with M.
ulcerans 1615 was 2.2- and 1.3-fold, respectively, compared to
the strain defective in mycolactone. Accordingly, the addition
of increasing amounts of mycolactone to BMDM cultures only
induced a moderate decrease in the production of MIP-2 (Fig.
5D), compared to the effect reported above for TNF produc-
tion (Fig. 4C). Moreover, this chemokine was still produced in
relevant amounts after the addition of the maximal dose of
mycolactone tested.
Overall, these results show that the infection of macro-
phages with a virulent strain of M. ulcerans induces the pro-
duction of important amounts of MIP-2, even at a high MOI,
which is in accordance with the occurrence of the inflammatory
responses observed in BU patients and experimentally infected
mice.
TNF plays a role in the control of infections by M. ulcerans.
Studies in the mouse model have shown that TNF is a critical
cytokine for protective immune responses against M. tubercu-
losis (25). This cytokine has been reported to be produced in
BU lesions (64, 66); however, its biological relevance following
M. ulcerans infection is not known.
Following the characterization of TNF production by mac-
rophages infected with M. ulcerans, we tested the biological
role of this cytokine in an experimental model of BU. WT or
TNF-P55 KO mice were infected with different strains of M.
ulcerans. The proliferation of mycobacteria in the infected
footpads was monitored for a period of 3 months. The growth
of strain 5114, which was found to be a strong inducer of TNF,
was hindered in vivo by WT mice but not by TNF-P55 KO mice
(Fig. 6). For this M. ulcerans strain, the increase in the bacterial
proliferation between TNF-P55 KO and WT mice was of 0.8
log10 over an 85-day period. In contrast, M. ulcerans 98-912,
which is not associated with the production of relevant
amounts of TNF in vitro, showed similar patterns of mycobac-
terial proliferation in both mouse strains, before the emer-
gence of ulceration (Fig. 6). Interestingly, we found an inter-
mediate increase of 0.5 log10 in bacterial counts, at day 40
postinfection, between TNF-P55 KO and WT mice infected
with strain 94-1327 (Fig. 6), for which an intermediate produc-
tion of TNF was seen in vitro, as shown above (Fig. 2).
FIG. 5. MIP-2 production by BMDM infected with WT M. ulcerans
1615 or with the mycolactone-defective mutant 1615A: kinetics and
effects of MOI and supplementation with mycolactone. BMDM were
infected with a 1:1 MOI (A and D) or with MOIs ranging from 10:1 to
1:15 (B and C) of M. ulcerans strain 1615A or 1615, in the presence
(D) or absence (A to C) of mycolactone. For cytokine measurement by
ELISA, supernatants of three independent wells were collected from
each experimental group. (A) Although M. ulcerans 1615A induces
larger amounts of MIP-2 in comparison with M. ulcerans 1615, signif-
icant amounts of the cytokine are produced with the mycolactone-
positive strain. (B and C) BMDM infected with M. ulcerans 1615A
produce large amounts of MIP-2 irrespective of MOI. M. ulcerans 1615
induces the production of small but important amounts of MIP-2 at
low MOIs. (D) Addition of mycolactone to M. ulcerans 1615A-infected
macrophages diminishes but does not abrogate the production of
MIP-2, even at high concentrations. Results are from one representa-
tive experiment out of two independent experiments.
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Overall, these results show that TNF plays a protective role
in M. ulcerans infection.
DISCUSSION
The histopathology of BU lesions in patients infected with
M. ulcerans has been characterized by a description of minimal
or absent cellular inflammation (1, 9, 11, 12, 22, 31–33, 35–37,
40, 41, 56, 65, 75), in contrast with what is known to occur in
response to infections by other pathogenic mycobacteria (6, 10,
14, 19, 47, 55, 62, 70, 71, 74, 85). Such a histopathological
hallmark has been associated with the M. ulcerans toxin my-
colactone that, among other effects, inhibits in vitro the
production by activated macrophages of the proinflamma-
tory cytokine TNF (13, 60). However, recent publications have
demonstrated that M. ulcerans induces cellular inflammatory
responses in specific areas of infection foci, both in BU pa-
tients (38) and in experimentally infected mice (59), with per-
sistence of recruited phagocytes at the periphery of mycolac-
tone-induced necrotic acellular areas (59, 84). These data
suggest that infection with viable M. ulcerans organisms in-
duces the production of cytokines and/or chemokines respon-
sible for the recruitment and, possibly, activation of inflammatory
cells.
In the present work we show that the levels of TNF produc-
tion by BMDM infected with different strains of M. ulcerans
are dependent on the cytotoxicity/virulence of the strain. Pro-
duction of TNF by macrophages was low, intermediate, or high
when they were infected with high, intermediate, or noncyto-
toxic/nonvirulent strains, respectively. The decreased produc-
tion of TNF by BMDM infected with highly cytotoxic/virulent
strains of M. ulcerans is not associated with a premature death
of macrophages in culture. Indeed, that production was quite
scant from the early time points of infection with these strains,
as well as in macrophage cultures infected with low MOIs that
did not induce cytotoxicity. Macrophages infected with the
highly virulent strains can, however, produce relevant amounts
of MIP-2, and the addition of mycolactone to cell cultures
infected with a mycolactone-defective strain does not abrogate
MIP-2 production. These results indicate that the decreased
production of TNF during intracellular infection with M. ul-
cerans is not due to a general toxic effect of mycolactone.
MIP-2 is the murine homologue of human IL-8 and plays a
central role in the recruitment of neutrophils in mice (27, 88).
This chemokine was previously shown to be induced in mice
infected with M. tuberculosis (68). Recently, the expression of
IL-8 was also reported in the lesions of patients infected with
M. ulcerans (64). The expression of this chemokine in BU
lesions is in accordance with the results from Guarner et al.
(38) and our own results (84) describing inflammatory infil-
trates containing neutrophils in the majority of the BU speci-
mens studied. Coutanceau and coworkers recently showed that
a mycolactone-producing strain of M. ulcerans induces expres-
sion of MIP-2 in infected macrophages (13). These and our
present results explain the occurrence of persistent inflamma-
tory infiltrates containing neutrophils in mice experimentally
infected with virulent strains of M. ulcerans (13, 59). In addi-
tion, it cannot be excluded that dead M. ulcerans, or bacilli not
producing mycolactone, may stimulate MIP-2 production and
contribute to the inflammatory response.
Our findings on the levels of virulence for mice, as well as on
the cytotoxic activity for infected macrophages, among M. ul-
cerans organisms that are mycolactone A/B or mycolactone C
producers are in accordance with previous reports showing a
higher cytotoxic effect of purified mycolactone A/B compared
to mycolactone C (56). It is clear from our data that the
outcome of infection by a particular M. ulcerans strain depends
on the type of mycolactone secreted by the pathogen. How-
ever, other factors contributing to the mycolactone-dependent
virulence of M. ulcerans cannot be discarded, namely, differ-
ences in the amount of toxin produced by each strain and even
FIG. 6. Proliferation of the mycolactone A/B-producing strain 98-912, mycolactone C-producing strain 94-1327, or mycolactone-negative strain
5114 in wild-type and TNF receptor-deficient mice. Mice (WT [closed symbols] or TNF-P55 KO [open symbols]) were infected subcutaneously in
the left hind footpad with 5.3 log10 AFB of M. ulcerans 5114 (diamonds), 94-1327 (triangles), or 98-912 (squares). The number of AFB in
homogenates from four footpads in each infected group was counted at the indicated time points. WT mice control the proliferation of M. ulcerans
5114 but do not eliminate the infection, whereas TNF-P55 KO mice are more susceptible to this strain. An increase in bacterial counts was also
found in the footpads of TNF-P55 KO mice infected with strain 94-1327 compared with the WT mice. No significant differences were found for
mice infected with M. ulcerans 98-912. For ethical reasons, mice were sacrificed after the emergence of ulceration. Statistical differences were
determined by comparing TNF-P55 KO mice with WT mice. Calculations were performed using Student’s t test. , P  0.05; , P  0.01; ,
P  0.001. Results are from one representative experiment out of two independent experiments.
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the possible regulation of toxin production that could be
switched on/off during defined periods of the pathogen’s life
cycle in the host, as previously discussed (84). In addition, the
possible existence of other M. ulcerans virulence factors cannot
be discarded. Further work is therefore necessary to elucidate
the causes for the variability in virulence found among M.
ulcerans strains.
As discussed above, the association between the mycolac-
tone profile and virulence in mice correlates inversely with the
capacity of M. ulcerans-infected BMDM to produce TNF. De-
creased production of TNF in response to virulent mycobac-
teria has been previously reported (28, 69). It is known, for
instance, that virulent M. tuberculosis H37Rv inhibits the pro-
duction of TNF by infected macrophages to a higher extent
than the nonvirulent strain H37Ra (23). However, the mech-
anisms for the decreased TNF production by these mycobac-
terial species are still unknown.
M. ulcerans is the only Mycobacterium known to produce a
cytotoxic exotoxin capable of inhibiting IL-2 and TNF produc-
tion from phorbol myristate acetate-ionomycin-activated T-cell
lines and lipopolysaccharide-activated human monocytes, re-
spectively (60). In the present work, we expand these observa-
tions by using a model of infection of primary macrophages
with live bacteria from a panel of M. ulcerans strains that
produce different amounts and types of mycolactone and that
exhibit diverse degrees of virulence for mice. The capacity of
virulent, mycolactone-producing M. ulcerans strains to down-
regulate the production of TNF might have consequences for
the outcome of infection, given that it has recently been
showed that M. ulcerans has a phase of intramacrophage res-
idence and proliferation (84). In fact, mice deficient in TNF or
in its P55 receptor are very susceptible to M. tuberculosis in-
fections (4, 26). From studies in the mouse model, it is known
that TNF is required to upregulate the macrophage bacteri-
cidal mechanisms, particularly in concert with IFN- (7, 24,
52). Our present data demonstrate that in experimental M.
ulcerans infection, the production of TNF also plays a protec-
tive role. By inhibiting the production of the macrophage-
activating cytokine TNF, virulent M. ulcerans strains would be
protected from the microbicidal mechanisms of macrophages,
allowing an extended time of intracellular proliferation until a
significant bacterial load is achieved.
The present and previous results (13, 60) show that myco-
lactone has an inhibitory activity on cytokine production in
vitro. It is still not clear whether this is an early manifestation
of impending cell death or a specific suppression of cytokine
production. Adusumilli and coworkers recently showed that
very low concentrations of mycolactone induce apoptosis in a
culture cell line (2). However, more studies are required to
address this question in vivo. The presence of TNF in the
lesions of BU patients has been inferred by the detection of
mRNA for this cytokine in samples of nonulcerative and ul-
cerative lesions (63, 64, 66), although a high variability in TNF
message has been detected in different patients (64, 66) as well
as in different areas within the same lesion (63).
These results show that production of TNF in BU lesions
can occur despite the presence of mycolactone, which may be
associated with bacilli or free in specific areas of the lesions. In
this context it is relevant to take into consideration that the
spatial relationship of TNF with the cytological pattern in
specific areas of a BU lesion, namely, the presence of macro-
phages and M. ulcerans bacilli, is still not clear (63). We can
hypothesize that TNF would be produced in BU lesions by (i)
macrophages infected with M. ulcerans bacilli in which myco-
lactone production would be temporarily switched off, (ii) mac-
rophages or other cell types distant from mycolactone-produc-
ing bacilli in areas not reached by the toxin but in contact with
mycobacterial molecules, and (iii) macrophages or other cell
types activated by proinflammatory molecules derived from the
process of tissue necrosis, regardless of the contact with M.
ulcerans or M. ulcerans-derived molecules.
It has been reported that the process of healing of necrotic
ulcers is associated with a granulomatous histopathology (1,
40, 41, 78, 86) and, in contrast, that disseminated disease and
osteomyelitis are associated with defects in granuloma forma-
tion (42, 78). It is well known that TNF has an important role
in the development and maintenance of the granuloma, a key
structure that prevents mycobacterial dissemination (4, 21, 26,
30, 48). The recently reported positive correlation between the
expression of proinflammatory cytokines, including TNF, and
the formation of granulomas in BU lesions (64) supports our
interpretation that TNF plays a protective role in M. ulcerans
infections and that a mycolactone-associated decreased pro-
duction of that cytokine would occur in the active phase of the
infection.
In conclusion, the data presented here show that macro-
phages infected with virulent, mycolactone-positive strains of
M. ulcerans produce amounts of the macrophage-activating
cytokine TNF that depend on the strain’s toxigenesis and that
this cytokine contributes to the protection of the infected host
against experimental M. ulcerans infection.
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ABSTRACT 
Not much is known about the immune response against Mycobacterium ulcerans, the 
etiological agent of Buruli ulcer (BU). The unique pathology caused by infections with this 
pathogen is closely associated with the production of the lipidic exotoxin mycolactone. Following 
the demonstration of an intramacrophage growth phase of M. ulcerans in the host, we 
investigated the biological relevance of interferon-gamma (IFN-γ) in vivo during an experimental 
M. ulcerans infection, as well as the protective mechanisms activated by this cytokine to control 
the intramacrophage proliferation of several M. ulcerans strains with different 
cytotoxicity/virulence for mice. 
We herein show that IFN-γ-deficient mice are more susceptible than wild-type mice to 
infection by nonvirulent and intermediate virulent strains of M. ulcerans but not to infection by a 
highly virulent strain. In accordance with the in vivo data, IFN-γ-activated cultured macrophages 
control the proliferation of the nonvirulent and intermediate virulent strains at a low multiplicity 
of infection. For the nonvirulent strain, the protective mechanism activated in macrophages was 
nitric oxide (NO)-dependent, since competitive-inhibition of the Nitric Oxide Synthase renders 
macrophages unable to control the proliferation of that strain. In contrast, NO production was 
not found in macrophages infected with the intermediate or highly virulent strains of M. 
ulcerans. However, macrophages infected with nonvirulent or intermediate virulent strains 
expressed high levels of LRG-47, a gene associated with phagosome maturation. These results 
suggest that intracellular M. ulcerans producing mycolactone interfer with the IFN-γ-dependent 
activation of macrophages that is responsible for the initiation of NO production and phagosome 
maturation required to control M. ulcerans proliferation. 
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INTRODUCTION 
Previous work from our laboratory has shown that, like other pathogenic mycobacteria, 
Mycobacterium ulcerans has a phase of intramacrophage proliferation (28). After the initial 
phase of intracellular residence and proliferation, lasting for a period of time that depends on 
the cytotoxicity of the strain, M. ulcerans kills the host cell becoming extracellular (28). Lysis of 
host cells, as well as destruction of tissues in infection foci is closely associated with the 
production of the M. ulcerans exotoxin mycolactone (10). Mycolactone was shown to passively 
diffuse through the plasmatic membrane of cells (24) inducing apoptosis and necrosis (1), 
having therefore an important impact on disease progression. Mycolactone is indeed a key 
pathogenic factor in Buruli ulcer (BU), namely by inducing death of inflammatory cells (28) 
recruited during M. ulcerans infection (13, 18) and by inhibiting tumor necrosis factor (TNF) 
production (19, 27). Therefore, the host immune response to M. ulcerans is determined by the 
mycobacterial nature of the pathogen compounded by the secretion of mycolactone. 
It is known that a protective immune response is mounted in individuals resistant to M. 
ulcerans that ultimately leads to the control of M. ulcerans without clinical manifestations (5). In 
addition, in a study of clofazamine treatment in patients with nodular lesions, the authors 
reported that 30% of nodules in the placebo group healed spontaneously (22). However, not 
much is known about the nature of the protective immune response against M. ulcerans 
infections. 
Different authors have reported the expression of several cytokines in BU lesions, 
including interferon-gamma (IFN-γ) (11, 12, 20, 21). This cytokine was firstly suggested to play 
a role in the control of M. ulcerans infections by Gooding and colleagues (11, 12). These 
authors found that peripheral blood mononuclear cells (PBMC) from patients with past BU, but 
not from healthy contacts, display low capacity to produce IFN-γ after stimulation with live M. 
ulcerans or Mycobacterium bovis BCG bacilli. In a posterior study, Westenbrink and colleagues 
found that, compared to matched community controls, PBMC from BU patients produce 
significantly higher levels of IFN-γ in late stages of the disease but not in early stages, when 
PBMC were stimulated with purified protein derivative (PPD) (30). When PCR analyses was used 
to quantify the expression of this cytokine in nodular or ulcerative BU lesions, Prevot and 
colleagues reported a higher expression of IFN-γ in the nodular lesions while a lower expression 
was detected in the more severe ulcerative lesions (21). On the other hand, in a more recent 
study, Phillips and colleagues reported a strong expression of IFN-γ in both nodular and 
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ulcerative lesions (20). Although with discrepant results, the reports discussed above suggest a 
protective role for IFN-γ in BU. 
IFN-γ is mainly produced by both CD4+ and CD8+ T cells and natural killer cells (8, 15). 
Being a powerful activator of the macrophage microbicidal mechanisms, IFN-γ is a key cytokine 
in the control of intracellular mycobacterial infections (8, 15). IFN-γ and TNF-activated 
macrophages show an increased fusion of phagosomes with endosomes and lysosomes, 
resulting in a decreased pH of the phagolysosomal compartment, which, in turn, leads to M. 
tuberculosis growth arrest (8). In addition, IFN-γ and TNF activate nitric oxide synthase 2 
(NOS2) to produce nitric oxide (NO), a powerful microbicidal molecule (8). In IFN-γ deficient 
mice, Mycobacterium tuberculosis grows unchecked, being this host extremely susceptible to 
this pathogen (4, 9). Lack of macrophage activation and NOS2 expression are the likely factors 
that contribute to the extreme susceptibility of these IFN-γ deficient mice (9).  
As discussed above, and although IFN-γ has been suggested to be associated with 
resistance to M. ulcerans infections (11, 12, 20), there is no direct evidence for a protective role 
of this cytokine in BU. The recent demonstration of an intramacrophage growth phase of M. 
ulcerans (28), directed us to study the role of IFN-γ in experimental M. ulcerans infections. 
Therefore, the objective of the present work was to investigate the biological relevance of IFN-γ 
in M. ulcerans infections and to dissect the anti-microbial mechanisms activated by this cytokine 
in macrophages infected with M. ulcerans.  
Our results show that IFN-γ is expressed in mouse M. ulcerans-infected footpads. In 
addition, the increased proliferation in IFN-γ-deficient mice of the mycolactone C-producing, 
intermediate virulent strain, M. ulcerans 94-1327 shows that IFN-γ induced during M. ulcerans 
infection is protective for the host. In vitro, IFN-γ-activated macrophages control the proliferation 
of the mycolactone-negative mutant strain 5114 as well as the virulent strain 94-1327. For the 
nonvirulent M. ulcerans 5114 strain, the bactericidal activity of activated macrophages is NO-
dependent. On the other hand, no increased NO production was detected in IFN-γ-activated 
macrophages infected with the mycolactone-producing strains M. ulcerans 94-1327 or 98-912. 
However, LRG-47 expression was detected in IFN-γ-activated macrophages infected with M. 
ulcerans 5114 and 94-1327, indicating enhanced phagosome maturation. These results are in 
accordance with previous data suggesting the involvement of cell-mediated immunity and 
delayed-type hypersensitivity in human and experimental BU, and provide a mechanism by 
which M. ulcerans proliferation is controlled in the host. 
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MATERIALS AND METHODS 
Bacterial strains and growth conditions. The M. ulcerans strains used in this study were 
selected based on their geographical origin and on the type of mycolactone produced. Strain 98-
912, a highly virulent strain (18, 27), was isolated from a Chinese patient and produces a 
mycolactone A/B slightly different from those in African strains (14). Strain 94-1327, an 
intermediate virulent strain (27), is an isolate from Australia and produces the characteristic 
mycolactone C (17) since its plasmid lacks the gene MUP053 encoding a P450 hydroxylase 
required to hydroxylate the mycolactone side chain at C-12 to produce mycolactone A/B (25). 
Strain 5114, a nonvirulent strain (18, 27), is an isolate from Mexico and does not produce 
mycolactone (17) due to the loss of key genes involved in the synthesis of this macrolide (25). 
All strains used in this work are from the collection of the Institute of Tropical Medicine (ITM), 
Antwerp, Belgium. 
The isolates were grown on solid 7H9 medium at 32ºC for approximately 1 month, 
recovered, diluted in PBS to a final concentration of 1 mg/ml and vortexed using 2-mm glass 
beads. The number of acid-fast bacilli (AFB) in the inocula was determined according to the 
method described by Shepard and McRae (23). The final suspensions revealed more than 90% 
viable cells as assessed with LIVE/DEAD Baclight Kit (Molecular Probes, Leiden, The 
Netherlands). 
Animals. Eight-week-old female BALB/c, C57BL/6 and IFN-γ-deficient mice, in a 
C57BL/6 background, were obtained from Charles River (Barcelona, Spain) and were housed in 
specific pathogen-free conditions with food and water ad libitum. 
Footpad model of infection and bacterial growth. Mice were infected in the left hind 
footpad with 0.03 ml of M. ulcerans suspensions containing 5 log10 AFB. The right hind footpad 
was used as a control.  At different time points after infection, M. ulcerans growth in footpad 
tissues of infected mice was evaluated as previously described (18). Briefly, tissue specimens 
were carefully minced on a petri dish. The tissues were resuspended in 2 ml PBS containing 
0.04% Tween 80 (Sigma) and vortexed vigorously with 2-mm glass beads to obtain homogenized 
suspensions. At different times postinfection, AFB counts were performed on samples from five 
footpads in each group by using the method of Shepard and McRae (23). 
Culture of murine bone marrow-derived macrophages (BMDM). Macrophages were 
derived from the bone marrow as follows: mice were euthanatized with CO2 and femurs 
removed under aseptic conditions. Bones were flushed with 5 ml cold Hanks' balanced salt 
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solution (HBSS) (Gibco, Paisley, United Kingdom). The resulting cell suspension was centrifuged 
at 500 x g and resuspended in Dulbecco's modified Eagle's medium (DMEM) (Gibco) 
supplemented with 10 mM HEPES (Sigma, St. Louis, MO), 1 mM sodium pyruvate (Gibco), 10 
mM glutamine (Gibco), 10% heat-inactivated fetal bovine serum (Sigma), and 10% L929 cell 
conditioned medium (complete DMEM [cDMEM]). To remove fibroblasts or differentiated 
macrophages, cells were cultured for a period of 4 hours on cell culture dishes (Nunc, 
Naperville, IL) with cDMEM. Nonadherent cells were collected with warm HBSS, centrifuged at 
500 x g, distributed in 24-well plates at a density of 5 x 105 cells/well, and incubated at 37°C in 
a 5% CO2 atmosphere. On day 4 after seeding 0.1 ml of L929 cell conditioned medium was 
added, and medium was renewed on the seventh day. After 10 days in culture, cells were 
completely differentiated into macrophages. Twelve hours before infection, macrophages were 
incubated at 32°C in a 5% CO2 atmosphere and maintained until the end of the experimental 
infection as described elsewhere (18).  
Macrophage infectivity assays and bacterial growth. Bacterial suspensions were prepared 
as described above and further diluted in cDMEM before infecting macrophage monolayers. M. 
ulcerans suspensions (0.2 ml) were diluted in cDMEM and added to each well in order to obtain 
a multiplicity of infection (MOI) indicated for each experiment (bacteria/macrophage ratio). Cells 
were incubated for 4 h at 32°C in a 5% CO2 atmosphere and then washed four times with warm 
HBSS to remove noninternalized bacteria and reincubated in cDMEM, in cDMEM with 100 Uml-1 
of recombinant IFN-γ or in cDMEM with 100 Uml-1 of recombinant IFN-γ and NG-monomethyl-L-
arginine (L-NmmA), an inhibitor of nitric oxide synthases (NOS) or NG-monomethyl-D-arginine (D-
NmmA), a molecule that does not have an effect in the function of NOS. To confirm the MOI, 
counting of AFB in infected macrophages was performed at the beginning of experimental 
infection as described previously (23). 
At different time points after infection, bacterial growth was assessed by counting colony 
forming units (CFU) from macrophage monolayers. Briefly, at the selected time point, 
macrophage monolayers were lysed with saponin (0.1% final concentration), and serial dilutions 
were seeded in 7H9 agar medium with OADC supplement. Plates were then incubated at 32ºC 
for 6 to 8 weeks. 
Nitrite quantification. Nitrite production by the macrophage monolayers was determined 
by the Griess assay as described elsewhere (26). Briefly, macrophage supernatants were 
thawed and diluted in a 96-well enzyme-linked immunosorbent assay plate (Nunc), and an equal 
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volume of Griess reagent (1% sulfanilamide, 0.1% napthylethylenediamine, 2.5% H3PO4) was 
added. The absorbance at 550 nm was measured on an enzyme-linked immunosorbent assay 
reader, and the concentration of nitrite was calculated by comparing optical density values to a 
standard curve of NaNO2 in cDMEM. 
Quantitative RT-PCR analysis. Total RNA from cultured BMDM was extracted with TRIzol® 
Reagent (Invitrogen, San Diego, CA) according to the manufacturer’s instructions. Reverse 
transcription was done with whole RNA in a final volume of 20 μl using SuperScript II 
(Invitrogen) and Oligo(dT) (Invitrogen) according to the manufacturer’s instructions. The cDNA 
was then subjected to real-time PCR for quantification of Hypoxanthine 
phosphoribosyltransferase (HPRT) and LRG-47. The LightCycler-FastStart DNA Master 
Hybridization Probes mixture was used according to the manufacturer’s instructions. The HPRT 
reaction mixture included 5 mM Mg2+, sense primer (5’-GCTGGTGAAAAGGACCTCT-3’), anti-
sense primer (5’-CACAGGACTAGAACACCT GC-3’) and the gene specific probes 5’-LC red640-
TCTGCAAATACGAGGAGTCCTGTTGP-3’ and 5’-AAAGCCTAAGATGAG CGCAAGTTGAF-3’. The 
cycling parameters were 1 cycle of 95ºC for 10 min, followed by 45 cycles of 94ºC for 10 sec, 
60ºC for 10 sec and 72 ºC for 11 sec. The temperature transition rate was 20ºC. The LRG-47 
reaction mixture included 5 mM Mg2+, sense primer (5’-CTCTGGATCAGGGTTTGAGGAGTA-3’), 
anti-sense primer (5’-GGAACTGTGATGGTTTCATGATA-3’) and the gene specific probes 5’-LC 
red640- AGGTCCACAGACAGCGTCACTCGGP-3’ and 5’-AACCAGAGAGCCTCACCAGGGAGCTGAF-
3’. The cycling parameters were 1 cycle of 95ºC for 10 min, followed by 45 cycles of 94ºC for 
10 sec, 58ºC for 10 sec and 72 ºC for 20 sec.  
The specific probes for each cytokine were designed and synthesized by TIB MolBiol 
(Berlin, Germany). Single acquisition was done in the end of each annealing step. 
Statistical analysis. Statistical significance of values was determined using the Student t 
test. 
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RESULTS 
IFN-γ is induced in murine footpads infected with either a mycolactone-negative mutant or 
mycolactone-producing strains of Mycobacterium ulcerans. Interferon-gamma (IFN-γ) production 
by the host is a hallmark of protection in infections by intracellular parasites, including 
Mycobacterium avium (2, 7) and Mycobacterium tuberculosis (4, 9). The role of IFN-γ in M. 
ulcerans infection was not experimentally addressed so far, even though some authors have 
suggested that resistance to M. ulcerans infection in humans is associated with IFN-γ 
production (11, 12, 20).  
To study the kinetics of IFN-γ expression following infection by M. ulcerans, mice were 
infected in the left hind footpad with different strains of M. ulcerans, which do not produce 
mycolactone or produce different types of mycolactone, showing different degrees of virulence 
for mice (18, 27). As represented in FIG. 1, all M. ulcerans strains tested induced the in vivo 
expression of IFN-γ following infection by the subcutaneous (s.c.) route. Nonetheless, the 
mycolactone-deficient M. ulcerans 5114 induced a higher expression of this cytokine, with a 
peak of expression at day 20 after infection (FIG. 1). The highly virulent, mycolactone-producing 
M. ulcerans 98-912 induced a low but sustained level of expression of IFN-γ with similar kinetics 
as compared with M. ulcerans 5114.  
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FIG. 1 – Infection with M. ulcerans 5114 or 98-912 induces the 
expression of IFN-γ in infected footpads. Mice were infected 
subcutaneously with 5.3 log10 of M. ulcerans 5114 (squares) or 98-912 
(diamonds) in the left hind footpad. Noninfected mice were used as 
controls. At different times postinfection, footpad cells were harvested, 
mRNA extracted and IFN-γ expression was evaluated by Real Time-PCR. 
Both M. ulcerans strains induce IFN-γ in the infected footpad; however, 
the nonvirulent M. ulcerans strain 5114 induces higher levels of IFN-γ 
expression when compared with M. ulcerans 98-912.  
 
 
 
These results show that, like in human BU lesions (11, 12, 20), IFN-γ  message is 
detected in the infectious focus of experimental infections with mycolactone-deficient or 
mycolactone producing strains of M. ulcerans. Additionally, the levels of IFN-γ message were 
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found to be different following infection with the different M. ulcerans strains. It is possible that 
the induction of IFN-γ is related with the virulence of the infecting strain, being low virulent 
strains high inducers of IFN-γ and highly virulent strains low inducers of this cytokine. These 
results could explain the incongruent results reported in the literature, regarding the expression 
of IFN-γ in Buruli ulcer (BU) lesions (20, 21). Indeed, among the different studies carried out in 
BU samples to elucidate the role of different cytokines in BU, there is no information on the 
cytotoxicity/virulence of the infecting strains. It is therefore possible that the variation in IFN-γ 
expression found in different studies (30) is associated with different degrees of virulence of the 
infecting strains.    
 
IFN-γ plays a role controlling M. ulcerans proliferation both in vivo and in vitro. Taking into 
consideration the fact that both the mycolactone-negative mutant and the mycolactone-
producing strains of M. ulcerans induced IFN-γ expression after infection by the s.c. route, we 
evaluated the role of this cytokine in experimental infections by M. ulcerans, in vivo and in vitro.  
To address the biological relevance of IFN-γ in an experimental model of BU, we 
compared the proliferation of the three M. ulcerans strains in the footpad of wild-type (WT) or IFN-
γ-deficient mice. The proliferation of mycobacteria in infection foci was monitored by counting 
acid-fast bacilli (AFB) in homogenates of the infected footpads at selected time points. As 
represented in FIG. 2A, the proliferation of M. ulcerans 5114 was controlled by WT mice but not 
by IFN-γ-deficient counterparts, with a difference of 1.47 log10 AFB at day 245 of experimental 
infection. In contrast, no differences were found in the proliferation of the highly virulent strain M. 
ulcerans 98-912 in WT or IFN-γ-deficient mice even when low infectious doses were used (FIG. 
2C). Interestingly, IFN-γ-deficient mice, were slightly more susceptible to the infection with the 
intermediate virulent M. ulcerans strain 94-1327 when compared with WT mice, with an 
increased proliferation of 0.4 log10 AFB over the first 35 days of infection (FIG. 2B). After this time 
point, this strain was found not to be controlled by either WT or IFN-γ-deficient mice.  
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FIG. 2 – IFN-γ-deficient mice have an increased susceptibility to M. ulcerans. Mice (WT [closed symbols] and IFN-γ-
deficient [opened symbols]) were infected subcutaneously in the left hind footpad with 5 log10 AFB of M. ulcerans 
5114 or M. ulcerans 94-1327 or 4 log10 AFB of M. ulcerans 98-912. The number of AFB in homogenates from four 
footpads in each infected group was counted at the indicated time points. Statistical differences were determined by 
comparing IFN-γ-deficient mice with WT mice. Calculations were performed using Student’s t test. *, p<0.05; ***, p< 
0.001. 
WT mice control the proliferation of M. ulcerans 5114 but do not eliminate the infection, whereas IFN-γ-deficient 
mice are susceptible to the infection with this strain, with a difference of 1.47 log10 AFB at day 245. An increased 
bacterial burden was also found in the footpads of IFN-γ-deficient mice infected with strain 94-1327, at day 40 after 
infection, as compared with WT mice. No significant differences were found for mice infected with M. ulcerans 98-
912. 
 
To further address the role of IFN-γ in BU, and considering our previous demonstration 
of an intramacrophage growth phase of M. ulcerans (28), bone marrow-derived macrophages 
(BMDM) were infected with the previously described strains of M. ulcerans in the presence or 
absence of IFN-γ. As represented in FIG. 3A, M. ulcerans 5114 proliferated inside BMDM over 
the 8 day-period studied. In accordance with the in vivo results obtained for this strain (FIG. 2A), 
in the presence of IFN-γ there was a 1.38 log10 reduction of the colony forming units (CFU) 
counts. On the other hand, no differences were found in the proliferation of the highly virulent 
strain M. ulcerans 98-912 in IFN-γ-activated or nonactivated macrophages (FIG. 3D) regardless 
of the MOI used to infect the BMDM cultures (data not shown). For BMDM infected with the 
intermediate virulent strain 94-1327, different results were obtained acording with the tested 
multiplicity of infection (MOI). At an MOI of 1:1, we found that this M. ulcerans strain was not 
controlled either by nonactivated or IFN-γ-activated BMDM (FIG. 3B). However, at the lower MOI 
of 1:3, IFN-γ-activated BMDM controlled the proliferation of M. ulcerans 94-1327 in the first 4 
days of infection, with a 0.2 log10 reduction of the CFU counts (FIG. 3C). 
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FIG. 3 – IFN-γ-activated macrophages control the proliferation of M. ulcerans 5114 and M. ulcerans 94-1327 but not 
M. ulcerans 98-912. BMDM infected with M. ulcerans 5114 (A) or 94-1327 (B) at a 1:1 MOI  or with M. ulcerans 94-
1327 (C) or 98-912 at a 1:3 MOI (D) were left untreated (closed symbols), or activated with 100 Uml-1 of 
recombinant IFN-γ every other day after infection (opened symbols). At different times postinfection, macrophages 
were lysed and CFUs were performed. Statistical differences were determined by comparing IFN-γ-activated with 
nonactivated macrophages. Calculations were performed using Student’s t test. *, p<0.05; ***, p< 0.001. 
All M. ulcerans strains were found to persist in nonactivated macrophages, but IFN-γ-activated macrophages were 
found to control the proliferation of M. ulcerans 5114 as well as M. ulcerans 94-1327 at the lower MOI of 1:3. On 
the other hand, proliferation of M. ulcerans 98-912 was similar in both IFN-γ-activated or nonactivated BMDM at the 
lower MOI of 1:3.  
 
Overall, these results show that IFN-γ plays a protective role in M. ulcerans infections, 
by activating macrophages to control M. ulcerans intracellular proliferation.  
 
IFN-γ-activated macrophages infected with M. ulcerans 5114 or 94-1327, but not M. 
ulcerans 98-912, show an increased production of NO or LRG-47 expression. IFN-γ has been 
shown to increase the bactericidal activity of macrophages by inducing the production of nitric 
oxide (NO) (6, 8) and phagosome-lysosome fusion (29), as well as by increasing the production 
of proinflammatory cytokines such as interleukin (IL)-1 and tumor necrosis factor (TNF) (3). The 
role of these effector mechanisms in the control of M. ulcerans is still not known. 
We first evaluated the production of NO, by measuring the accumulation of nitrite in the 
culture medium, by IFN-γ-activated BMDM following infection by the three different strains of M. 
ulcerans. As represented in FIG. 4, IFN-γ-activated macrophages infected with the mycolactone-
negative strain 5114 produced high amounts of nitrite over the 8 days of experimental infection. 
However, macrophages infected with the mycolactone-producing strains 98-912 or 94-1327 
were found not to produce significant amounts of nitrite, even after stimulation with IFN-γ. These 
results suggest that mycolactone-producing strains of M. ulcerans inhibit the production of NO 
by macrophages activated with IFN-γ. 
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FIG. 4 – IFN-γ-activated macrophages infected with M. ulcerans 
5114 produce higher amounts of nitrite. BMDM infected with M. 
ulcerans 5114 (squares), 94-1327 (triangles) or 98-912 
(diamonds) were left untreated (closed symbols) or activated with 
100 Uml-1 of recombinant IFN-γ every other day after infection 
(opened symbols). Noninfected macrophages (opened circles) or 
macrophages activated with IFN-γ and LPS (closed circles) were 
used as negative and positive control, respectively. At different 
times postinfection, levels of nitrite production were assayed in the 
culture medium by using the Griess method. Statistical differences 
were determined by comparing IFN-γ-activated with nonactivated 
macrophages, infected or noninfected. Calculations were 
performed using Student’s t test. ***, p< 0.001. 
***
***
***
***
IFN-γ-activated BMDM infected with M. ulcerans 5114 produce higher amounts of nitrite when compared to the 
amounts produced by IFN-γ-activated BMDM infected with M. ulcerans 94-1327 or 98-912. Noninfected or infected 
but nonactivated BMDM do not produce nitrite. 
 
The biological relevance of NO in the control of the intramacrophage proliferation of M. 
ulcerans was further evaluated following infection of BMDM with strain 5114 in the presence of 
the competitive nitric oxide synthase (NOS) inhibitor L-NmmA. The molecule D-NmmA was used 
as a control. As represented in FIG. 5, the competitive inhibition of NOS reduces the capacity of 
IFN-γ-activated macrophages to control the infection by this strain of M. ulcerans, showing that 
NO production is essential to control the proliferation of intramacrophage M. ulcerans 5114. 
Interestingly, in the presence of L-NmmA, there is still some control of M. ulcerans 5114 
proliferation, suggesting that other macrophage microbicidal mechanisms, independent of NO 
production, are also important to control the intramacrophage proliferation of M. ulcerans. 
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FIG. 5 – Nitric oxide produced by IFN-γ-activated macrophages plays a 
key role in the control of M. ulcerans 5114. BMDM infected with M. 
ulcerans 5114 nonactivated (closed symbols) or activated with 100 
Uml-1 of recombinant IFN-γ every other day after infection (opened 
symbols) were treated with L-NmmA (triangles) or, as a control, with D-
NmmA (squares). Statistical differences were determined by comparing 
IFN-γ-activated with nonactivated macrophages for the same condition. 
Calculations were performed using Student’s t test.*, p<0.05; **, 
p<0.01;***, p< 0.001. 
**
*
***
BMDM activated with IFN-γ and treated with the NOS inhibitor L-NmmA 
were unable to control M. ulcerans 5114, whereas macrophages 
treated with D-NmmA killed the bacteria, showing that nitric oxide plays a key role controlling the proliferation of this 
M ulcerans strain. 
 
The phagosome-lysosome fusion is another important mechanism involved in resistance 
to infection by intracellular parasites (8, 15). LRG-47 expression was shown to be associated 
with phagosome maturation (16). Taking this into consideration, we measured the level of 
expression of LRG-47 in M. ulcerans-infected macrophages. As represented in FIG. 6, IFN-γ-
activated BMDM infected with M. ulcerans 5114 showed high levels of LRG-47 expression 12 
hours after infection. Interestingly, IFN-γ-activated, M. ulcerans 94-1327-infected macrophages 
showed a decreased expression of LRG-47 when compared to macrophages activated with IFN-γ 
alone. On the other hand, there was a complete inhibition of LRG-47 in activated macrophages 
infected with M. ulcerans 98-912. This set of results suggests that mycolactone-producing M. 
ulcerans strains inhibit the maturation of the phagosome, probably providing these strains a 
nonacidic environment to survive and proliferate within macrophages. However, this effect 
seems to be dependent on the type of mycolactone produced by M. ulcerans, since the 
intermediate virulent strain 94-1327, a mycolactone C producer, does not inhibit phagosome 
maturation at the same extent as the highly virulent M. ulcerans 98-912 strain, a mycolactone 
A/B producer. The higher expression of LRG-47 by M. ulcerans 94-1327-infected macrophages 
explains the control of this strain by IFN-γ-activated macrophages (FIG 3D). However, this 
control is not as efficient when compared with M. ulcerans 5114, since there is no production of 
NO by M. ulcerans 94-1327 infected, IFN-γ-activated macrophages (FIG. 4). 
 
 96 
 
R
el
at
iv
e 
IF
N
-γ
m
R
N
A
 e
xp
re
ss
io
n 
x 
10
-3
N
D
12 hours
1:
1
51
14
94
-1
32
7
98
-9
12
N
I
1:
1
1:
3
1:
3
1:
1
1:
3
IFN-γ - - - - +     +     +   +  
MOI
1
2
3
4
Strain
1:
1
51
14
94
-1
32
7
98
-9
12
N
I
1:
1
1:
3
1:
3
1:
1
1:
3
0
R
el
at
iv
e 
IF
N
-γ
m
R
N
A
 e
xp
re
ss
io
n 
x 
10
-3
N
D
1:
1
51
14
94
-1
32
7
98
-9
12
N
I
51
14
94
-1
32
7
98
-9
12
N
I
1:
1
1:
3
1:
3
1:
1
1:
3
FIG. 6 – Infection of BMDM with M. ulcerans 5114 or 94-1327 
induces LRG-47 expression. BMDM infected with M. ulcerans 
5114, 94-1327 or 98-912 were left untreated (closed bars) or 
activated with 100 Uml-1 of recombinant IFN-γ every other day 
after infection (dashed bars). Macrophages noninfected, 
activated or nonactivated (opened bars) with IFN-γ were used 
as control. At 12 hours after-infection, mRNA was extracted 
and LRG-47 expression was evaluated by Real Time-PCR. 
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BMDM infected with M. ulcerans 5114, and in a lesser extent, 
infected with M. ulcerans 94-1327 express LRG-47, indicative 
of phagosome maturation. On the other hand, no expression of 
this gene was detected in BMDM infected with M. ulcerans 98-
912. ND, not-detected. 
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5.1.   GENERAL DISCUSSION 
Buruli ulcer (BU) is a serious skin disease caused by infections with Mycobacterium 
ulcerans. Although this pathogen was described for the first time in 1948 by MacCallum and 
colleagues (50) in Australia, it has received little attention until the last decade. BU affects 
inhabitants of different tropical regions, mainly in poor rural areas in Africa where inadequate or 
no health services are available. All ages and sexes are affected; however most patients are 
among children younger than 15 years old (5). Since the 1980s, the disease has emerged 
dramatically in West African countries and, in some communities, has become more prevalent 
than tuberculosis and leprosy (43).  
BU is difficult to treat and can result in serious sequelae, deformities and functional 
disabilities. Different measures have been suggested to control BU (22). However, associated 
with this disease, there is a strong social stigma and many communities in Africa see BU as a 
curse rather than as a disease. For that reason, vaccination to prevent BU would be the most 
satisfactory strategy to control the disease. Although BCG vaccination to prevent BU was shown 
to confer some degree of protection, the protection conferred was short lived (76, 84), and thus a 
specific and more effective vaccine is urgently needed. To develop such a vaccine against BU, it 
is required to understand the very first stages of the interaction of M. ulcerans with the host’s 
immune system, which cannot be studied in the human infection because samples of initial BU 
lesions are not available. 
M. ulcerans is genetically closely related with Mycobacterium marinum and 
Mycobacterium tuberculosis (85); however the disease caused by M. ulcerans is particular in 
some key aspects. In fact, unlike other pathogenic mycobacteria, M. ulcerans produces a lipidic 
toxin, mycolactone, that was shown to have a key role in M. ulcerans pathogenesis (33). It was 
shown that injection of purified mycolactone in guinea pig skin induces an ulcer similar to that 
induced by virulent M. ulcerans bacilli (33, 48). Additionally, mycolactone-negative mutant M. 
ulcerans strains were shown to be nonvirulent for mice and guinea pigs (33, 58), supporting the 
central role played by this toxin in the pathogenesis of BU. 
When we started our work on M. ulcerans infection, it was not clear whether: (i) M. 
ulcerans was always an extracellular pathogen, as it has been described in the literature, or if 
there was an intracellular phase in the life cycle of this pathogen; (ii) what cytokines and 
chemokines were produced upon infection with this pathogen, as well as their relevance to 
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control M. ulcerans proliferation; and (iii) what microbicidal mechanisms were required to prevent 
the proliferation of this pathogen in the host.  
The propose of the present dissertation was to contribute to address these questions, 
that will be very important to better understand the characteristics of a protective immune 
response against M. ulcerans and, in the future, for the development of a vaccine or better 
therapeutic strategies.  
 
 
Intramacrophage growth phase of M. ulcerans. The characterization of a bacterial pathogen as an 
intracellular parasite is based on a set of characteristics: (i) they promote phagocytosis by 
professional phagocytes, usually macrophages, and express genes that allow them to survive and 
multiply intracellularly  (55, 72), although they usually also have a phase of extracellular 
multiplication (18, 38); (ii) the pathology caused after infection is associated with their 
intracellular life style (45, 61); and (iii) the immune response involves cell-mediated immunity 
(CMI) mechanisms which generally requires cytotoxic T lymphocytes or a T helper (Th)1-type 
response (45, 61). 
 
We and other groups have shown that M. ulcerans is cytotoxic for cultured macrophages 
(34, 58).  Although being intracellular parasites, several mycobacterial species have cytotoxic 
activity against macrophages or other cell types (49, 69), however, M. ulcerans is the most 
cytotoxic of all known mycobacteria (20). Due to its cytotoxicity, associated with mycolactone 
production, M. ulcerans has been considered unable to grow inside cultured macrophages (3, 
70). Moreover, BU lesions are characterized histopathologically by large numbers of extracellular 
bacilli in necrotic acellular areas (10, 20, 23, 37, 44). These two sets of observations led most 
investigators to classify M. ulcerans as an extracellular pathogen (3, 11, 14, 20, 33, 37, 40, 60). 
In what regards the presence of phagocytes in BU infection foci, previous work from our 
laboratory showed that experimental infections with M. ulcerans in the mouse footpad induce a 
persistent inflammatory response with a profile  that is dependent on the cytotoxicity/virulence of 
the strain (58). The inflammatory infiltrate induced by virulent, mycolactone-producing strains 
was found at the periphery of the lesion, while large clumps of M. ulcerans bacilli were present in 
a central necrotic acellular area. More importantly, M. ulcerans bacilli were consistently found co-
localizing with phagocytes in the areas of inflammation (58). Therefore, considering this constant 
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availability of inflammatory cells to interact with M. ulcerans, and that resistance to infections by 
M. ulcerans in humans and mice has been associated with CMI and delayed-type hypersensitivity 
(DTH) responses (21, 35, 36, 40, 47, 50, 51, 57, 63, 66, 74, 77, 79, 82, 88), led us to 
consider that the typical histopathology of BU lesions (large numbers of extracellular bacilli in 
necrotic acellular areas) may not reflect the actual host-parasite interactions at the active foci of 
infection in patients with BU and that M. ulcerans, like other pathogenic mycobacteria, would 
have an intracellular growth phase in the host. In this context, it is relevant that some early 
investigators have reported intracellular M. ulcerans inside macrophages and neutrophils both in 
human lesions as well as in experimental models of infection (48, 50, 71).  
 
Therefore, our initial studies were directed toward the evaluation of the interactions 
between phagocytes and M. ulcerans in human infections, interactions that so far have not been 
analysed in detail. 
In our analysis of 19 samples from confirmed BU cases (chapter 2), inflammatory 
infiltrates were observed in 15, a result that agrees with a recent report describing cellular 
inflammatory responses in a high percentage of BU cases, although with a minimal extension 
(39). Eight of the 15 specimens with inflammatory infiltrates and acid-fast bacilli (AFB) revealed 
intramacrophage M. ulcerans in the periphery of the necrotic lesion. It should be stressed that in 
BU samples, intramacrophage bacilli were not seen as often as in mice footpads infected with M. 
ulcerans, since the mouse footpad model allows a histopathological evaluation of the complete 
footpad, whereas in human samples the lesion is usually too extensive to be included in a single 
biopsy. Consequently, due to the extensiveness of the human lesions, inflammatory infiltrates 
and AFB were not always represented in the same tissue sample, even when different sections of 
the same sample were analysed. Altogether, these results direct us towards the re-evaluation of 
the interactions between M. ulcerans and the host phagocytes in the more controlled model of 
bone marrow-derived macrophages (BMDM) infection. 
We quantitatively showed that, like the intracellular mycobacteria M. tuberculosis and 
Mycobacterium bovis BCG, M. ulcerans is efficiently phagocytosed by BMDM at a 1:1 
(bacilli/macrophage ratio) multiplicity of infection (MOI). In this in vitro model of infection, as 
shown by electron microscopy, M. ulcerans was found surrounded by the macrophage 
phagosomal membrane. In the mouse footpad model of infection, M. ulcerans was also found to 
be extensively phagocytosed by macrophages and neutrophils, in accordance with previous data 
from our own group (58) and others (16). 
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The inhibition of M. ulcerans phagocytosis and the lack of intramacrophage growth 
previously described by other authors may be explained by the use of high MOIs (10:1) (3, 70), 
resulting in early mycolactone-dependent damage of macrophages. In support of our 
interpretation, it is known that at high MOIs other pathogenic mycobacteria also show cytotoxic 
activity against cultured cells. Ramakrishnan and colleagues (69) showed that, when 
macrophages of the J774A.1 cell line were infected with M. marinum at an MOI of 1:1 or less, no 
cytopathic effect was observed in the macrophage’s monolayers. However, at higher MOIs, 
macrophage cell death was detected by the piknotic appearance of cell nuclei (69).  Similar 
results were found by other authors in infections by M. tuberculosis (31, 49). 
 
However, the demonstration of M. ulcerans inside phagocytes in vivo and of the capacity 
of macrophages to phagocytose this pathogen in vitro is not conclusive of M. ulcerans being an 
intracellular pathogen. Using the in vitro model of BMDM infection, we showed for the first time 
that after phagocytosis, M. ulcerans grows inside macrophages, as is the case of other 
pathogenic mycobacteria. The period of intramacrophage growth was dependent on the 
cytotoxicity of the strain. Low cytotoxic strains grew within macrophages for extended periods of 
time, whereas highly cytotoxic strains grew within macrophages for shorter periods of time, killing 
the macrophage after a period on intracellular multiplication due to the activity of mycolactone, 
becoming thereafter extracellular. 
   
One of the characteristics of intracellular pathogens is their relative low cytotoxicity (4). In 
fact, it would be intuitive to expect intracellular pathogens to have low direct cytotoxicity, so that 
no damage would be imparted to the host cells. However, it is becoming progressively evident 
that a fundamental step in the pathogenic cycle of intracellular pathogens is their ability to lyse 
and egress from the host cell after termination of intracellular replication, to infect other cells 
within the same host, or to be transmitted to a new susceptible host (4). In fact, the production of 
toxins that directly lyses host’s cells is a mechanism commonly used by extracellular pathogens, 
but not uncommon among intracellular pathogens (87). Different intracellular pathogens induce 
cell death in the host cell to subvert normal host defense responses, mainly by producing toxins 
that express their enzymatic activity in the cell cytosol (87). Shigella Spp are known to induce 
apoptosis of the host cell, both in vitro and in vivo (90, 91). These species cause a diarrheal 
disease with a variable clinical picture and the killing of the host cell is a critical point, so the 
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bacteria can be transmitted through fecal/oral route (87). The Shigella genes responsible for 
invasion and cytotoxicity are located in a plasmid that encodes a secretion type-III apparatus and 
the toxins. Escape from the phagosome and induction of apoptosis is dependent on the 
expression and secretion of the plasmid antigens (8, 9). Unlike Shigella Spp, Salmonella 
typhimurium is able to grow inside macrophage’s phagolysosome (2, 7, 67) but also induces 
macrophage apoptosis through a type-III secretion mechanism (54). In the case of Legionella 
pneumophila, upon termination of its intracellular replication, which is the hallmark of 
Legionnaires’ disease, the pathogen induces cytolysis of infected macrophages to allow egress of 
intracellular bacteria. This process of cytolysis is induced by a pore-forming toxin and it was 
shown to play a major role in pulmonary immunopathology in vivo (4).  
The above observations show that several intracellular pathogens reconcile cytotoxicity 
with intracellular parasitism, inducing cell death after a period of intracellular multiplication to 
spread to different cells in the same host or to a new host. 
Although in some cases, killing of the host cell is detrimental to the host response, 
apoptosis of macrophages infected with other infectious agents, mainly intracellular pathogens, 
may be beneficial to the host. In fact, apoptosis of human monocytes has been shown to limit M. 
bovis BCG and Mycobacterium avium growth (28, 53). In addition, low virulent strains of M. 
tuberculosis induce high levels of macrophage apoptosis when compared with highly virulent 
strains (68).  
  
The machinery required to mycolactone production is encoded in a giant plasmid (80). It 
is still not known if and how mycolactone production is regulated by M. ulcerans. In this sense, if 
the expression of the polyketide synthases required to produce mycolactone are subjected to an 
orchestrated pattern of transcriptional control during the initial phase of intracellular growth, that 
would allow the pathogen a period of growth inside the host cell. After reaching a significant 
intracellular bacterial load, mycolactone synthesis would be activated, resulting in lysis of the 
host cell. Our data showing that M. ulcerans infection of the J774A.1 macrophage’s cell line at 
different MOIs induces cell death when a similar bacterial load is achieved, although at different 
time points, is in accordance with such a putative mechanism of switching off mycolactone 
production. As discussed above, this kind of mechanism is used by other pathogenic bacteria 
including L. pneumophila (4). 
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Another argument in favor of M. ulcerans being an intracellular pathogen is the presence 
in this pathogen of genes known to be important for the intracellular multiplication of other 
pathogenic mycobacteria, such as M. tuberculosis. It has been shown that during periods of 
survival within macrophages, M. tuberculosis specifically express several genes and that some of 
them are essential for its survival. Namely, genes of the fadE28 gene cluster appear to be critical 
for M. tuberculosis to survive inside macrophages (72). These genes have been proposed to be 
involved in lipid transport and degradation, and its likely function consists in assimilating 
exogenous lipids from the host cell membranes (72). Additionally, genes of the lpqY system were 
shown to be important for survival in nonactivated macrophages and are also important for M. 
tuberculosis growth in vivo. Also PstA1 and pstC2, members of a putative operon, are each 
essential for M. tuberculosis to grow in macrophages (72). PhoP/PhoQ, are known to control 
transcription of key virulence genes essential for survival in host cells in diverse intracellular 
bacterial pathogens, including Salmonella sp., Shigella sp.,  Yersinia sp. and M. tuberculosis 
(62). Erp codes for a surface-exposed protein required for multiplication and intracellular growth 
(13). The genes referred above are also present in the genome of M. ulcerans, showing that this 
species has genes required for intracellular growth.   
With the publication of the complete M. ulcerans genome sequence (81), a 
comprehensive search for other M. ulcerans genes required to intracellular growth will be 
important to better understand the biology of the infection caused by this pathogen. 
 
Our observation, in experimental mouse infections and in BU biopsies, of progressive 
enlargement of the clumps of extracellular AFB away from the areas of colocalization with 
inflammatory cells suggests that there is extracellular growth of M. ulcerans following the 
shedding of the bacilli from lysed, infected macrophages. Taking into consideration this 
observation and the results showing that M. ulcerans bacilli (i) are efficiently phagocytosed by 
mouse macrophages in vivo and in vitro, (ii) are present inside macrophages in mouse footpad 
and peritoneal infections and in BU tissues, and (iii) grows within cultured macrophages, we 
propose that the growth of M. ulcerans would take place, in a manner similar to that of M. 
tuberculosis (18, 38), by both intracellular and extracellular multiplication in distinct areas of the 
lesion. 
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The impact of extracellular M. ulcerans in the progression of BU is still not elucidated but 
our results suggest that intramacrophage M. ulcerans has an impact in the progression of the 
disease, as it will be discussed below. 
 
 
Mycolactone-mediated inhibition of tumor necrosis factor production by M. ulcerans-infected 
macrophages. Tumor necrosis factor (TNF) is a key cytokine in the activation of the 
macrophage’s effector mechanisms (25). However, its role and relevance in M. ulcerans 
infections was not yet evaluated. Moreover, it has been shown that mycolactone inhibits TNF 
production by phorbol myristate acetate-ionomycin-activated T-cell lines and lypopolysacharide 
(LPS)-activated human monocytes (59). As previously discussed, M. ulcerans induces a cellular 
inflammatory response in specific areas of the infectious lesion, with the recruitment of 
macrophages, both in BU patients (39; chapter 2) and in experimental models of infection (58). 
These results suggest that M. ulcerans induces the production of cytokines and chemokines 
responsible for the recruitment and, possibly, activation of immune cells. 
 
In chapter 3, we first characterized the TNF production by BMDM infected with different 
strains of M. ulcerans and showed that BMDM produce different amounts of TNF, depending on 
the cytotoxicity/virulence of the strain. Indeed, macrophages infected with highly 
cytotoxic/virulent strains produce low amounts of TNF, whereas macrophages infected with low 
cytotoxic/virulent strains produce higher amounts of TNF. The low production of TNF by 
macrophages infected with mycolactone-producing M. ulcerans was not due to an early death of 
macrophages, since, even at low MOIs, for which no cytotoxic effect was seen, there was no 
relevant production of this cytokine. Moreover, macrophages infected with the same virulent M. 
ulcerans produced significant amounts of another cytokine (see below). The decreased 
production of TNF observed in macrophages infected with highly virulent mycolactone-producing 
M. ulcerans strains was shown to be mycolactone dependent. Indeed, macrophages infected with 
a mycolactone-negative mutant strain of M. ulcerans produced high amounts of TNF, and this 
production was inhibited by the addition of mycolactone. 
Inhibition of TNF by other pathogenic mycobacteria has been shown in the past (24, 30, 
75). In fact, it is known that strains of M. avium that proliferate extensively in cultured 
macrophages are able to delay the TNF production by the host cell, when compared with strains 
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with lower capacity to grow in these cells (30). In accordance, the same authors showed that 
addition of TNF in the beginning of the infection leads to the inhibition of the proliferation of 
strains that grow in macrophages, with no significant effect for strains with reduced capacity to 
grow in these cells (30). Likewise, the virulent reference strain M. tuberculosis H37Rv inhibits the 
production of TNF by infected macrophages in a higher extent when compared with the 
nonvirulent strain H37Ra (24). It is possible that this inhibition may be a strategy used by 
mycobacteria to prevent macrophage activation, allowing for an extended period of intracellular 
residence and multiplication. The production of mycolactone by intramacrophage M. ulcerans, 
and the consequent inhibition of TNF production by macrophages, may be a similar mechanism 
used by M. ulcerans to allow an extended intracellular growth in the host, rendering 
macrophages unable to control the proliferation of mycolactone-producing strains. Supporting 
this hypothesis, we have shown that TNF p55 deficient-mice are more susceptible to infection by 
low and intermediate virulent strains of M. ulcerans, but not to the infection by a highly virulent 
strain that induces the production of negligible amounts of TNF in infected macrophages. 
 
TNF was shown to have important roles in mycobacterial infections (78) including, 
among others: (i) orchestration of leukocyte recruitment and development of the granuloma; (ii) 
activation of effector functions of macrophages, such as RNI and ROI production (discussed 
bellow); (iii) maturation of dendritic cells (DC).  
The in vivo role of TNF in protective responses to mycobacterial infections, such as M. 
tuberculosis and M. avium infections, has been assessed through neutralization with anti-TNF 
antibodies as well as using TNF p55 deficient-mice (27, 46). Both approaches resulted in the 
decreased development of granulomas, failure to restrict mycobacterial growth, and decreased 
survival of infected mice. In M. ulcerans infection, the role of TNF is still not completely 
understood. However, due to its important role in the organization and maintenance of the 
granuloma, which has been shown to be a protective structure in infections by intracellular 
mycobacteria (6, 27, 32, 46), it is possible that TNF plays an important role in the organization 
and maintenance of this histological structure. In BU, granulomatous histopathology has been 
indeed associated with the healing of lesions (1, 40, 41, 79, 86). On the other hand, 
disseminated disease and osteomyelitis have been associated with defects in granuloma 
formation (42, 79). Accordingly, a correlation between the level of TNF expression and the 
formation of granulomata has been found in BU lesions (64), supporting our conclusion that TNF 
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plays a protective role in experimental BU. However, more studies are required to further 
elucidate this point.  
Another important observation in our study was the fact that BMDM infected at low MOIs 
with mycolactone-producing M. ulcerans produce levels of macrophage chemoattractant protein-
2 (MIP-2) similar to those produced by BMDM infected with mycolactone-negative mutant strains. 
MIP-2, being the murine homologue of human interleukin (IL)-8 (83), plays a central role in the 
recruitment of neutrophils in mice (29, 89). The expression of this chemokine was already 
reported in lesions of patients infected with M. ulcerans (64). Recently, Coutanceau and 
colleagues showed that a mycolactone-producing strain of M. ulcerans induces the expression of 
MIP-2 in infected macrophages (16). The expression of this chemokine in BU lesions, as well as 
its production by macrophages in vitro, is in accordance with the results presented by Guarner 
and colleagues (39) and the results from our laboratory (58), showing that M. ulcerans induces 
inflammatory responses containing neutrophils.  
 
Recently (15), it was shown that purified mycolactone blocks the emigration of DC from 
the skin to the draining lymph nodes as well as its maturation. Additionally, these authors also 
showed that DC treated with noncytotoxic concentrations of mycolactone were unable to activate 
allogeneic T cells. Surprisingly, these effects were not related with TNF, since mycolactone 
treated, LPS-stimulated DCs were able to produce TNF (15). It is well known that TNF is 
important for triggering the maturation programme in DCs, inducing DC migration and the 
upregulation of the molecular pattern required for the activation of T cells (52). Although 
interesting, the real impact of these results in infections by M. ulcerans requires further 
investigation. In this context, the diffusion of mycolactone in the tissue, the different types of 
mycolactones as well as the amount of mycolactones produced by different strains of M. ulcerans 
may be factors to take into consideration. In fact, in chapter 3 we showed that mycolactone A/B 
producing strains were more virulent for mice and more cytotoxic for BMDM when compared with 
mycolactone C producing strains. These results are in accordance with previous data showing 
that purified mycolactone A/B is more cytotoxic than mycolactone C (56).   
Although it is clear from our data that the outcome of the infection by M. ulcerans 
depends on the type of mycolactone produced, the existence of other factors, such as regulation 
of mycolactone production, amount of mycolactone produced or, even, other virulence factors, 
can not be ruled out.  
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 Although, in vitro, mycolactone was shown to inhibit TNF production, the expression of 
this cytokine, has referred above, has been detected in BU lesion samples (64, 66). It is still not 
clear which cells produce TNF in BU lesions. It can be hypothesized that TNF may be produced 
by: (i) infected macrophages when the M. ulcerans genes required to produce mycolactone 
would be switched off; (ii) newly recruited macrophages or other cell types in areas not affected 
by the toxin; (iii) macrophages or other cell types activated by inflammatory molecules derived 
from the process of tissue necrosis, regardless the contact with M. ulcerans or M. ulcerans-
derived molecules. It is also not clear if TNF detected in BU lesions has any impact in the control 
of M. ulcerans proliferation. The dose-dependent inhibitory effect of mycolactone on the in vitro 
production of TNF, as shown by us, suggests that this cytokine may have increased biological 
relevance in areas of the lesion where mycolactone concentration is low. In fact, it is known that 
BU lesions can heal spontaneously (73), but the role of TNF and other inflammatory cytokines in 
this process is currently not known. However, the lack of available methodologies, at the present 
time, to detect mycolactone in host tissues makes it impossible to clarify this hypothesis. The 
development of such methodologies will be essential to clarify the role of this and other cytokines 
in in vivo infections by M. ulcerans. 
 
 
Role of interferon-gamma on the activation of the effector mechanisms of macrophages infected 
with M. ulcerans. Interferon-gamma (IFN-γ), in association with TNF, is a key cytokine for the 
activation of macrophage’s effector functions. To date, IFN-γ-deficient mice are the most 
susceptible to M. tuberculosis infection (12, 26). In these mice, macrophage activation has been 
shown to be defective, and production of intermediate radicals, such as nitric oxide (NO), is low. 
These are probably the factors that contribute to the high susceptibility of IFN-γ-deficient mice to 
M. tuberculosis infection (17, 26). However, the existence of other IFN-γ-dependent, NO 
production-independent, anti-mycobacterial mechanisms can not be ruled out (25). 
 In human infections by M. ulcerans, production of IFN-γ has been suggested to be 
protective. However, until now, there are no reports showing a direct evidence for the protective 
role of this cytokine. Therefore, we used the previously developed footpad mouse model of M. 
ulcerans infection, as well as the in vitro infection of BMDM, to study the biological role of IFN-γ 
in M. ulcerans infections, and to clarify the macrophage’s effector mechanisms activated upon 
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infection with different strains of M. ulcerans. As compared to wild-type (WT) counterparts, we 
found that IFN-γ-deficient mice are more susceptible to sub-cutaneous infection by the 
mycolactone-negative strain 5114, and slightly more susceptible to the intermediate virulent 
mycolactone-producing M. ulcerans 94-1327. For the tested infection doses, no differences were 
found in the proliferation and in the levels of pathology induced by the highly virulent strain M. 
ulcerans 98-912. 
In vitro, at a 1:1 MOI, BMDM activated with IFN-γ controlled the proliferation of M. 
ulcerans 5114 but not of M. ulcerans 94-1327 or 98-912. Interestingly, at lower MOIs we found 
that IFN-γ-activated macrophages controlled the proliferation of the intermediate virulent strain M. 
ulcerans 94-1327.  
Macrophage’s effector functions were shown to be NO-dependent, since the competitive 
inhibition of NOS rendered IFN-γ-activated macrophages unable to control M. ulcerans. However, 
mycolactone-producing strains, including M. ulcerans 94-1327, did not trigger the production of 
NO by macrophages. Interestingly, LRG-47 was shown not to be inhibited significantly by M. 
ulcerans 94-1327, which can contribute to the control of proliferation found at low MOIs. On the 
other hand, a complete inhibition of LRG-47 expression was found in macrophages infected with 
M. ulcerans 98-912. 
 
 As previously mentioned, different studies have suggested that IFN-γ is associated with 
protection in human M. ulcerans infections (35, 36, 63, 64). All the data published until now are 
based on the expression of this cytokine in BU lesion samples (64, 66) or on its production by 
peripheral blood mononuclear cells (PBMC) after stimulation with M. ulcerans, M. ulcerans 
antigens or M. bovis BCG (35, 36, 63, 66).  
 The first studies suggesting a role for IFN-γ in the protection against M. ulcerans 
infections were performed in Australian patients with a history of past BU and showed that PBMC 
from patients, but not from healthy contacts, display a low capacity to produce IFN-γ after in vitro 
stimulation with live M. ulcerans bacilli or M. bovis BCG (35, 36). Since household contacts of 
BU patients showed antibodies against M. ulcerans, suggesting a previous contact with this 
pathogen without any signs of active disease, those authors interpreted this observation as 
indicating that, in an environment where M. ulcerans is endemic, subjects who have not 
developed clinical disease have been exposed to M. ulcerans and developed a protective immune 
response mediated by IFN-γ (36). In accordance, it has been suggested that a significant 
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proportion of the population residing in areas of M. ulcerans endemicity may be exposed to M. 
ulcerans but do not develop disease (19). Interestingly, Gooding and colleagues found that PBMC 
from the majority of individuals in the affected group express IL-10, suggesting that this 
immunosuppressive cytokine was the responsible for the reduced expression of IFN-γ observed in 
BU patients. Accordingly, Prevot and colleagues (66) showed, in a different study, that the 
production of IL-10 by PBMC stimulated with killed M. ulcerans or M. bovis BCG was higher in 
PBMC from BU patients than from controls.  Some of the limitations of these studies with PBMC 
is the long time of stimulation (6 and 7 days) and the low number of patients involved. It is also 
possible that the cytokines produced were not M. ulcerans-specific, due to the long time of 
stimulation. In a larger study in Ghana, using overnight stimulation of PBMC with M. ulcerans 
sonicate, it was found that the IFN-γ levels in patients with ulcers were similar to those in patients 
with healed BU, but higher than those in patients with nodules (63). IL-10 production was found 
to be higher in patients with active M. ulcerans disease than in those with healed lesions, being 
the pattern of response similar to that seen in tuberculosis (88). An interesting observation by 
these authors was the wide variation in IFN-γ and IL-10 production among patients which, in part, 
explains the discrepancies found in Gooding and Prevot’s studies that used a lower number of 
patients. 
 
 When PCR analyses was used to quantify the cytokine expression in nodular or ulcerative 
BU lesions, Prevot and colleagues (66) found a higher expression of IFN-γ and lower expression 
of IL-10 in the less severe nodular forms, in contrast with lower expression of IFN-γ and higher 
expression of IL-10 in the ulcerative lesions (66), suggesting that there was suppression of IFN-γ 
and increased IL-10 production in longer established lesions, as previously suggested by studies 
of PBMC stimulation (36). However, in a more recent study, using a high number of BU samples, 
Phillips and colleagues found a median expression of IFN-γ lower in nodules, but in some cases 
the production of this cytokine was above the median, when compared with the group of 
ulcerative lesions, showing a high variability in IFN-γ expression among patients (63). The 
suggestion of Prevot and colleagues (66) that IL-10 was responsible for the low IFN-γ responses 
in BU patients was not confirmed by Phillips and colleagues (63). In fact, these authors found 
that patients with the nodular forms of the disease did show low IFN-γ responses in the presence 
of higher IL-10 responses, but patients with ulcerative disease had the highest IL-10 responses 
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and, at the same time, showed high IFN-γ expression (63). In fact, these authors did not find any 
inverse correlation between IFN-γ and IL-10 (63). 
 
 As clearly stems from the reports discussed above, although different studies have been 
done to clarify the nature of the protective immune response to M. ulcerans infections, the 
results are not conclusive and, in some cases, are clearly contradictory. In that sense, the use of 
the mouse model will be essential to disclose the role of different cytokines, due to the high 
number of available gene-deficient strains and immunological reagents. In addition to the aspects 
discussed above, the discrepancies reported by the different authors could be explained by the 
fact that these studies were performed in different geographical regions of the world. It is known 
that different isolates of M. ulcerans show small differences in their 16s RNA (65), as well as in 
the types of mycolactones they produce (56). Therefore, differences in virulence of the isolates 
may also lie at the basis of the discordant results. However, from these studies we know that a 
high number of patients have to be used in order to obtain accurate results, and, in future 
studies, it will be important to determine the virulence of the isolate, or isolates, infecting each 
patient, their cytotoxicity and profile of mycolactones produced. These results may be important 
for the identification of other M. ulcerans’ putative virulence factors. 
 
FINAL REMARKS 
In the present dissertation we showed for the first time that M. ulcerans has a phase of 
intracellular residence and multiplication in the host. Additionally, we showed that M. ulcerans 
induces TNF production from infected macrophages, being this cytokine essential to control M. 
ulcerans proliferation in vivo. However, mycolactone-producing M. ulcerans strains inhibit TNF 
production from infected macrophages, which leads to an ineffective control of the infection in 
vivo. We also showed that mycolactone-producing strains are able to inhibit several IFN-γ-
dependent microbicidal mechanisms of macrophages.  
The findings here presented have important consequences for the host’s resistance to 
the infection. Additionally, the intramacrophage growth phase of M. ulcerans, as well as the role 
of the inflammatory cytokines TNF and IFN-γ, has to be taken in consideration for the future 
development of a specific vaccine or new drug therapies against BU. 
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